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2 Preface 
Apurinic/apyrimidinic Endonuclease 1 / Redox factor 1 (APE1/Ref-1) is a 
multifunctional and an essential protein in mammals [1]. It plays an essential role in 
cellular response to oxidative stress conditions [2] and contributes to maintenance of the 
genome integrity [3]. It is expressed ubiquitously and at high levels in tumor cells, 
approximately 4 × 107 molecules per cell [4][5], albeit the intracellular localization pattern 
can be heterogeneous among different tissues [6]. Its acronym reflects its, at least, dual 
nature: apurinic/apyrimidinic (AP) endonuclease, or APE1, was first discovered as a 
major constituent of the base excision repair (BER) pathway [7] that copes with DNA 
damages induced by oxidative and alkylating agents, including chemotherapeutics [8]. 
Ref-1, the acronym for redox effector factor-1, refers, instead, to APE1 transcriptional 
regulatory activity in modulating gene expression through a redox-based co-activating 
function on several transcription factors involved in cancer promotion and progression [9-
11]. These two activities are split into two functionally independent domains of the protein 
itself: the N-terminal portion of the protein, which contains a bipartite nuclear localization 
signal (NLS), is devoted to the transcriptional co-activating function; on the other hand, 
the C-terminal domain exerts the endonuclease activity on DNA abasic sites. The latter 
domain is highly conserved; conversely, the N-terminal region presents wider variability 
among different organisms, being more conserved in mammals and thus suggesting a 
recent acquisition during evolution.  
Due to its emerging role as a new target for chemotherapy, comprehension of the 
functional regulation of this pleyotropic protein represents a scientific frontier in 
translational medicine. 
Over the past two decades, knowledge of the biological functions, mechanisms of 
action, interactions and regulation of the protein APE1/Ref-1 has grown exponentially. It 
has been shown that APE1/Ref-1 participates in multiple cellular processes that are not 
only confined to DNA repair and maintenance of genome stability. Notably, this concept 
is emerging as a new paradigm in the DNA repair field. Emerging evidences have indeed 
pointed out that also other DNA repair enzymes may play important roles in 
transcriptional regulation of genes suggesting that nucleic acid processing enzymes are 
more strategically promiscuous than originally thought.  
Beside its dual nature as a DNA repair enzyme and as a redox factor, several other 
functions have been indeed discovered for APE1/Ref-1.  
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Recent findings demonstrated that APE1/Ref-1 N-terminal portion also interacts 
with different proteins involved in ribosome biogenesis, pre-mRNA maturation/splicing 
and ribonucleotide catabolism, highlighting an unexpected role of APE1/Ref-1 in RNA 
metabolism [12][13]. In addition, at least two independent studies have shown that 
APE1/Ref-1 cleaves abasic RNA in vitro and in vivo [14], as well as a specific coding 
region of c-myc mRNA in vitro, likely influencing the expression of the oncogene in cells 
[15]. Accordingly, APE1/Ref-1 has been proposed as a main candidate factor in the 
abasic RNA cleansing process, explaining some of the activities exerted by APE1/Ref-1 
on gene expression through post-transcriptional mechanisms. 
Another interesting, though yet poorly investigated, function of APE1/Ref-1 was 
discovered during investigation of trans-acting factors that act as Ca2+-dependent 
repressor of the parathyroid hormone (PTH) gene by binding to the negative Ca2+ 
responsive elements (nCaRE) in its promoter [16]. Expression of the PTH gene is down-
regulated in response to an increase in intracellular calcium concentration, which is 
mediated by two DNA sequences, i.e. nCaRE-A and nCaRE-B, which were first 
discovered in the promoter of PTH and later in other promoters including APE1 promoter 
itself. Subsequently, further experiments have demonstrated that APE1 requires other 
factors, such as heterogeneous ribonucleoprotein L (hnRNPL) [17], Ku antigen (KuAg) 
[18] and PARP-1 [19] to stably bind nCaRE elements. It was also shown that APE1/Ref-1 
affinity for nCaRE elements is enhanced when p300/CBP acetylates protein Lys6 and 
Lys7 residues as a result of an increase in extracellular Ca2+ concentration [20].  
At present, information is still inadequate regarding the molecular mechanism 
responsible for the coordinated control of APE1/Ref-1 several activities. Regardless of 
transcriptional control, the fine-tuning of the multiple functions of this essential protein 
may reside on its post-translational modifications (PTM) and on the modulation of its 
interactions with other proteins under different conditions. While for some PTMs a 
functional role has been proposed (i.e. acetylation at Lys6/7 and Lys27/31/32/35 and 
ubiquitination at Lys24/25/27) [21] the identity of proteins that interact and modulate 
APE1/Ref-1 biological functions is still under investigation.  
Several reports indicated that deregulation of APE1/Ref-1 in both expression and 
subcellular localization is associated to different tumorigenic processes [22]. Different 
studies have also shown a correlation between high level of APE1/Ref-1 and tumor 
resistance against chemotherapeutic drugs and ionizing radiation, implying that 
APE1/Ref-1 enhances repair and survival of these tumor cells [23], and, furthermore, 
other studies have demonstrated that subcellular distribution of APE1/Ref-1 has also 
been linked to tumor aggressiveness. For these reasons, APE1/Ref-1 is actually 
considered a promising and powerful pharmacological target. However, APE1/Ref-1 is a 
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pleiotropic protein playing a critical role not only in DNA repair but also in regulating 
apoptosis, cell proliferation and an adaptive cell response to oxidative stress. Therefore, 
the question remains to understand the relative importance of attenuation of APE1’s 
repair or transcriptional functions by small molecule inhibitors as a potential approach for 
reversing drug resistance. Thus, dissecting the molecular mechanism underlying 
APE1/Ref-1 regulation and functions in mammalian cells is extremely interesting 
especially for the translation relevance in the field of molecular medicine. 
 
4 
 
3 Synopsis 
Apurinic/apyrimidinic Endonuclease 1 / Redox factor 1 (here after referred to as 
APE1) is a multifunctional protein contributing to genome stability, through its central role 
in the BER pathway of DNA lesions, caused by oxidizing and alkylating agents. It also 
plays a role in gene expression regulation, as a redox co-activator of several transcription 
factors and in RNA metabolism. Another interesting and yet poorly characterized function 
for this non-canonical DNA repair protein is associated to its ability to bind to negative 
calcium responsive elements (nCaRE) of some gene promoters, thus acting as a 
transcriptional regulator. Since nCaRE sequences are located within ALU repeats, 
transposable elements that occupy at least one tenth of the human genome, many other 
functional nCaRE sequences could exist and play a role in the transcriptional regulation 
of genes. However, at present, specific information concerning an accurate number and 
the identity of genes containing these sequences within their own promoter are still 
evanescent, as well as the knowledge of how these elements plays an active biological 
function. Thus, the quest for functional nCaRE sequences on human genome would 
provide new insights on APE1 multifunctional roles and, in particular, it would identify new 
potential genes whose expression may be regulated by APE1 through nCaRE binding 
opening new hypothesis for understanding the functional link existing between DNA 
repair and transcriptional regulation. 
The present work is devoted to address this issue and is focused on the 
characterization of the molecular mechanisms responsible for APE1 binding to nCaRE 
sequences and its relevance in DNA-damage induced transcriptional regulation of genes 
during cell response to genotoxic damage. 
To this aim, a bioinformatic analysis systematically looking for functional nCaRE 
sequences within the human genome has been performed by filtering expression profile 
data of genes resulting deregulated upon APE1 knockdown. This analysis revealed the 
presence of multiple nCaRE sequences in genes deregulated upon APE1 silencing and 
conserved in mouse genome. Among the list of genes, whose expression is potentially 
regulated by APE1, attention was focused on the deacetylase sirtuin1 (SIRT1) due to its 
relevant involvement in cell stress, including senescence, apoptosis, tumorigenesis and, 
in particular, its role in the cell response to genotoxic agents through its deacetylating 
activity on APE1 N-terminal domain. Through a multidisciplinary approach, based on 
SPR, limited proteolysis, ChIP and gene reporter assays, it has been found that the 
APE1 N-terminus is required for the stable binding to nCaRE elements present within 
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SIRT1 promoter. APE1 was demonstrated to be part of a multi-protein complex, that 
includes hOGG1, Ku70 and RNA Pol II, which is quickly recruited on SIRT1 promoter 
upon oxidative damage playing a central role in the regulatory function of SIRT1 gene 
expression.  
These findings show that recruitment of repair enzymes to the transcription initiation 
site of the SIRT1 promoter occurs during early cell response to oxidative stress. All 
together, our data underline the importance of APE1 during the transcriptional initiation 
process, in positively promoting transcription of genes under genotoxic conditions. Our 
findings provide a general model unveiling BER enzymes involvement in controlling 
specific gene expression at the transcriptional level. 
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4 Introduction 
4.1 DNA repair pathways 
The genome of eukaryotic cells is permanently exposed to endogenous and 
exogenous DNA-damaging agents. DNA damage resulting from endogenous agents 
includes oxidation by reactive oxygen species (ROS) generated from normal metabolic 
processes, alkylation by agents such as S-adenosylmethionine, adduct formation 
resulting from attack by reactive carbonyl species formed during lipid peroxidation, 
hydrolytic depurination leading to the formation of abasic sites, or deamination of bases 
[24]. Exogenous agents, instead, comprise different environmental insults (chemicals, 
carcinogens, UV light), chemotherapeutic agents, and radiation damage [25]. If not 
repaired, DNA damage can result in mutations, diseases and cell death [26]. However, 
organisms have evolved several DNA-repair pathways to promptly correct the DNA 
damage preventing genome instability and mutagenesis. Each repair pathway is directed 
to specific types of damage and a given type of damage can be targeted by several 
pathways. Figure 1 reported the major DNA repair pathways which are mismatch repair 
(MMR), nucleotide excision repair (NER), base excision repair (BER), homologous 
recombination repair (HR), and non-homologous end joining (NHEJ) [23][27][28] (Figure 
1). Distinct DNA damage is repaired by different pathways and mechanisms, however, 
overlap and interaction between the various pathways and, in addition, some overlap in 
mechanisms can occur. Knowledge about the number of DNA-repair proteins and factors 
involved in the cellular response to DNA damage, as well the regulatory networks that are 
induced by persistence of DNA damage in the cell, is increasing as more and more 
information is obtained [29]. Interaction of different DNA-repair pathways and 
mechanisms furnish the most efficient defense for the cell to prevent genomic instability. 
Several diseases has been reported to be associated with defects in DNA repair, 
including Xeroderma pigmentosum, Cockayne syndrome, trichothiodystrophy, Werner 
syndrome, and Bloom syndrome [30][31].  
The description of each DNA repair pathways is far from my intention, for a 
comprehensive reviews on each DNA-repair pathway the reader is directed to [32-38] 
and to the following link for an updated information on the individual repair proteins 
http://sciencepark.mdanderson.org/labs/wood/dna_repair_genes.html [29]. What follow is 
instead an overview of BER pathway to provide a context for understanding the role of 
APE1 protein in DNA repair. 
Introduction 
Tesi di dottorato di Giulia Antoniali, discussa presso l’Università degli Studi di Udine                            7 
The BER pathway is responsible for the repair of DNA damage arising from 
alkylation, deamination, or oxidation of bases [39]. Alkylation of bases arises from 
exposure to either endogenous agents such as S-adenosylmethionine or exogenous 
agents, including environmental and chemotherapeutic agents, whereas deamination of 
cytidines and adenines occurs spontaneously. Oxidative damage can result from ROS 
generated by normal cellular processes, in addition to environmental or 
chemotherapeutic agents. 
4.2 Oxidative DNA damage and its repair in mammalian cells 
The genome content of eukaryotic cells is constantly subjected to reactive oxygen 
species (ROS) exposure. ROS are formed during a variety of biochemical reactions and 
cellular functions which can be derived from the external environment, but predominantly 
from endogenous byproducts of respiration [40]. Another major source of ROS production 
is represented by phagocytic NADPH oxidases during inflammatory responses and by 
non-phagocytic NADPH oxidases, as determined in different cell systems [41]. ROS are 
also produced by cellular oxidase in response to different external insults including 
environmental chemicals and chemotherapeutic drugs, ultraviolet (UV) light or ionizing 
radiation. 
Figure 1 - Schematic overview of DNA-repair pathway.  
Genome stability is maintained by several DNA-repair pathways, including direct repair (DR), base-excision repair 
(BER), nucleotide-excision repair (NER), mismatch repair (MMR), homologous recombination (HR), and non-
homologous end joining (NHEJ). (Image from Luo M. et al., Antiox. Redox Signal., 2010) 
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In its ground state, molecular oxygen (O2) is relatively unreactive. However, during 
normal metabolic activity O2 is capable of generating harmful reactive excited states such 
as free radicals and derivatives. All ROS are extremely reactive and can cause molecular 
damage, leading to cell death [42]. All the intermediate oxygen species can interact with 
i) proteins, ii) lipids and iii) nucleic acids to cause several damages [43].  
Exposure of nucleic acids to reactive species may result in strand breakage, nucleic 
acid-protein crosslinking, and nucleic base modification. Base modification, crosslinking 
of DNA-DNA and DNA-proteins, sister chromatid exchange, and single- or double-strand 
breakage may lead to block of transcription, translation, and DNA replication [44]. 
Therefore it is not surprising that ROS-induced genome damage has been implicated in 
number of diseases, including cardiovascular dysfunction, arthritis, and cancer, as well as 
in the aging process and aged-related neurodegenerative disorders. 
The most abundant oxidative genome damage product is oxidation of purines 
leading to various chemical modifications: the highly mutagenic guanine derivate 8-
hydroxyguanine (8-oxoG) and the formamidopyrimidines (FapyG and FapyA) (Figure 2). 
The common oxidized pyrimidines are the thymine glycol (TG) and 5-hydroxyuracil (5-
OHU); the latter is generated via oxidative deamination of C. Except for TG, these 
abnormal bases do not block DNA replication but could be mutagenic if not correctly 
recognized and repair. For example, the miscoding effect of 8-oxoG lesion is due to DNA 
polymerase activity which inserts adenine opposite to 8-oxoG, resulting in G:C to A:T 
transition mutations, therefore generating a DNA base mutation. The less common 
oxidized base lesions such as 8-oxoA, 5-formylU and 5-OHC could be also mutagenic. 
All these described oxidized base are recognized by different DNA glycosylases, 
which remove the damaged nitrogenous base by cleaving the N-glycosylic bond and 
generating an abasic (AP) site while leaving the sugar-phosphate backbone intact. This 
reaction represents the initiation step of the BER pathway.  
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Figure 2 - Chemical structures of the four canonical bases and of the oxidized nucleotides processed by the 
BER pathway.  
Oxidative modifications are shown in gray. (Image from Hegde M.L. et al., Prog Mol Biol Transl Sci., 2012) 
4.3 The Base Excision Repair pathway  
Damage to mammalian genomes, induced by a variety of ROS includes a plethora 
of oxidative damaged bases, abasic sites and DNA single-strand breaks (SSBs). It is 
generally estimated that more than 104 base lesions and SSBs are induced daily in a 
mammalian cell genome [45]. These base lesions and SSBs are typically repaired via the 
evolutionarily conserved DNA base excision repair (BER) pathway.  
BER is primarily responsible for repairing non-helix distorting base lesions 
produced by alkylation, oxidation or deamination of bases [46]. The currently accepted 
model for the core BER pathway reveals the presence of five distinct and coordinated 
enzymatic steps, as reported in Figure 3 [28]. The BER pathway is initiated by the 
removal of oxidated, alkylated or deaminated bases through enzymes called DNA 
glycosylases. Cells contain several DNA glycosylases, each of them exhibiting a specific 
substrate spectrum. Glycosylases catalyzes the hydrolysis of the N-glycosidic bond of the 
damaged nucleoside, the damaged base is released and an AP site is created. An AP 
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site can also occur spontaneously and represents damage itself. Glycosylases are of two 
types, monofunctional and bifunctional. Monofunctional glycosylases [e.g., N-methyl 
purine DNA glycosylase (MPG or AAG)] excise the damaged base to generate an AP 
site, which is successively processed by the multifunctional AP endonuclease, APE1. 
Bifunctional glycosylases such as the human 8-oxoguanine DNA glycosylase (hOGG1), 
human endonuclease VIII–like DNA glycosylase (NEIL1-3), and E. coli endonuclease III 
(NTH) glycosylase have an intrinsic AP lyase function [47][48] that cleaves the sugar-
phosphate backbone 3′ to the AP site. The resulting AP site is processed by APE1, which 
hydrolyzes the phosphodiester backbone immediately 5' to the AP site, creating 3' OH 
and 5' deoxyribose phosphate (5' dRP) termini. At this step, the resulting single-strand 
break (SSB) can be processed by either two pathways, the “short-patch” (SP-BER), 
where a single nucleotide is replaced, or the “long-patch” BER (LP-BER) where several 
new nucleotides are synthesized by a DNA polymerase. In SP-BER, the one-nucleotide 
gap is filled by DNA Polymerase β (Pol β) which incorporates a nucleotide and its 
deoxyribophosphodiesterase (dRPase) activity removes the 5′ moiety and uses the 3' OH 
terminus to insert the correct base. In LP-BER pathway a segment or flap of three to 
eight nucleotides surrounding the AP site is displaced, followed by insertion of the correct 
nucleotides by DNA polymerase δ, ɛ, or β, along with proliferating cell nuclear antigen 
(PCNA) and replication factor-C (RF-C). After resynthesis, flap endonuclease 1 (FEN1) 
removes the displaced strand. Finally a DNA ligase, DNA ligase III/XRCC1, can complete 
the repair process and restore the integrity of the helix by sealing the single-stranded 
DNA nick. Beside these enzymes, a number of accessory proteins are also involved, 
such as the scaffold protein X-ray cross-complementation group 1 (XRCC1), and the 
poly(ADP-ribose) polymerase 1 (PARP-1) which is an enzyme capable of immediately 
binding to an incised AP site, recruiting other BER proteins and increase overall process 
efficiency [49].  
All the steps of the BER pathway must be finely orchestrated both from 
thermodynamic and the kinetic point of view, to provide an accurate repair of the damage 
base. In this context, APE1 plays a crucial role since evidences from reconstituted 
systems and from cell extracts suggest that, besides providing the AP endonuclease 
activity, APE1 contributes also to the coordination of the different BER steps by 
interacting directly or indirectly with other BER enzymes and with other repair pathways. 
APE1 can interact with different glycosylases (OGG-1, MYH, MPG), with Pol β, with 
XRCC1, which in turn stimulates APE1 endonuclease activity, or with FEN1, directly 
stimulating its activity [6]. Due to its ability to recruit different protein factors, APE1 can be 
considered as one of the key elements capable of aggregating together different proteins 
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to form large DNA-repair factories. The molecular basis of the specificity of these 
interactions, as well as their biological significance, remains to be largely determined. 
Figure 3 - Schematic representation of BER pathway illustrating both short- and long-BER pathway. (Image from 
Hoeijmakers J., Nature, 2001) 
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4.3.1 Proteins involved in BER 
DNA Glycosylases 
DNA glycosylases (DG) catalyze the first step of BER pathway. Individual base 
lesions are recognized by distinct DNA glycosylases. These classes of enzymes flip the 
damaged base out of the double helix, while leaving the sugar-phosphate backbone 
intact, creating an apurinic/apyrimidinic site (AP). Eleven different mammalian 
glycosylases have been characterized so far, which can be broadly divided into two 
different mechanistic subclasses: the monofunctional or “pure” glycosylases and the 
bifunctional glycosylases (Table 1). Monofunctional glycosylases have only glycosylase 
activity, whereas bifunctional glycosylases also possess AP lyase activity that permits 
them to cut the phosphodiester bond of DNA, creating a single-strand break without the 
need for an AP endonuclease. The peculiarity of DNA glycosylases is the specific 
recognition of different damaged bases. Lesion recognition, particularly in chromatin of 
mammalian which is highly condensed, poses a serious challenge for DNA glycosylases 
which has not been extensively understand. Analysis of crystal structure of DNA 
glycosylase have revealed that the mechanism of base lesion excision involved the 
flipping of the damaged base out of the double helix into the DG active site pocket. DNA 
glycosylases bind to the minor groove of DNA, kinking it at the site of damage, and flip 
the lesion nucleotide out of the major groove of DNA. Only those lesions that could 
accommodate in the active pocket after nucleotide flipping are removed. To cleave the N-
glycosidic bond, monofunctional glycosylases use an activated water molecule to attack 
the anomeric carbon of the substrate. Bifunctional glycosylases, instead, use an amine 
residue as a nucleophile to attack the same carbon, going through a Schiff base 
intermediate. While the high-resolution structures of a number of DNA glycosylases 
provided important information about the mechanism of action of glycosylases towards its 
specific substrates, it remains still elusive how DNA glycosylases are coordinated with 
the enzymes that follow them in the BER pathway. It is likely that protein-DNA interaction 
surfaces play a large role coupled to protein-protein interactions and steric 
displacements.  
Based on structural similarity, glycosylases are grouped into four structural 
subfamilies and inside these into more groups based on the specificity to substrate and 
subcellular localization. The UDG and AAG families contain small, compact glycosylases, 
whereas the MutM/Fpg and HhH-GPD families comprise larger enzymes with multiple 
domains [50].  
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Table 1 - The mammalian DNA glycosylases and their specificity towards different substrates. (Table from 
Vascotto C. and Fishel M., Academic Press, 2012 ) 
AP Endonucleases 
Removal of damaged base by DNA glycosylases leads to the formation of AP sites, 
which can also arise spontaneously. Moreover, AP sites could be generated as a results 
of free radicals and alkylating agents that promote the release of bases by introducing 
base modifications that destabilize the N-glycosylic bond [45]. In the BER pathway, 
cleavage of baseless sites in DNA is performed by an AP endonuclease. The major 
human AP endonuclease is APE1 protein (also known as Ref-1 or HAP1), a homolog of 
bacterial Exonuclease III [51]. The fundamental role of this enzyme is highlighted by 
genetic studies demonstrating that nullizygous mice for APE1 gene result in early stage 
embryonic lethality (E5 to E9) and attempts to isolate stable APE1-knockout cell lines 
were totally unsuccessful [52]. Moreover, downregulation of APE1 expression levels in 
human cells through RNAi leads to AP site accumulation, reduced cell proliferation and 
triggering of apoptosis [53]. APE1, in a Mg2+-dependent manner, is able to recognize an 
AP site and cleave the phosphodiester bonds 5’ to the AP site, leaving a 3’-hydroxyl 
group and 5’-deoxyribose phosphate (dRP) termini flanking the nucleotide gap (see also 
4.5.2) [54]. 
In addition to its crucial role in the BER pathway, APE1 also exerts other different 
functions within the cells: it works as a redox protein stimulating the DNA binding activity 
of several transcription factors that are known to be involved in cancer promotion and 
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progression. Reader is redirected to chapter 4.5 for full comprehensive annotations of all 
APE1 activities and functions. 
DNA Polymerases 
Excision of a damaged base and subsequent processing of AP site by APE1 
endonuclease results in an intermediate containing a 3’-hydroxyl, which represents the 
suitable priming strand for the resynthesis operated by a DNA polymerase and a 5’-dRP 
that must be removed prior to completion of repair by a DNA ligase [55]. In the SP-BER, 
where a single nucleotide is removed and replaced, both DNA resynthesis and removal 
of the blocking 5’-dRP residue are carried out by Pol β a member of the X family of 
polymerases together with Pol σ, Pol λ, Pol μ and terminal deoxynucleotidyl transferase 
(TdT). The polymerase activity is located in the C-terminal domain of Pol β, while in the 
N-terminal resides the dRP lyase activity [56]. Pol β lacks any intrinsic proof-reading 
activity and the error frequency of short-patch base excision repair in mammalian cell 
extracts has been calculated to be of the order of 5-10x10-4. Due to its essential function 
in BER pathway and therefore in the maintenance of genome integrity, overexpression of 
Pol β has been correlated with a number of cancer types, whereas deficiencies in Pol β 
result in hypersensitivity to alkylating agents, induced apoptosis, and chromosomal 
breaking [57][58]. 
As discussed above, Pol β removes the blocking 5’-dRP moiety through a β-
elimination reaction, after the insertion of the nucleotide. However, if the dRP formed 
after incision of AP endonuclease is refractory to dRP lyase activity and therefore cannot 
be processed by Pol β, then a polymerase switch may occur with Pol δ and Pol ε 
continuing the strand synthesis with displacement of the DNA strand ahead of the 
polymerase. In this case, the repair is re-routed through the PCNA-dependent long-patch 
pathway in which between 2 and 8 nucleotides are removed and replaced [59]. 
DNA Ligases 
The sealing of the nick with 3’OH and 5’P termini is operated by a DNA ligase ATP-
dependent that utilizes the energy of phosphoanhydride hydrolysis to make a 
phosphodiester bond [60]. In human cells, two DNA ligases have been implicated in BER: 
DNA ligase I (Lig I) and DNA ligase III (Lig III). Lig I plays an essential role in DNA 
replication where it is active in joining Okazaki fragments [61]; however, Lig I has also 
been implicated in several DNA repair pathways including BER pathway [62]. Indeed, 
human cell lines containing a partially inactive Lig I exhibit hypersensitivity to such DNA-
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damaging agents as ionizing radiation and alkylating agents, supporting the notion of a 
crucial role for Lig I enzyme in BER pathway and in particular in long-patch repair 
[63][64]. 
In mammals, DNA ligase III is present in two isoforms, Lig IIIα and Lig IIIβ. 
However, it is DNA Lig IIIα that has a crucial role in BER pathway as demonstrated by the 
fact that this enzyme was originally purified in complex with XRCC1 [65] and further 
analysis unveiled the biological relevance of this protein:protein interaction in short-patch 
BER [66]. 
4.3.2 Scaffold proteins involved in BER pathwayAll the enzymes 
discussed above constitute the core of BER pathway and are sufficient to reconstitute 
BER in vitro. However, several other accessory proteins are involved in BER in vivo and 
although they do not exert a specific enzymatic activity, they provide a scaffold for the 
core BER enzymes. XRCC1 and PARPs are other key factors with direct roles in BER. 
XRCC1 participates in BER as a scaffold to recruit BER proteins at AP site. It has been 
demonstrated that physically interacts with different proteins such as NEILs, APE1, Pol β 
and Lig IIIα. Relevance of XRCC1 is evidenced by the fact that its knockout results in 
embryonic lethality [67]. 
PARPs proteins act as a sensor of single strand break. PARPs constitute a 
superfamily with regulatory functions in various cellular processes. PARP-1 and PARP-2 
are the ones implicated in BER pathway. They are activated by SSB when they transfer 
ADP-ribose moiety from NAD to a variety of proteins including themselves. However, 
PARPs direct involvement in BER pathway has not been fully characterized. It is likely 
that the main role of PARP-1 may be related to histone poly(ADP)-ribosylation, a 
modification that could facilitate the access of BER enzymes to the site of damage, or to 
recruitment of XRCC1 and Pol β through their interaction with automodified PARP-1 itself 
[68]. 
Other proteins have also been described to be involved in the process of BER: the 
proliferating cell nuclear antigen (PCNA) and the heterotrimer constituted by Rad9, Rad1 
and Hus1, named 9-1-1. The first protein, PCNA, is required during LP-BER as support 
for Pol δ [69]. 9-1-1, as well PCNA, has been demonstrated to interact with and stimulate 
many BER proteins such as MYH, NEIL1, TDG, APE1, Pol β, FEN1 and Lig I, suggesting 
their involvement in replication-associated BER. 
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4.3.3 Complexity of BER pathway 
An in vitro complete nuclear BER requires only four or five enzymes. Until recently, 
in fact, BER was believed to be the simplest among the DNA repair pathways. However, 
recent studies have revealed that BER is much more complex, involving a network of 
distinct cell cycle-dependent as well as genome region-specific repair sub-pathways and 
could also involve non-BER proteins.  
Several non-canonical proteins have been demonstrated to participate in BER, 
even if their in vivo functions are yet to be fully unraveled. The list of non-BER proteins 
includes: YB-1, which has been shown to interact with NEIL2 [70], NTH1 and APE1 [71]; 
NEIL2 was also found to interact with hnRNP-U, a RNA-binding protein [72]; HMGB1 has 
been implicated in single strand break repair involving Pol β [73]; the tumor suppressor 
p53 was also shown to play a role in DNA damage repair through the binding of APE1 
and Pol β [74]. The list of these non-BER proteins is still growing, highlighting the 
paradigm that BER in vivo is far more complex than in vitro repair. The observation and 
the characterization of the BER interactome which involves multiprotein interactions and 
complexes has led to a new paradigm where complete repair occurs in the BER complex 
(BERosome) [75]. The initial prevailing view of BER mechanism, based on co-crystal 
structure analysis of substrate-bound BER proteins, proposed that BER comprises a 
sequence of steps with individual repair enzymes carrying out reactions independently of 
one another. Since recent studies shown that BER enzymes stably interact with most 
downstream repair components, this initial view of BER as ‘hand-off’ or ‘passing the 
baton’ process has been revisited by Hedge et al. who proposed, rather, a new BER 
paradigm in which collaboration of multiple proteins in a coordinated fashion involving 
dynamic protein-protein interactions enhances repair efficiency. Although in vivo role of 
‘hand-off’ versus interactome modes of repair is not yet clear, Hedge et al. proposed that 
preformed BER complexes predominantly repair endogenous base lesions, while repair 
via hand-off mechanism by sequential recruitment could occur with induced DNA 
damage. Further characterization of the dynamics of BERosomes is required to unravel 
the repair processes. 
4.4 DNA repair enzymes and their involvement in gene 
regulation 
A growing body of evidences points out that several DNA repair enzymes of BER 
pathway exert non-canonical functions that differ from the “orthodox” activity in 
maintenance of genome stability. Current reports indicate indeed the participation of 
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numerous DNA repair enzymes in other cellular processes distinct to DNA repair. This is 
an emerging paradigm observed for many proteins belonging to DNA repair pathways. 
Among these enzymes, for example, many papers have reported the relevance and 
involvement of PARP proteins and APE1 in multiple steps of gene regulation. PARP-1 
and PARP-2 were originally described in connection to DNA repair and in physiological 
and pathophysiological processes associated with genome maintenance. PARP-1’s 
enzymatic activity is stimulated dramatically by the binding of PARP-1 to damaged DNA 
and hence, most studies of PARP-1 to date have focused on its role in DNA repair and 
cell death pathways. Following DNA damage, PARP-1 protein located near the damaged 
region binds DNA breaks, activating the catalytic site, and begins to transfer ADP-ribose 
groups to the chromatin proteins located in the immediate vicinity. The modified proteins 
are released from the DNA, allowing repair enzymes to access the damaged region. 
However, rather than simply functioning as a repair enzyme, PARP-1 has been shown to 
be necessary for viability and to organize the chromatin structure of nucleoli, 
heterochromatin, and other sequences during development and under physiological 
condition evidencing its involvement in multistep events for regulated activation of gene 
transcription [76-79]. Recent reports have also identified important rearrangements in 
gene expression upon knockdown of PARP-2 suggesting the emerging transcriptional 
roles of this DNA-repair protein [80].  
APE1, another critical enzyme in the BER pathway, is emerging as a key factor in 
multiple aspects of DNA and RNA metabolism. APE1 acts as the predominant AP site 
incision enzyme in mammalian cells. Genetic knockout of APE1 in mice causes 
postimplantation embryonic lethality [1][52] and any attempt to isolate stable APE1-
knockout cell lines has been so far unsuccessful, underlining that APE1 is essential for 
cell viability. The essentiality of APE1 for mammalian cells seems to be mainly due to its 
DNA-repair activity in BER pathways [2]. However, attempts to restore this activity in cells 
not expressing APE1 by using the yeast homologous Apn1 [2], which lacks the redox-
transcriptional activation domain, or an APE1 mutant lacking the acetylation sites but not 
the DNA-repair activity [81], were unsuccessful. These observations indicate that 
essentiality of APE1 may be due to its pleiotropic biological effects rather than merely to 
its DNA- repair activity. Previous works that combined mRNA expression profiling and 
proteomic analysis to determine the molecular changes associated with APE1 loss-of-
expression were in agreement with this notion [53]. This approach has indeed identified 
that APE1 acts as a hub in coordinating different and vital functions in mammalian cells 
including cell growth, apoptosis, intracellular redox state, mitochondrial function, and 
cytoskeletal structure. Therefore, despite the central role played by APE in the BER 
pathway, APE1 is to be considered as a pleiotropic protein playing also a critical role in 
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the regulation of apoptosis, cell proliferation and an adaptive cell response to oxidative 
stress. The following chapter is dedicated to an update review describing the molecular 
basis for the multifunctional roles of this protein. 
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4.5 APE1: not only a DNA repair enzyme 
Human APE1 was first cloned by Demple and colleagues in 1991 and successively, 
the same group also characterized its enzymatic activity on AP site-containing DNA [51]. 
One year later, Xanthoudakis and Curran described a protein which stimulated AP-1 
DNA-binding activity through the conserved Cys residues in Fos and Jun and named this 
protein Ref-1, acronym of Redox Effector Factor-1. They also suggested that the newly 
identified protein may represent a novel redox component of the signal transduction 
processes that regulated eukaryotic gene expression [82]. It turned out that the two 
groups independently identified the same protein and described its endonuclease and 
redox functions which are exerted by two functionally independent domains. 
4.5.1 APE1 structure and domain organization 
The APE1/Ref-1 protein is 318 amino acids in length and has a MW of ~ 37 kDa. 
The structure of the human APE1 consists of two symmetrically related domains with 
similar topology and has a significant structural similarity to both bovine DNase I and its 
E. coli homologue Exonuclease III. APE1/Ref-1 is a globular alpha/beta protein consisting 
of two domains: N-terminal domain core residues 44-136 and 295-318; C-terminal 
domain core residues 137-260. Each domains is made up of a six-stranded beta-sheet 
surrounded by an alpha-helix which pack together to form a four layered α/β sandwich 
with overall dimensions of 40x45x40 Å (Figure 4) [83]. 
Besides these two structural domains of the protein, three functionally independent 
domains can be distinguished: i) the first 33–35N-terminal unstructured sequence is 
essentially involved in protein–protein interaction and is important for the RNA-binding 
activity of the protein [84] and the modulation of its catalytic activity on abasic DNA 
[5][85]; ii) the redox domain which spans the region between amino acids 35 and 127; 
and iii) the DNA repair domain which spans the C-terminal domain of the protein from 
about residue 161 onwards. Furthermore, whereas APE1 C-terminal domain involved in 
AP endonuclease activity is conserved from bacteria to humans, the redox function is 
unique to mammals. In fact, APE1 and E. coli Exonuclease III, the major AP 
endonuclease found within E. coli, are closely related in terms of structure and with also 
very similar endonuclease active sites. The sequence identity between APE1 and 
Exonuclease III is 27.7%. The most obvious structural difference between human APE1 
and Exonuclease III is an additional 62 N-terminal residues found only in APE1. Within 
this N-terminal region of APE1 is a nuclear localization sequence. However, addition of 
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N-terminal residues alone does not confer redox activity; zebrafish APE1 includes a 
similar N-terminal addition but lacks redox activity [86]. 
Figure 4 - Ribbon representation of the APE1 structure.  
An α/β-sandwich is formed by the packing of two six-stranded β-sheets surrounded by α-helices, with strand order β3-β4-
β2-β1-β14-β13 and β5-β6-β7-β8-β12-β9 from domains 1 and 2, respectively. The α-helices and β-strands are numbered 
sequentially from the N-terminus. (Image from Gorman MA et al., EMBO J., 1997) 
C-term domain exerts APE1 endonuclease activity 
This domain is responsible for APE1 endonuclease activity. The active site, which 
lies in a pocket at the top of the α/β sandwich, consists of several critical residues 
(His309, Glu96, Asp283, Thr265, Tyr171, Asn68, Asp210, Asp70, Asn212) determined 
by site-directed mutagenic studies [83][87]. Within the active site, at least one divalent ion 
(Mg2+) is present bound to Glu96 and it is an essential cofactor critical for high level of AP 
endonuclease activity [88]. It has been postulated that APE1 orients a rigid pre-formed 
DNA binding face and penetrates the DNA helix from both the major and the minor 
grooves, stabilizing an extra-helical conformation for the target abasic deoxyribose and 
excluding any normal DNA nucleotide. Interactions between APE1 and DNA are 
preferentially at the strand containing the abasic site involving the phosphates at 5’ and 
3’. Met270 inserts through the minor groove to pack against the orphan base. Meanwhile, 
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Arg177 inserts through the DNA major groove and delivers a hydrogen bond to the AP 
site 3’ phosphate. Together, Arg177 and Met270 effectively lock APE1 onto AP-DNA. 
The catalytic process implicated is still under investigations since there is not consolidate 
view concerning the hypothetical catalytic mechanism. 
N-term domain is responsible for redox regulation 
Recent data pointed out that two distinct regions has to be considered when looking 
at APE1 N-terminal domain. The first 33-35 amino acid region consists of a structural 
disordered segment which is essential for the interaction with other proteins and harbors 
sites for post-translational modifications [75]. The region comprised between residues 43 
and 65 is, instead, necessary for APE1 redox transcriptional co-activation activity. APE1 
acts in a redox mode, reductively activating several oxidized transcription factors. In this 
process, APE1 controls transcriptional regulation of gene expression by enhancing the 
DNA binding activity of proteins like p53 [10], AP-1 [82], HIF-1α [89], NF-κB [90], CREB 
[91], Egr-1 [9]. The structural data indicate that this region forms an extended loop which 
lies across the β-strands β13 and β14 making a number of hydrogen bond and salt 
bridge interactions with the globular core of the molecule. Cys65 is the key residue 
implicated in the redox activity of the APE1 together with Cys93 [88]. Cys65 is located 
into a hydrophobic pocket away from the central β sheet and is not accessible to solvent 
suggesting that Cys65 is unable to directly interact with residues from other proteins 
unless APE1 may undergo a conformational change, which involves exposure of Cys65 
and creates a binding site that will accommodate the different transcription factors [86]. 
However, factors capable of stimulating this conformational rearrangement are still under 
investigations. A redox-independent mode of action by APE1 on transcription factors 
activities has also been hypothesized, as in the case of p53 [92], subsequently extended 
to AP-1 [93]. 
N-term domain: functions of a disordered terminal extension 
Recent experimental evidences have demonstrated that the non-conserved N-
terminal segment of the human APE1, absent in the E.coli prototype Xth, consists of an 
unstructured domain [94]. Long disordered segments are a common features recently 
observed for a large percentage of proteins under physiological conditions. Such 
disordered tails were also shown to be more common in DNA binding proteins than in 
other proteins, particularly in the ones that are involved in target sequence binding that 
includes early repair proteins and transcription factors [95][96]. It is likely that their 
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structural flexibility and plasticity provides major functional advantages. Commonly used 
disordered prediction tool (PONDR and PrDOS) were used to compare the secondary 
structure of human and bacterial early BER proteins and correlated them with their 
available structural information [75]. This analysis showed that mammalian DNA 
glycosylases are endowed with an unique structural feature absent in their homologs in 
lower organisms because of the presence of a non-conserved extension at N or C 
terminus (Figure 5). hNEIL1 contains an extended disordered region spanning about 100 
residues in the C-terminus which is absent in E. coli Nei-like protein. Similar comparison 
of predicted structures of human DNA glycosylases NTH1, MYH and their E. coli 
prototypes Endonuclease III and MutY, respectively, indicates that both hNTH1 and 
hMYH have extended disordered tails at the N-terminus that are absent in the E. coli 
enzymes. Similarly, the N-terminal disordered region present in hAPE1 is absent in Xth, 
its E. coli prototype. The size range of disordered extension is almost between 50-100 
residues. In the case of human APE1 consists of approximately 65 residues being the 
most disordered.  
Figure 5 - Disordered terminal extensions in human early BER proteins as compared to their E. coli prototypes. 
(Image from Hegde M.L. et al., Prog Mol Biol Transl Sci., 2012) 
These disordered regions are essential for their biological functions including 
damage sensing, protein-protein interactions, repair regulation via post-translational 
modifications and nuclear localization signal (NLS). The unique presence of disordered 
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segments in eukaryotic proteins but not in the prokaryotic counterparts, with the highest 
degree of disorder in mammals, suggests its evolutionary development. The disorder 
segment provides advantage of limiting molecular size as complexity increases, by 
providing common interface for multiprotein binding and sites of modifications. Thus 
disorder regions may help higher organisms to limit protein size and to reduce 
intracellular crowding. 
4.5.2 APE1 canonical functions 
APE1/Ref-1 is a master regulator of cellular response to oxidative stress conditions. 
Its acronym reflects its dual nature: APE1 is a major constituent of the Base Excision 
Repair (BER) pathway of DNA lesions generated as a consequence of oxidant-induced 
base damages and highly contributes to the maintenance of the genome stability; Ref-1, 
the acronym for redox effector factor-1, refers to its redox abilities exerted on different 
redox-regulated transcription factors (TFs) during adaptive cellular response to oxidative 
stress (Figure 6) [97]. Therefore, beside APE1 crucial role in the maintenance of genome 
stability as the major apurinic/apyrimidinic endonuclease in mammalian cells, its 
involvement in redox signalling and in the regulation of gene expression suggest that 
APE1 is to be considered as a multifunctional protein with hallmarks that transcend the 
classical activities of a DNA repair enzyme. Non-canonical functions of APE1 are 
represented by its transcriptional repressor activity through binding of particular 
regulatory sequences, the negative calcium responsive elements (nCaRE) and by the 
recently unsuspected function in RNA metabolism. APE1 was demonstrated to bind RNA 
acting as a cleansing factor of abasic RNA. Furthermore, a recent paper demonstrated 
that APE1 may control c-myc expression by cleaving its mRNA [15]. 
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Figure 6 - The many different functions of APE1.  
Above, the schematic organization of the human APE1 structure reporting some critical residues. Ribbon representation 
of the APE1 structure and the main function of APE1 are reported. (Image from Tell G. et al., Cell. Mol. Life Sci., 2010) 
Base excision repair 
APE1 hydrolyzes the phosphodiester backbone immediately 5′ to an AP site to 
produce 3′ OH group and 5′ deoxyribose-5-phosphate [98]. After the removal of this 
blocking group via dRP lyase activity of DNA polymerase β, the repair DNA synthesis is 
followed by DNA ligase action which restores genome integrity [99]. Oxidized base-
specific DNA glycosylases have intrinsic AP lyase activity and cleave the DNA strand 3′ 
to the AP site [100]. The resulting 3′ blocking group is removed by APE1 in the next step 
of repair [48]. APE1's 3′ phophodiesterase activity is also involved in repairing DNA 
single-strand breaks with 3′ blocking group directly generated by ROS [101]. Unrepaired 
AP sites lead to DNA strand breaks, apoptosis, and increases cytotoxicity [102]. Thus, 
the DNA repair function of APE1 protects the cell from both endogenous and exogenous 
DNA damage. All APEs have dual activities as an endonuclease and a 
3′phosphodiesterase [98]. However, mammalian APE1's endonuclease activity is quite 
strong relative to its 3′ exonuclease/phosphodiesterase activity [48][98][103]. 
Furthermore, unlike E. coli Xth with potent 3′ phosphatase/phosphodiesterase activities, 
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the mammalian APE1 has extremely weak 3′ phosphatase activity that would be required 
to remove 3′ phosphate directly generated by ROS or due to AP lyase activity of 
mammalian glycosylases, NEIL1 and NEIL2 [104][103]. APE1 also coordinates BER as 
an assembly factor by interacting with downstream BER protein such as DNA 
Polymerase β, X-ray cross-complementing-1 (XRCC1), proliferating nuclear antigen 
(PCNA), and flap endonuclease (FEN1) [105-107]. Due to its ability to recruit different 
protein factors, APE1 can be considered as one of the key element in the BER pathway. 
Redox regulation of transcription factors 
Reactive oxygen species represent a danger for all aerobic organisms since 
elevated levels of ROS can damage lipids, protein, carbohydrates and nucleic acids. Of 
notice the observation that sub-toxic levels of ROS could lead to a variation of 
intra/extracellular redox balance that can result in an alternation of gene expression. The 
molecular mechanism at the basis of this regulation is exerted through the modulation of 
transcription factors (TFs) activity. In particular, the redox status of reactive Cys residues, 
located within the DNA-binding domain of some TFs, may control the transcriptional 
activity of the TFs itself. APE1 has been identified as a protein capable of nuclear redox 
activity, inducing the DNA binding activity of several transcription factors, such as AP-1 
[82], NF-κB [90], Myb [91], PEBP2 [108], HLF [109], NF-Y [110], Egr-1 [9][111], HIF-1α 
[89], ATF/CREB family [91], p53 [10][112][113], and Pax proteins [114-116]. In each 
case, this effect was accomplished by maintaining the cysteine residues of the TFs in the 
reduced state, through a redox cycle in which the thioredoxin (Trx) would restore the 
reduced form of APE1 [117-120]. It has been shown that APE1 Cys65 is the redox-active 
site of the protein [86][121]. Since Cys65 is located inside the 3-D model structure of the 
protein [83][87], the redox regulation may implicate the occurrence of unfolding or 
conformational change of APE1 to allow interaction with redox-sensitive TFs.  
Recently, a novel mechanism by which APE1 may regulate DNA binding activity of 
various transcription factors has been proposed. Ando K. et al. discovered a novel activity 
of APE1 termed “redox chaperone activity” by which APE1 promotes reduction of TF 
cysteine residues by other reducing molecules, such as GSH and thioredoxin [122]. This 
chaperone activity seems to be mediated by direct interactions between APE1 and target 
transcription factor (Figure 7). 
In conclusion, this APE1 redox and the redox chaperone activities are crucial to 
preserve the cell from the genotoxic insults due to increased ROS concentration. 
However, since APE1 could modulate several TFs belonging to different classes with 
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opposing effects on cell biology, further works are required to comprehend the 
mechanism responsible for targeting this APE1 activity in response to a specific stimulus. 
Figure 7 - Schematic representation of APE1 redox and redox-chaperone activities.  
APE1 is responsible for the reduction of oxidized cysteines within DNA-binding domain or regulatory domain of a number 
of transcription factors. (Image from Tell G. et al., Cell. Mol. Life Sci., 2010) 
Inhibition of RAC1-mediated intracellular ROS production by 
APE1 
In recent years, numerous evidences have suggested that reactive oxygen species 
(ROS) can induce a number of functional changes either deleterious or adaptive in the 
eukaryotic cells. ROS, in fact, are known to play a dual role in biological systems, since 
they can be either deleterious or beneficial to living systems. Beneficial effects of ROS 
involve physiological roles in cellular responses such as during organism’s defense 
against infectious agents and as second messengers of cellular signalling systems. As 
concern this latter case, several evidences have demonstrated that functional triggering 
of membrane-bound receptors (such as those for TSH, CD40L, ATP, IL-2, etc.) can lead 
to APE1 functional activation through intracellular generation of sublethal doses of ROS 
[6]. Noteworthy is the observation that APE1 is also directly responsible in endothelial 
cells for the control of the intracellular ROS levels through its inhibitory effect on Rac1, 
the regulatory subunit of a membrane nonphagocytic NADPH oxidase system [123][124]. 
This enzyme, composed of multiple membrane-associated (Mox and p22phox) and 
cytosolic components (p67phox, p47phox, and Rac1), catalyzes the transformation of the 
molecular oxygen to the superoxide anion by transferring an electron from the substrates 
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NADH or NADPH [125]. Activation of NADPH Oxidase results in generation of ROS, 
which are important in the host defense against infection [126] and in vascular cell 
function. The Rac1 protein has been shown to play a critical role in the assembly and 
activation of NADPH oxidase in the neutrophil form of the enzyme complex. RAC1 is a 
small GTP binding protein belonging to the Ras superfamily. The exact mechanism by 
which RAC1 is involved in the activation of the vascular NADPH oxidase remains unclear 
[127]; however, it seems that one of the oxidase complex subunits, p67phox, could be 
sequestered by p40phox. RAC1 binding to p67phox could result in the disruption of 
p67phox/p40phox association, allowing NADPH oxidase activation [128]. Endothelial 
cells, subjected to TNFα treatment or hypoxia/reoxygenation (H/R), respond activating 
NADPH oxidase in a RAC1 dependent manner. Angkeow P. et al. discovered that APE1 
overexpression in an endothelial cell line could prevent oxidative stress induced by TNFα 
or H/R, even if the molecular mechanism was not characterized. The authors 
hypothesized that APE1 could interfere with RAC1 activation, presumably perturbing 
either an activation (GEF) or inactivation (GAP) process of RAC1 (Figure 8). Moreover, 
since it has been reported that NADPH oxidase, RAC1 and oxidative stress are related to 
regulation of cell motility and cell adhesion, thus, through the ability of controlling RAC1 
mediated ROS production, APE1 could play also a fundamental role in regulating actin 
network organization in endothelial cells. However, further experiments are required to 
understand these aspects. Very recently, an interesting evidence concerning the ability of 
APE1 to control intracellular ROS levels has been obtained shedding lights on the 
molecular mechanism involved. Zou G.M. and Maitra A. found that human pancreatic 
cancer PANC1 cell lines treated with E3330, which is a specific inhibitor of APE1 redox 
activity [129], displayed an increased ROS levels [130]. In this work the authors did not 
investigate the molecular mechanism; however since pancreatic cells express NADPH 
oxidase [131], thus it could be speculated that E3330 could influence the pathway 
involving RAC1. Therefore, it is possible that APE1 could exert a redox-like activity also 
in cytoplasm or that the RAC1 inhibition could be attributable to APE1 redox activity, 
therefore one of its substrates should be a factor involved in RAC1 activation/inactivation 
cycle. Further experiments are required to better clarify these mechanisms, which are still 
unknown. 
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Figure 8 - Role of APE1 in intracellular ROS production control.  
APE1 is capable of inhibiting intracellular H2O2 production, through modulation of a Rac1-regulated NADPH oxidase. 
(Image from Tell G. et al., Cell. Mol. Life Sci., 2010) 
4.5.3 APE1 non-canonical functions for a DNA repair protein 
Role of APE1 in RNA metabolism 
There is a growing body of evidences that links DNA repair proteins to RNA 
metabolism. The mechanism by which cells cope with damaged RNA is currently 
unknown. However, specific surveillance mechanism is needed to remove damaged 
molecules of RNA that can impair protein synthesis. Barzilay et al. were the first to 
demonstrated APE1 RNase H-activity [132]. They showed that APE1 binds with relatively 
low affinity to undamaged single- and double-stranded nucleic acid substrates (RNA and 
DNA) but does not exhibit general nuclease activity against them. However, their findings 
let hypothesize a possible involvement of APE1 in RNA metabolism. Subsequently, it has 
been suggested that APE1 can also bind to RNA molecules in vivo [6] and it was found to 
be associated with protein factors involved in ribosome assembly and RNA maturation 
within cytoplasm [13][17][71] suggesting a direct involvement of APE1 in RNA metabolic 
pathways.  
Very recently, Berquist BR et al. discovered that APE1 possesses the ability to 
cleave AP sites within ssRNA molecules which depends on molecule conformation [14]. 
This finding further supports the idea that APE1 serves as a “cleansing” factor for 
oxidatively damaged abasic RNA. It is known that RNA is oxidized to a greater extent 
than cellular DNA by treatment with H2O2 [133] and that oxidized RNA molecules are 
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present in huge amounts in brains from Alzheimer patients [134]. Although the biological 
relevant question is whether the formation of abasic RNA molecules is a spontaneous or 
guided process, the results propose APE1 as an ideal candidate for a novel RNA 
cleansing process [12][14]. Furthermore, in line with this hypothesis, very recently, 
Barnes et al. [15] identified APE1 as the endonuclease capable of cleaving a specific 
region of the c-myc mRNA in vitro therefore influencing c-myc mRNA level and half-life in 
cells. Altogether, these results clearly demonstrate that APE1 acts on RNA molecules 
and is involved in RNA metabolism. Further studies are needed to verify if APE1 role in 
controlling mRNA expression is mRNA-specific or if APE1 cleaves other types of RNA 
hence affecting a broad range of cellular function. 
APE1 transcriptional activity through nCaRE binding 
Another intriguing function of APE1 as a trans-acting factor was discovered when APE1 
was identified as one of the regulatory proteins that bind to the negative calcium 
responsive elements, nCaRE-A and nCaRE-B, in the intracellular calcium [Ca2+]i–
dependent downregulation of the human parathyroid hormone (PTH) gene [16]. An 
increase in hematic PTH concentration mobilizes Ca2+ from the storage tissues [135]: 
high levels of extracellular calcium inhibit PTH transcription with a negative feedback 
mechanism which involves the binding of the trans-acting complex to the nCaRE 
sequences [136][137]. Subsequently, other nCaRE elements were identified on the 
promoter sequences of other genes, like renin [138] and APE1 itself [139]. Thus, 
experimental observations suggest that APE1 could down-regulate its own gene and this 
negative feedback mechanism would represent the first example of such a transcriptional 
self-regulatory mechanism for a DNA repair enzyme. 
The reader is directed to chapter 4.8 for further details concerning sequence and function 
of nCaRE element. 
4.6 Modulation of APE1 different functions 
APE1 is a multifunctional protein that exerts several different and in some ways 
antithetic functions within cells: APE1 is indeed correlated with cell survival but, at the 
same time, with proapoptotic pathway as well. The regulatory functions of the different 
APE1 activities must be therefore fine-tuned. This could be implemented via at least 
three different mechanisms: (i) increase in APE1’s level after transcriptional activation; (ii) 
re-localization of APE1 from the cytoplasm to the nucleus; and (iii) modulation of APE1’s 
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post-translational modifications (PTMs). Together with PTMs, changes in the interactome 
of APE1 could target it towards a specific biological function. 
4.6.1 APE1 transcriptional regulation 
The gene encoding the APE1/Ref-1 protein spans 2.6 kbp and maps to 
chromosome 14 bands q11.2–12 in the human genome [140][141]. The complete gene 
consists of four introns and five exons, the first of which is untranslated. The APE1/Ref-1 
promoter lacks a TATA box and, as many TATA-less genes [142], has multiple 
transcription start sites clustered around 130 bp upstream from the first splice junction, 
though the assignment of the major site is disputed. The functional basal promoter is 
approximately 300 bp and is located in a CpG island [141][143][144]. Several potential 
recognition sites has been reveled by in silico analyses: Sp-1, USF, CREB, ATF and AP-
1 [6][141]. However, as suggested by results of independent groups, AP-1 putative 
binding site seems not to exert any effect [141][145]. APE1 transcription is tightly 
coordinated with the cell cycle [146]: the mRNA levels increase before the onset of DNA 
synthesis, continue to rise during the S-phase of cell cycle and depend on a specific DNA 
element, which can be bound by Sp1 transcription factor. As shown in Figure 9, APE1 
promoter bears two distinct Sp1 binding sites, the first located close to the CCAAT box 
(Sp1-1), and the second located downstream of the transcription start site (Sp1-2). While 
Sp1-1 site is involved in basal gene expression, the Sp1-2 site is required for cell cycle 
coordinated APE1 gene transcription [146]. More recently, downregulation of APE1 
expression by p53 has been suggested. No p53 binding sites were revealed by in silico 
analysis; however it was hypothesized that p53 was indirectly recruited to APE1 promoter 
although the exact mechanism is still not clear. Zaky et al. proposed that p53 could 
physically interact with Sp1 bound to Sp1-1 element, inhibiting basal APE1 gene 
transcription [147]. This study suggests an intriguing hypothesis concerning an inverse 
relationship between the pro-apoptotic factor p53 and the expression of pro-survival 
factor APE1. The tumor resistance to chemotherapy observed in certain malignancies 
could be associated with an increase APE1 gene expression when p53 gene is mutated 
or downregulated.  
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Figure 9 - Schematic representation of APE1 gene promoter region.  
In the distal promoter region (between -3,000 and -1,000 bp relative to the transcription start site) there are three nCaRE 
elements; in the proximal promoter region (between -500 and +200 relative to the transcription start site), there are two 
Sp1 binding elements, an Egr-1 binding site and a CCAAT box. Moreover, several other putative binding sites for other 
transcription factors are also reported. (Image from Tell G. et al., Cell. Mol. Life Sci., 2010) 
APE1 expression is stimulated with hormones, such as TSH [148], or upon oxidative 
stress. Subtoxic doses of ROS strongly increase APE1 mRNA levels in different cell lines 
[149-151]. However, the molecular mechanism of ROS-induced transcriptional activation 
of APE1 is still under investigation. Two reports provided important indications about 
APE1-inducible transcriptional regulatory mechanisms; much work still remains to be 
done. By performing transfection experiments on CHO cells, Grosch and Kaina [152] 
identified a CREB binding site (CRE) approximately 600 bp upstream of APE1 
transcription start site. They discovered that this element is bound by a complex of ATF2 
and c-Jun and it is required for APE1 induction by ROS. Successively, it has been 
characterized a specific sequence on APE1 promoter, which could be directly bound by 
Egr-1 and that is involved in ROS inducible APE1 gene transcription [153].  
Finally, the upstream region of the promoter contains also negative regulatory 
elements: one negative calcium responsive element-A type (nCaRE-A) sequence and 
two nCaRE-B type sequences: B1 and B2 [139]. Deletion of the nCaRE-A sequence 
does not repress a reporter gene, suggesting that it may not be important for negative 
regulation. Conversely, the nCaRE-B2 element represses expression of the reporter 
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gene and interacts with APE1/Ref-1 to form complexes. These data suggest that 
APE1/Ref-1 can autoregulate by binding to its own promoter and inhibiting transcription.  
4.6.2 Post-translational modifications 
Post-translational modifications represent a quick and usually reversible way to 
regulate protein activities or functions. Concerning APE1 protein, knowledge of PTMs 
affecting APE1 function has grown exponentially in the last decade [3][21]. Several PTMs 
have been described occurring in vitro, but only a few having a function in vivo: 
acetylation, phosphorylation, ubiquitination, S-nitrosation, proteolytic cleavage of the N-
terminal 33 amino acids domain and redox regulation, which is at the basis of APE1 
redox activity (Figure 10). A detailed discussion of critical PTMs on APE1 can be found in 
Busso et al.’s review [21]. 
Phosphorylation 
APE1 has several putative phosphorylation sites for different kinases, like Casein 
Kinase 1 and 2 (CK-I and CK-II), Glycogen Synthase Kinase 3 (GSK-III) and Protein 
Kinase C (PKC). Yacoub et al. showed that in vitro phosporylation of APE1 by CK-II (at 
residues 19T, 123S, or 233T) inhibited endonuclease activity [154]; moreover, in vivo CK-
II mediated phosphorylation of APE1 was also suggested, even if not directly shown 
[155]. However, in vivo experiments performed using CK-II specific inhibitors didn’t 
Figure 10 - Schematic representation of the PTM acceptor sites on APE1 sequence. (Adapted image from Tell G. et 
al., Cell. Mol. Life Sci., 2010) 
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confirm in vitro results. In vitro PKC phosphorylation exerted no effect on the 
endonuclease activity of APE1, but was able to increase its redox activity, since it was 
found to enhance the in vitro binding of c-Fos and c-Jun to AP-1 binding elements. In 
agreement with these findings, in vivo studies by Hsieh et al. showed that, under 
oxidative stress conditions capable of stimulating PKC activity, APE1 phosphorylation 
level increased, stimulating its redox activity [156]. Despite the potential significance of 
APE1 phoshorylation, its biological relevance has not been investigated further. 
Acetylation 
APE1 acetylation has been studied fairly extensively. In 2004, Bhakat et al. [20] 
showed that APE1 was acetylated by histone acetyl transferase (HAT) p300. The same 
group achieved to generate an antibody specific to acetylated APE1 and confirmed its 
endogenous presence in vivo [71]. APE1 has 29 lysines, however, up to date, only 
lysines K6 and K7 have been identified as target of acetylation. Acetylation of these two 
lysine residues was associated to an increase APE1 DNA binding activity to nCaRE 
sequences, followed by repression of PTH gene in parathyroid cells and presumably of 
APE1 gene itself in different cell types.  
More recently, our group observed that other Lys residues within the APE1 N-
terminal domain, K24, K27, K31, K32, and K35, may undergo in vivo acetylation under 
basal conditions. Fantini et al. have previously demonstrated that these residues are 
crucial for APE1 interaction with rRNA and NPM1 and for modulating its catalytic activity 
on abasic DNA through regulation of product binding [85]. Very recently, we also 
demonstrated that K27, K31, K32, K35 are acetylated during genotoxic stress condition 
influencing APE1 subnuclear distribution [5] (see list of papers published during PhD 
course). In particular, we showed that genotoxic-induced acetylation of K27-35 
determines APE1 relocalization out of the nucleoli thus influencing DNA repair activity 
and cell proliferation. We demonstrated that cells expressing a specific K-to-A multiple 
mutant are APE1 nucleolar deficient and are more resistant to genotoxic treatment 
accordingly to an augmented APE1 enzymatic activity on DNA. Of interest, we also found 
that the charged status of K27-35 modulates acetylation at K6/K7 residues through a 
mechanism regulated by the sirtuin 1 (SIRT1) deacetylase. We found that SIRT1 is able 
to bind and possibly deacetylate APE1 K27-35 residues and that its ability to efficiently 
deacetylate APE1 K6/7 residues relies on the presence of positive charges at K27-35 
suggesting the existence of a cross-talk between the charged state of K27-35 and the 
acetylation status of K6/7. 
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If p300 has already been established as the main enzyme responsible for APE1 
acetylation in vivo, less information are available about the process of APE1 
deacetylation. Bhakat KK et al. were the first to suggest the involvement of a class I 
HDAC enzymes [20]. Recently, Yamamori T. et al. showed that acetylated APE1 may 
undergo deacetylation by means of a class III HDAC enzyme: SIRT1 [157]. Yamamori T. 
et al. demonstrated that SIRT1 deacetylates lysines 6 and 7 both in vitro and in vivo. 
Genotoxic insults stimulate lysine acetylation of APE1 which is antagonized by 
transcriptional upregulation of SIRT1. Activation of SIRT1 promotes binding of APE1 to 
the BER protein X-ray cross-complementing-1 (XRCC1) suggesting that SIRT1 plays a 
vital role in maintaining genome stability. 
Ubiquitination 
Ubiquitin is a highly conserved 76 amino acids polypeptide that can be covalently 
attached to target proteins in a three step-enzymatic reaction involving E1, E2 and E3 
ubiquitin ligases [158]. The attachment of a single ubiquitin to a target protein can alter its 
function or localization [159]; the tandem attachment of multiple ubiquitin to form a 
polyubiquitin chain can also alter function or localization, however it usually marks the 
substrate for degradation by the 26S proteasome. Busso C.S. et al. were the first to 
demonstrate that APE1 is target of ubiquitination in vivo. They discovered that the E3 
ligase MDM2 (murine double minute 2) can carry out the APE1 ubiquitination reaction 
both in vitro and in vivo, and showed that the target site should be one among the 
residues K24, K25 and K27 [160]. MDM2 is the most important negative regulator of the 
p53 tumor suppressor. Under basal conditions, MDM2 ubiquitinates p53 protein through 
direct interaction and addresses it to proteosomal-mediated degradation pathway. Upon 
genotoxic stress, MDM2-p53 interaction is prevented through multiple mechanisms such 
as phosphorylation and acetylation of p53, or induction of ARF expression, which is in 
turn able to sequester MDM2 in the nucleolus. Even if MDM2 is by far the most crucial 
regulator for p53, it is able to recognize and ubiquitinate other substrates, such as histone 
H2B [161], protein component of hnRNP K [162] and FOXO4 [163]. In later years, Busso 
et al. further deepen into APE1 ubiquitination process and reported that there is a 
delicate balance between ubiquitination and phosphorylation of APE1. They 
demonstrated indeed that ubiquitination activity of MDM2 is increased for T233E APE1, a 
mimicry of phospho-T233 APE1. They showed that monoubiquitinated APE1 was present 
in the nucleus and through global gene expression profiles with or without induction of a 
ubiquitin-APE1 fusion gene they also suggested that monoubiquitination enhanced the 
gene suppression activity of APE1.  
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However, even if evidences of APE1 ubiquitination in vivo were obtained, much 
work has to be done in order to understand many unclear aspects concerning the 
occurrence of this PTM. In fact, despite the observation of Busso and co-workers of 
MDM2 involvement, very recently Meinsenberg et al. using an in vitro ubiquitylation 
assay, purified the human E3 ubiquitin ligase UBR3 as a major enzyme that 
polyubiquitylates APE1 at multiple lysine residues clustered on the N-terminal tail [164].  
4.6.3 Proteolytic cleavage 
APE1 was found to undergo a very peculiar proteolytic PTM, which generates a 
protein lacking the first N-terminal 33 or 35 amino acids. First in vivo evidences of such a 
PTM were reported by Yoshida A et al., who purified a 34-kDa, Mg2+ dependent 
endonuclease, from apoptotic human promyelocytic leukemia HL-60 cells treated with 
etoposide [165]; only 5 years later, the same group discovered that this enzyme was just 
a truncated form of APE1, lacking a N-terminal portion spanning 33 amino acids 
(NΔ33APE1) obtained by an unidentified trypsin-like enzyme, activated by caspase-3 
during apoptosis [166]. 
Successively, the truncated form of APE1 was discovered to be also involved 
during a granzyme-induced caspase-independent type of apoptosis. Granzymes are 
serine proteases, released by cytotoxic T cells and natural killer cells, whose function is 
to induce cell death within virus-infected cells [167]. Granzyme A (GzmA) activates a 
caspase-independent cell death pathway with morphological features of apoptosis. 
Single-stranded DNA damage is initiated when the endonuclease NM23-H1 becomes 
activated to nick DNA after granzyme A cleaves its inhibitor, SET. SET and NM23-H1 
reside in an endoplasmic reticulum-associated complex (the SET complex) that 
translocates to the nucleus in response to superoxide generation by granzyme A [168]. 
Fan et al. reported APE1 binds to GzmA and is contained in the SET complex. GzmA 
cleaves APE1 after Lys31 and destroys its known oxidative repair functions. In this way, 
GzmA may block cellular repair and force apoptosis [169]. An APE1 role within the SET 
complex in preventing HIV autointegration was also recently demonstrated [170]. It has 
been suggested that the formation of the truncated form of APE1 protein could be 
induced during different cell death pathways, and could exert a nuclear function by 
contributing to the accumulation of single strand breaks on DNA molecules. However, 
some aspects still remain to be elucidated concerning NΔ33APE1 function. In fact, it is 
known from early studies on different APE1 deletion mutants, that the NΔ33APE1 keeps 
both redox and AP endonuclease activities [121], without acquiring a general nuclease 
activity. Furthermore, it is to be clarified the mechanism by which NΔ33APE1 could be 
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translocated to the nucleus of the apoptotic cell since the truncated protein lacks both 
nuclear localization signals, previously identified by Jackson E.B. et al. [171]. Since it has 
been associated with cell death, this peculiar irreversible APE1 PTM is extremely 
intriguing but unfortunately several studies are needed to solve many questions regarding 
the identification of the protease, of the stimuli that induces such PTM, and the effects of 
this modification on APE1 subcellular localization and function. 
S-nitrosation 
S-nitrosation is a ubiquitous redox-related modification of cysteine thiols by nitric 
oxide. S-nitrosation has been implicated in the regulation of gene transcription [172], 
enzymatic activity [173], and protein intracellular trafficking [174]. 
Qu J. et al. discovered that APE1 can undergo S-nitrosation at Cys93 and Cys310 
after S-nitroglutathione treatment and this PTM can induce a complete exclusion of APE1 
from cell nucleus [175]. APE1 can inducibly translocate from nucleus to cytoplasm in 
response to nitric oxide stimulation. The mechanism of nuclear export is not the canonical 
one, since it resulted to be Exportin1-independent, and requires further analysis. Since 
the alteration of APE1 subcellular localization may result in defects in DNA repair and 
redox APE1 functions, this finding may establish a novel role for APE1 in NO-related 
physiological and pathological processes. Moreover, it has been reported that redox 
modification of Cys310 of APE1 can repress its AP endonuclease activity [176]. Thus it is 
reasonable to expect that also NO may exert influence on APE1 DNA repair function 
through S-nitrosation of this site. Very recently, it has been demonstrated that the 
augmented APE1 S-nitrosation induced its cytoplasmatic relocalization in various lung 
cancer promoting malignancy via NF-κB activation by p53 aberration and resulting in 
poor outcome in non-small cell lung cancer (NSCLC). These results underline the 
importance of S-nitrosation in determining APE1 cytoplasmatic distribution that has been 
observed in some human tissues. However, it remains to clarify which stimuli and which 
transduction pathways could lead to NO production and induce a nuclear exclusion of 
APE1.  
4.7 Modulating APE1 activities as a cancer therapeutic approach 
APE1 relevance in normal and tumor cell survival is demonstrated by the fact that 
knocking out APE1 gene induces either activation of apoptosis in differentiated cells [81] 
or developmental failure during embryogenesis [177]. Thus, due to the fundamental role 
played by APE1 within cells, it was then hypothesized its involvement in human 
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pathologies. Accumulating evidences have demonstrated that the heterogeneity of APE1 
expression pattern is associated to different pathologies conditions ranging from 
metabolic to differentiative disorders, including cancer and neurodegenerative diseases. 
Upregulation or dysregulated APE1 expression has been found in a variety of cancers 
including prostate, pancreatic, ovarian, cervical, germ cell tumor, rhabdomyosarcoma and 
colon [23][129]. Elevated APE1 levels are typically associated with aggressive 
proliferation, increased resistance to therapeutic agents, and poor prognosis [26]. 
Anomalous intracellular localization of APE1 is also be correlated with human cancer. 
Generally, APE1 is mainly localized in the nucleus while in several carcinomas a nuclear, 
cytoplasmatic, and nuclear/cytoplasmatic staining was observed [178]. This peculiar 
localization correlates with aggressiveness and prognosis of the tumor. In fact, in tumors 
where APE1 expression is mainly nuclear there is always a positive correlation with 
better prognostic features; while an APE1 cytoplasmatic localization, as observed in 
hepatocellular carcinoma, is associated with a significant lower degree of differentiation 
and with a shorter survival time. Furthermore, several studies have shown that 
decreasing APE1 levels by using specific anti-sense oligonucleotides and siRNA leads to 
the blockage of cell growth and to an increase of cellular sensitivity to DNA-damage 
agents such as methylmethanesulfonate (MMS), H2O2, bleomycin, temozolomide (TMZ) 
and gemcitabine [179-182].  
Considering that APE1 expression appears to be linked to chemoresistance, APE1 
is altered in a variety of cancers as well as in multiple myeloma [183], and, in addition, 
given that APE1 plays an important role in the tumor microenvironment through the 
regulation of HIF-1α both in normal and cancer-associated endothelial cell function, APE1 
represents a promising target for pharmacological treatment. However, it still debates 
whether the enhanced sensitivity to cytotoxic agents observed when APE1 functions are 
blocked is solely due to the loss of APE1 DNA repair activity or also due to the loss of its 
transcriptional regulatory function or both. Efforts to determine the effects of inhibiting 
either the redox or repair function of APE1 are ongoing. 
A list of published APE1 inhibitors of DNA repair or redox function is reported below 
(Figure 11). A description of all the compounds is far beyond my scope, for an exhaustive 
reviewed of APE1 inhibitors, the readers is redirected to [23][184]. 
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Figure 11 - Published inhibitors of each function are listed below as well as the effects of APE1 siRNA on tumor 
cell viability and function. (Adapted image from Vascotto C. and Fishel M., Academic Press, 2012) 
Briefly, as concern the blockade of APE1 DNA repair activity, this will result in an 
accumulation of DNA damage, especially if paired with a chemotherapeutic agent that 
generates DNA base damage leading to tumor cell death. It is well clear that since both 
short- and long-patch BER pathways contribute to the maintenance of genomic integrity 
in cells, manipulation of the processing of these pathways has the potential to shift the 
balance from repair to apoptosis or cell death, a favorable outcome in tumor cells. Many 
chemotherapeutic agents kill cancer cells by damaging their DNA, therefore inhibiting the 
action of BER in cancer cells could render them more sensitive to these agents. Several 
chemotherapeutic agents generate lesions that are subject to BER pathway, including 
TMZ, melphalan, thiotepa, methyl-lexitropsin (Me-lex), dacarbazine/procarbazine, and 
streptozotocin [26]. More recently, it has become clear that some chemotherapeutic 
agents generate ROS secondary to their primary mechanism of action. BER proteins are 
the predominant mechanism to cope with the oxidative DNA damage. 
Chemotherapeutics such as platinum-based drugs, anthracyclines, i.e. daunorubicin, 
doxorubicin, and paclitaxel generate ROS, indicating that BER may play a role in cellular 
response to these drugs even though they have not been considered to generate single 
base lesions. Another frequent treatment modality in cancer is ionizing radiation (IR) and 
BER is one of the DNA repair pathways that contributes to the repair of the DNA damage 
generated. 
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Small molecule inhibitors have been identified for several other DNA-repair 
enzymes, including MGMT, poly ADP-ribose polymerase (PARP1), ataxia–telangiectasia 
mutated kinase (ATM kinase) and DNA PKCs [26]. Inhibitors of DNA repair of APE1 are 
under development. They can be distinguished in two classes of molecules: molecules 
like methoxyamine (MX) which binds to aldehyde in the AP site on DNA and stops APE1 
in performing its endonuclease activity, and small molecules that would directly bind to 
APE1 and inhibit activity on AP site-containing DNA (Figure 11). 
Inhibition of APE1’s redox activity in promoting cancer cell death and inhibition of 
tumor cell growth is a novel approach that has been unexplored to date. The redox 
activity of APE1 affects the DNA binding activity of several crucial transcription factors in 
cancer survival and growth signaling pathways. Transcription factors including HIF-1α, 
p53, NF-κB, CREB, and AP-1 have all been implicated in major aspects of cancer 
survival, including angiogenesis and tumor promotion and progression. Therefore, 
targeting APE1’s redox activity would render these transcription factors unable to bind to 
DNA, thereby halting tumor cell signaling of angiogenesis and uncontrolled growth and 
possibly impairing the tumor’s ability to respond to hypoxia and nutrient deprivation and 
thereby sensitize the tumor to chemotherapeutic agents.  
The most selective and well-characterized APE1 redox inhibitor is the naptho-
quinone compound, E3330 (2E-3-[5-(2,3dimethoxy-6-methyl-1,4-benzoquinolyl)]-2-nonyl-
2-propenoic acid). Previous studies demonstrated that the quinone derivative E3330 
selectively inhibited NFκB-mediated gene expression without affecting any other 
regulatory steps such as phosphorylation or translocation to the nucleus [185]. 
Successively, it has been demonstrated that E3330 blocks the redox function of APE1 
with AP-1 as the downstream target in vitro, as well as after the treatment of ovarian 
cancer cells with E3330 [186]. Additionally it has been found that E3330 blocks APE1 
redox activity with HIF-1α and other downstream transcription factors. This demonstrates 
that the redox inhibition is not specific for the downstream target. Although E3330 blocks 
the redox function of APE1, it has no effect on APE1-repair endonuclease activity or BER 
activity of an AP site. Kelley’s group has extensively characterized the effect of E3330 on 
APE1 redox activity in cancer cell lines and endothelial cells as well as developing more 
potent analogs (RN8-51) demonstrating a new role of APE1 in angiogenesis, and 
inhibition of APE1 redox function by E3330 abrogates this role [186]. E3330 also has 
been shown to inhibit the growth of pancreatic cancer cell lines, an effect that is 
enhanced under hypoxic conditions [187], as well as pancreatic cancer–associated 
endothelial and endothelial progenitor cells [181]. 
In addition to E3330, a number of natural products reported to affect either directly 
or indirectly the redox function of APE1 in cells were recently reviewed [26][188]. Among 
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those, soy isoflavones [189][190] and resveratrol [191][192] have reported activity against 
the redox activity of APE1 (Figure 11). Soy isoflavones, a component in soybeans, are 
thought to have potential as chemopreventive agents in prostate cancer [193]. 
Resveratrol was shown to inhibit both the endonuclease activity of APE1 and the DNA-
binding activities of AP-1 in cellular extracts, presumably through inhibition of APE1 redox 
function. However, there are conflicting reports regarding this compound’s efficacy for 
inhibition of APE1, since it has not been corroborated by others, nor it has been shown to 
be effective at levels that are physiologically relevant. 
Thus, collectively all these data demonstrated that targeting APE1 DNA repair activity 
and/or redox function will have important implications for human health and cancer 
therapeutic development. 
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4.8 nCaRE sequences: features and functioning of a negative 
regulative mechanism 
Okazaki and co-workers firstly identified and characterized a pair of negative 
regulatory elements between 2.4 and 3.6 kbp upstream the transcription start site of the 
human parathyroid hormone (hPTH) gene [16]. They evidenced the negative regulatory 
function of these elements showing a reduced chloramphenicol acetyltransferase (CAT) 
activity when transfecting various types of cultured cells (BHK, CV1 and NIH3T3) with a 
fusion plasmid containing the 4.7 kilobase pairs of the 5’-flanking portion of the hPTH 
gene linked to CAT-coding sequence. Further deletion analyses clearly revealed that 
there were two separate upstream DNA elements in the hPTH gene promoter 
responsible for the negative regulation observed and gel retardation experiments, 
performed with nuclear extract from BHK or CV1 cells, demonstrated that both these 
elements were bound by common nuclear factors. Successively, the same authors, 
through Southwestern cloning were able to identify APE1 as one of the proteins involved 
in the specific binding of these sequences [136]. In particular, they also showed that 
hPTH gene suppression was dependent to extracellular calcium concentration levels 
demonstrating that higher Ca2+ concentration increased APE1 binding activity to these 
sequences. Since this mechanism of negative regulation depends on extracellular 
calcium levels, these sequences were called nCaRE standing for negative calcium-
responsive element.  
After the first evidence of a negative regulation mechanism for PTH, Okazaki et al., 
showed that the expression of other genes was negatively regulated by extra-cellular 
calcium through the analogous nCaRE sequence [194]. Searching for the DNA sequence 
homologous to the nCaRE-PTH, by using the EMBL gene bank, they found that other five 
genes bear DNA sequences that were identical or very similar to the nCaRE-PTH in their 
5'-flanking regions: the mouse myeloperoxidase, the human ATP synthase beta subunit, 
the human endogenous retrovirus-like sequence (HuERS-P1-2) 5’-LTR, the rat 
vasopressin and the rat atrial natriuretic polypeptide (ANP).  
Atrial natriuretic peptide (ANP) hormone is released by atrial myocytes in response 
to high blood pressure which acts to reduce the water, sodium and adipose loads on the 
circulatory system, thereby reducing blood pressure [195]. Okazaki et al. demonstrated 
that the rat ANP gene, was negatively regulated in the heart by extracellular calcium by 
using an in vivo infusion system comparing by Northern blot analysis the level of ANP 
mRNA obtained from the heart rat infused with calcium-free solution to that infused with 
calcium-containing solution [194]. Furthermore, transfection of BHK cells with a reporter 
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gene containing the nCaRE element found on ANP promoter confirmed that this DNA 
functions as a negative calcium-responsive DNA element. 
Hence, the presence of nCaREs in the regulatory region of APE1 gene itself has 
been showed suggesting a possible mechanism for its own homeostatic regulation [139]. 
Analysis of APE1 sequence promoter revealed the presence of three nCaRE sequences: 
one nCaRE-A type sequence which is identical in 11 out of 13 internal bases to the 
element 1 of the PTH gene and two nCaRE-B sequences, denoted nCaRE-B1 and 
nCaRE-B2, with a 2 base pair gap, and a gap along with a mismatch relative to the 
element 2 of the PTH gene, respectively. Analysis of APE1 promoter activity by transient 
expression of the luciferase reporter gene in human HeLa and TK6 cells displayed that 
only the two nCaREB-like sequences were responsible for inhibiting reporter gene 
expression while no repression of luciferase reporter was observed for nCaRE-A, 
suggesting that this element may not be essential for the negative regulation of APE1. 
Competitive electrophoretic mobility shift assay with HeLa nuclear extract indicated that 
the nCaRE sequences of the APE1 and PTH genes were recognized by the APE1 
polypeptide. These results suggested that the APE1 gene may regulate its own 
expression product. However, conversely to the original work of Okazaki in which the 
expression of PTH was affected by altering extracellular Ca2+ level in parathyroid cells, in 
this work, Izumi et al., did not show if APE1 protein binds to its promoter in a Ca2+–
dependent fashion. 
In later years, Fuchs et al. identified the molecular mechanism by which the human 
renin gene is negatively regulated in chorio-decidual cells by calcium increase in the 
same way as described for PTH, through APE1 binding to nCaRE [138].  
Renin, also known as angiotensinogenase, is an aspartic acid protease secreted by 
juxtaglomerular cells of kidneys, that participates in the body's renin-angiotensin system 
(RAS) that mediates extracellular volume (i.e., that of the blood plasma, lymph and 
interstitial fluid) and arterial vasoconstriction thus regulating the body's mean arterial 
blood pressure [196]. 
Analysis of the human renin proximal promoter led to the identification of a nCaRE 
element (-1781bp), which is identical to the region of the PTH promoter. Transfection 
experiments in renin-expressing chorio-decidual cells demonstrated the transcriptional 
functionality of the human renin promoter nCaRE. Validation of the involvement of 
nCaRE in the negative regulation of human renin came also by additional analysis in 
which mutation of nCaRE, as performed in the PTH promoter by Okazaki [16], 
suppressed sensitivity of the renin promoter to the increase in intracellular calcium. Gel 
shift assays confirmed that also in chorio-decidual cells the nuclear factor involved in 
nCaRE sequence binding is APE1, and furthermore, immunohistochemistry localization 
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of APE1 in chorio-decidual cells allowed suggesting that an increase in Ca2+ 
concentration induces the translocation of Ref-1 from the cytoplasm to the nucleus.  
4.8.1 Molecular features of nCaRE sequences 
The sequence of the two nCaRE elements originally found by Okazaki et al. were 
determined exposing the DNA-protein mixtures to DNase I and analyzing the footprints of 
the retarded bands after electrophoresis [16]. In Figure 12 are shown the footprinting 
results of Okazaki and the relative sequence composition of the two elements. They 
showed that several regions present in element 1 and one region in element 2 were 
protected from DNase I digestion. These sites present in AT-rich regions of the element 1 
and in a cluster of 17 thymidines in the element 2. The sequence of the most clearly 
delineated footprinting on the element 1 is GCATACACAA. The protected region in the 
element 2 consists of 12 palindromic bases in a 15-residue sequence, 
TGAGA(AGG)GTCTCA; the three bases in the parentheses were not protected from 
DNase I digestion. These two sequences were then distinguished as nCaRE-A (element 
1) and nCaRE-B (element 2). Okazaki et al. demonstrated other peculiarities of these 
elements which were both bound by the same nuclear complexes: nCaRE-A functions as 
a negative transcriptional element when present in both orientations on PTH promoter, 
while nCaRE-B functions only in the native orientation. Furthermore, when the 4 
thymidines preceding the palindromic nCaRE-B are removed, this oligonucleotide does 
not bind to APE1 protein-complex anymore suggesting that not only the palindrome but 
also these thymidine-rich sequences play important roles in the negative gene regulation. 
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Figure 12 - DNase I footprinting analysis of nCaRE element found on PTH promoter. 
 Original footprinting analysis of element 1 (A) and element 2 (B) performed by Okazaki et al.. DNA sequences protected 
from DNase I digestion are indicated on the right side of each gel. (Image from Okazaki T. et al., J. Biol. Chem., 1991) 
After the first discovery of nCaRE sequences in PTH gene promoter, other nCaRE 
elements were described [19][139][138]. Figure 13 reports the three nCaRE elements 
found on APE1 promoter which are not identical in bases composition with respect to 
those found in the PTH promoter as shown by the alignments [139]. The nCaRE-B 
element identified within the APE1 promoter where denoted nCaRE-B1 and nCaRE-B2 to 
distinguish them from that of PTH. Both nCaRE-B1 and nCaRE-B2 are bound by APE1 
and are responsible for inhibiting reporter gene expression. This finding denotes that 
even in the presence of a variation in the nCaRE sequence, APE1 binding is still possible 
and therefore it means that this type of binding is not only sequence-dependent but could 
involve also a recognition mediated by the secondary structure adopted by these 
elements. 
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Figure 13 - Characterization of nCaRE sequences found on APE1 promoter. 
Sequence similarity of nCaRE sequences found on PTH and APE1 promoters. Arrows within nCaRE-B’s indicate 
inverted repeats. (Modified imagine from Izumi T. et al., Biochemistry, 1996) 
4.8.2 Origin of nCaRE elements in an ALU-Repeat 
In 1995 McHaffie and Ralston evidenced the origin of the nCaRE-B sequences in 
an ALU-repeat thus suggesting that other nCaRE elements might also exist, raising the 
possibility that nCaRE binding may be a common mechanism by which extracellular 
calcium regulates gene transcription [197].  
ALU repeats belong to SINE (short interspersed nucleotide elements) family of 
repetitive sequences. Detailed sequence analysis of the structure of ALU element RNAs 
has indicated that the ALU elements were ancestrally derived from the retrotransposition 
of the small cytoplasmic 7SL RNA, a component of the signal recognition particle [198]. 
The event of reverse-transposition of a copy of the 7SL RNA is an evolutionarily recent 
event that coincided with the radiation of primates in the past 65 million years [199]. 
When McHaffie et al. analyzed the 7SL RNA sequence, they found an nCaRE 
"core" sequence in reverse orientation lying immediately upstream of the poly-A tail. They 
envisaged a mechanism by which nCaRE-B is derived from retrotransposition of 7SL 
RNA and forms an integral part of many ALU elements. Figure 14 describes how during 
the process of reverse transcription, poly-T residues are added adjacent to the nCaRE 
core. If the insertion of the ALU into the genome occurs in the opposite orientation, this 
does not result in a functional nCaRE. 
ALU elements have been broadly classified into three subfamilies: Old (ALU Js), 
Middle (ALU S) and the Youngest (ALU Ys) [200][201]. Beside nCaRE, ALUs have been 
shown to harbor a number of other regulatory sites [202]. Table 2 displays the positional 
conservation of the regulatory sites across all subfamilies in which they are represented. 
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The regulatory elements are most abundant in the middle subfamilies and least 
represented in the younger ALUs. Very interestingly, nCaRE are present in older and 
middle ALUs but poorly represented in the younger as well as polymorphic ALUs. This is 
very curious since nCaRE are also present in ancestral progenitor of ALU, the 7sl RNA.  
Figure 14 - Suggested mechanism of ALU formation from 7SL RNA retrotransposition.  
Described is the proposed sequence of events whereby the 7SL RNA is reverse transcribed and reinserted into genome 
in reverse orientation, giving rise to an nCaRE element at the 5’ end of an ALU repeat. (Image from McHaffie G.S. and 
Ralston S.H. Bone, 1995) 
Another intriguing features of ALU is that their distribution has been shown to be 
non-random in the human genome [203-205] and increasing evidences show that these 
elements are implicated in different functions such as transcription, translation, response 
to stress, nucleosome positioning and imprinting. A retrospective analysis of putative 
functional sites of various evolutionary aged ALU, such as the RNA pol III promoter 
elements, pol II regulatory elements like hormone responsive elements and ligand-
activated receptor binding sites, demonstrated a progressive loss of the RNA pol III 
transcriptional potential with concomitant accumulation of RNA pol II regulatory sites 
[202]. Moreover, it has been observed a significant over-representation of ALUs 
harboring these sites in promoter regions of signaling and metabolism suggesting that 
ALU elements, through retrotransposition, could distribute functional and regulatable 
promoter elements, which in the course of subsequent selection might be stabilized in the 
genome. In this way ALUs could thus have contributed to evolution of novel regulatory 
networks of preexisting gene in primate genome. 
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Table 2 - Position of regulatory sites analyzed in ALU repeats in various subfamilies. (Shankar R. et al., BMC Evol. 
Biol., 2004)  
4.8.3 Proteins involved in nCaRE recognition 
Through Southwestern cloning, Okazaki et al. demonstrated the presence of APE1 
in the nCaRE binding complex; however, they also suggested that APE1 alone could not 
explain all the features of nCaRE-binding activity postulating the existence of another 
nuclear protein(s) that could cooperate with APE1 for functional binding. This was 
particularly evident from gel shift assay in which they revealed two nCaRE-protein 
complexes when using smaller amounts of HeLa nuclear proteins (6-15 μg) [136]. The 
lower retarded complex co-migrated with APE1-nCaRE complex. In this condition, 
addition of recombinant APE1 protein to the HeLa nuclear proteins increased the binding 
of both nCaRE-protein complexes at almost the same positions. Since APE1 alone could 
not produce the slower migrating complex, Okazaki et al. suggested that APE1 may form 
a heterodimer with another nuclear protein to efficiently bind to nCaREs. 
By the employment of oligonucleotide affinity column and amino acid 
microsequencing, in a later work, the group of Okazaki identified another partner of 
nCaRE binding: the Ku Antigen (KuAg) [18]. The Ku antigen is a heteromeric 
(Ku70/Ku80) protein that participates in multiple nuclear processes from DNA repair to 
V(D)J recombination to telomere maintenance to transcriptional regulation and serves as 
a DNA binding subunit and allosteric regulator of DNA-dependent protein kinase [206-
209].  
Chung et al. demonstrated that both subunits of KuAg, p70 and p80, interact with 
the N-terminal portion of APE1 to bind nCaRE-A sequence. In particular they evidenced 
that KuAg binds to nCaRE-A in a cooperative manner with APE1, giving rise to a 
reinforced binding specificity, respect to the less stringent binding observed for the 
purified KuAg alone. Electromobility shift assay (EMSA) showed the formation of two 
migrating complexes bound to nCaRE-A. Differential silencing of p70 and p80, allowed to 
demonstrate that there are two distinct steps in the formation of these two complexes in 
which p70 and p80 act separately. At first, APE1 and p80, but not p70, take part in the 
formation of the complex with higher molecular weight; then, there is shift to a second 
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complex in which p70 cooperates with APE1. Notably, this second complex with a higher 
mobility contained both the subunits and the reassociation of these both subunits of KuAg 
was predicted to be essential for the transcriptional suppression mediated by Ca2+ since 
an abrogation nCaRE-mediated transcriptional repression by Ca2+ was observed only in 
the case of combined silencing of both p70 and p80. 
Similarly to the situation of nCaRE-A-binding complex, which was shown to include 
APE1 together with KuAg protein, Kuninger et al., utilizing DNA affinity chromatography, 
eluted the protein hnRNP-L bound to nCaRE-B2 sequence in association with APE1 [17]. 
Heterogeneous nuclear ribonucleoprotein L (hnRNP-L) belongs to hnRNP family, which 
consists of about 20 members that are stably associated with heterogeneous nuclear 
RNAs, pre-mRNAs, which required extensive post-transcriptional processing to generate 
mature mRNAs [210]. hnRNP complexes were described to be involved in the formation, 
packaging, processing, and function of mRNA. Identification of this protein bound to 
nCaRE sequence was therefore completely unexpected even if different studies 
suggested broader and unrelated functions for hnRNP proteins, e.g. in transcriptional 
regulation of gene expression and other cellular processes[211][212]. hnRNP-L binding 
with nCaRE-B2 sequence was verified by EMSA analysis and by reconstitution of the 
nCaRE-B2 binding activity. Consistent with data reported by Okazaki, recombinant 
protein alone displayed a weak binding activity toward nCaRE-B. However, this binding 
was increased in presence of HeLa nuclear extract suggesting that some other 
component are required for the ideal complex formation. Furthermore, Kuninger et al., 
demonstrated by GST-pull down assay, that the interaction between APE1 and hnRNP-L 
was not dependent on the presence of nCaRE elements indicating that these proteins 
could be complexed in vivo in the absence of the nCaRE-B2 oligo. The hnRNP-L 
polypeptide contains a stretch of basic amino acids similar to those found in the 
transcription factors HLF, c-Fos and c-Jun. The N-terminal redox domain of APE1 has 
been shown to be required for reductive activation of these transcription factors at 
specific, conserved cysteine residues in these proteins [213][214]. It has been proposed 
that this region may function as an interaction domain that mediates the coupling of 
hnRNP-L and APE1 without implicating a reductive activation of hnRNP-L, as the 
conserved cysteine in hnRNP-L is replaced by arginine. This would involve an interaction 
of the N-terminal region of APE1 with a region near the C-terminus of hnRNP-L. This 
model is consistent with the interaction between APE1 and Ku70/Ku86, which has been 
shown by Chung et al. [18] to require the N-terminal region of APE1, i.e. the region 
encompassing the redox domain. Chung et al. identified a sequence, AALCR, 
corresponding to residues 395–399 in Ku70, which is involved in this interaction. This is 
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compatible with Kuninger’s proposal that this region may function as a common protein–
protein interaction domain for APE1. 
The inability of the recombinant APE1 alone to bind to nCaRE-A or nCaRE-B in the 
PTH promoter indicated a requirement for additional factors in the complexes. Later 
studies demonstrated that APE1 binding to nCaRE sequences on PTH promoter is 
influenced not only by other proteins but also by the acetylation status of APE1 itself [20]. 
Treatment with Ca2+ significantly increased APE1 acetylation in BHK-21 cells, which 
could explain the original observation that an increase in Ca2+ enhanced the binding 
activity of BHK-21 cell extract for nCaRE-B [136]. Bhakat et al., indeed, showed that 
APE1 is acetylated in vivo and in vitro by the transcriptional co-activator p300 which is 
activated by Ca2+. Mass spectrometric analysis confirmed APE1 acetylation and indicated 
that this modification occurs preferentially on Lys 6 and Lys 7 in APE1 N-terminal 
domain. They observed an increased HAT activity of p300 upon Ca2+ treatment and 
suggested CAM kinase IV as the kinase responsible for Ca2+-dependent activation of 
p300 HAT. Acetylation of APE1 at Lys6/7 by p300 resulted in an increased APE1 binding 
to nCaRE-B on PTH promoter. Moreover, the authors found that APE1 
immunoprecipitates with class I HDACs (HDACs 1-3) and the acetylation status of APE1 
is not essential for the stable binding of the two proteins. Interaction of APE1 with HDAC 
1-3 could at least partially explain how APE1 acts as a transcriptional repressor. Based 
on their results, Bhakat et al. proposed a model for Ca2+-dependent repression of the 
PTH gene. APE1, present partly as the APE1-HDAC complex in vivo, is unacetylated. A 
rise in Ca2+ increases the HAT activity of p300, which then acetylates APE1. Acetylation 
stimulates association of APE1 with its partner hnRNP-L, and binding to nCaRE-B in the 
PTH promoter. This promoter-bound repressor complex turns off PTH transcription by 
deacetylating histones in the promoter region. Finally, deacetylation of AcAPE1 by HDAC 
in the nCaRE complex reduces APE1's affinity for hnRNP-L (and possibly other proteins) 
in the nCaRE-B complex; subsequent release of APE1 from the complex leads to 
restoration of transcription. Thus the negative feedback regulation is mediated by the 
acetylation/deacetylation cycle of APE1. 
Another described APE1 partner of nCaRE binding is Poly (adenosine diphosphate-
ribose) polymerase 1 (PARP-1) which was identified by Bhattacharyya et al. in the 
context of gastric epithelial cell (GEC) infected by Helicobacter pylori [19]. Bhattacharyya 
et al. evidenced a negative calcium responsive element (nCaRE-B) in the human Bax 
promoter. Bax (Bcl-2–associated X protein), is a protein of the Bcl-2 gene family that 
promotes apoptosis by competing with Bcl-2. Upon initiation of apoptotic signaling, Bax 
undergoes a conformation shift which determines its shuttling from the cytoplasm where, 
under basal condition it is found, to the outer mitochondrial membrane where it can 
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induce the release of cytochrome c and other pro-apoptotic factors from the 
mitochondria, leading to activation of caspases. H. pylori infection enhances Bax 
expression [215] determining GEC death which can finally be the cause of gastritis, 
duodenal and gastric ulcer and gastric cancer [216]. Bhattacharyya et al. provided 
evidences that, in the context of H. pylori infected GEC, APE1 manifests antiapoptotic 
properties suppressing bax expression through the binding of nCaRE sequence on bax 
promoter (Figure 15).  
Figure 15 - APE1 acetylation suppresses H. pylori-mediated apoptosis in GEC by negative regulation of Bax 
transcription.  
H. pylori infection induces an increase in Ca
2+
 which promotes nuclear translocation of APE1. Ca
2+
 and ROS promote 
p300 binding to nuclear APE1 leading to APE1 acetylation. ac-APE1 binds to the nCaRE present in the Bax promoter 
and attracts HDAC-1 thus repressing Bax transcription mediated by p53; PARP-1 recruits the repressor complex to the 
Bax nCaRE. (Image from Bhattacharyya A. et al., Gastroenterology, 2009) 
 
In particular, in this work it has been proposed that H. pylori infection of GEC induces an 
increase in the intracellular levels of Ca2+ which in turn augment APE1 acetylation at Lys 
6/7 by p300 increasing APE1 binding to bax nCaRE leading to a reduced bax expression. 
Repression of bax transcription is due to the formation of a multiprotein repressor 
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complex. They reported that PARP-1 binds directly to nCaRE-B on bax promoter and 
recruits the acetylated APE1 (ac-APE1)/HDAC-1 repressor complex. Further studies are 
needed to demonstrate that PARP-1 binding to nCaRE is specific for GEC or occurs in all 
cell types. 
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5 Results 
Data reported in this chapter have been the subject of a submitted publication: Antoniali 
et al., SIRT1 gene expression upon genotoxic damage is regulated by APE1 through 
nCaRE-promoter elements 
 
5.1 Bioinformatic searching for nCaRE sequence-containing 
genes reveals SIRT1 gene as a novel candidate target of 
APE1 regulation 
Systematic searching for functional nCaRE sequences on human genome would 
provide new insights into APE1 multifunctional roles and in particular it could help in 
defining new genes whose expression may be potentially regulated by APE1 through 
nCaRE binding. To this aim, bioinformatic analysis for the systematic retrieval of 
functional nCaRE sequences in the human genome was carried out filtering through 
biological data obtained in our previous work, in which changes of gene expression 
profile, associated with the loss of APE1 expression, were analyzed through microarray 
analysis [53]. Here, I developed a method that integrates different approaches aiming to 
address the problem on a whole genome scale while minimizing the number of false 
positives. To this purpose, classical DNA pattern matching studies were integrated with 
independent information on gene regulation. Three main sources for data filtering were 
used: i) functional annotation data collected in GO; ii) gene expression data derived from 
the microarray profile of APE1 knock-down HeLa cells [53]; iii) human-mouse gene 
sequence comparisons. In fact, both expression data and functional annotation database 
are known to provide a wealth of information about co-regulation. This is of particular 
interest, since co-regulated genes likely share similar transcriptional regulatory 
mechanisms. At the same time, comparison with orthologous gene promoters highlighted 
sequences retained during evolution, whose conservation suggests their potential 
functionality. As a final result, a set of genes that passed the previously mentioned filters 
were obtained and might be considered bona fide as candidates co-regulated through 
nCaRE sequences (Figure 16A).  
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Figure 16 - Bioinformatic research of nCaRE sequences on human genome.  
Panel A. Schematic representation of the pipeline steps used for the identification of putative nCaRE elements within the 
human genome.  
Panel B. Results obtained from the application of the different filters. Upper panel, data derived from alignment research 
of nCaRE sequences on human gene promoters and the subsequent cross-check with microarray data. Bottom panel, 
final results deriving from the combined Gene ontology and phylogenetic footprinting analyses. 
Experimentally, 6000 bp upstream regions of all human and mouse protein coding 
genes were collected. The extension of the chosen region was based on the knowledge 
of the localization of previously identified nCaRE elements [16][138][139]. Although 
nCaRE elements seem to be active also at downstream regions [139], I focused only on 
the upstream sequence of human genes; in a near future, I plan to extend this approach 
also to downstream and intron regions. Retrieved promoters were then analysed for the 
presence of nCaRE-B elements using Glsearch as program for local alignment [217]. 
8724 human genes were found to contain one or more nCaRE matches within their 
promoters; similarly, 2173 matches were retrieved in the mouse genome. We then cross-
checked candidate genes with gene expression data obtained from APE1 knock-down 
cells [53], thus verifying some evidences of co-expression between genes carrying 
nCaRE elements. Through this analysis, 384 common genes were identified in the two 
datasets (Figure 16B). Then, I considered the GO annotations of these 384 genes, 
searching for statistically significant common annotations. In general, a GO annotation 
term was considered to be significantly overexpressed when the corresponding p-value 
(not corrected for multiple testing) was lower than 1E-4. Through this approach, it has 
been observed a strong over-representation of terms related to RNA processing and 
metabolism, in accordance to our previous studies [53]. All the significant associations 
between genes and GO terms are reported in Supplementary Table 4 in Appendix. 
Finally, the “phylogenetic footprinting filter” was applied to evaluate whether the 
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significant fraction of the genes, obtained through the GO filter, shares homologous 
genes, containing nCaRE related sequences in the upstream region, with the mouse 
gene dataset. As a final result, 57 genes were extracted that may be considered bona 
fide candidates bearing the putative nCaRE sequences within their regulatory elements. 
The complete list of the 57 genes retrieved is reported in Supplementary Table 5 in 
Appendix. Finally, a functional enrichment analysis was performed to unveil if the 57 
genes found are involved in common biological processes. This examination showed that 
candidate genes were associated with processes related to gene expression, activation 
or increment of the extent of transcription from an RNA polymerase II promoter (Figure 
17 and Supplementary Table 6 in Appendix). Among these 57 genes, several are 
involved with DNA repair process and cellular response to external stimuli and DNA 
damage, e.g. SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 (SMARCA4), sirtuin 1 (SIRT1), valosin-containing 
protein (VCP), multiple endocrine neoplasia I (MEN1), structural maintenance of 
chromosomes protein 6 (SMC6), early growth response 1 (EGR-1) and APE1 itself. 
Particular attention was focused on SIRT1, a NAD-dependent histone deacetylase 
belonging to the class III of the sirtuin family because it occurs most frequently among the 
functional enriched categories (see Supplementary Table 6 in Appendix) and based on 
the recent demonstration of a functional involvement of this enzyme in the deacetylation 
of some K residues in the N-terminal region of APE1 [5][157](see also list of papers 
published during PhD). The latter information and the data derived from our bioinformatic 
analysis, led us to hypothesize the existence of an auto-regulatory loop between APE1 
and SIRT1. 
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Figure 17 – GeneCodis functional enrichment analysis of the 57 putative genes bearing nCaRE sequences 
performed according to biological process.  
The histogram reported the list of the first seventeen co-occurrence terms. On the horizontal axis it is shown the number 
of genes for each category together with the statistical significance. For clarity only the most representative functional 
categories are reported. See Supplementary Table 6 in Appendix for the complete list. 
5.2 APE1 binds the nCaRE sequences present in the human 
SIRT1 promoter 
In order to prove the functional relevance of the nCaRE sequences identified in the 
human SIRT1 promoter, I first tested in vitro the ability of APE1 to specifically bind to 
these elements. Thus, EMSA analyses were performed using different APE1 
recombinant proteins and two double stranded (ds) oligonucleotides containing the 
SIRT1 nCaRE elements corresponding to the sequences found at -2701 (SIRT1-A) and -
1754 bp (SIRT1-B) from the transcription start site (TSS), respectively (Figure 18A). Full 
length human wild type APE1 (APE1WT), the N-terminal APE1 deletion mutant (APE1NΔ33) 
and the homologous APE1 from zebrafish (zAPE1) expressed in E. coli were used to this 
purpose. As clearly demonstrated by the EMSA analyses, only the APE1WT protein was 
able to stably bind both the nCaRE sequences (Figure 18B, lanes 2 and 6), while a 
complete absence of retarded complex was observed in the case of the truncated 
APE1NΔ33 form (Figure 18B, lanes 3 and 7). These findings underlined the importance of 
the first 33 amino acids present at APE1 N-terminus for the proper binding of the protein 
to nCaRE sequences. A similar poor DNA binding activity was also evident in the case of 
zAPE1 (Figure 18B, lanes 4 and 8), which bears a non-related N-terminal domain [85]. All 
together, these results suggest that the phylogenetically evolved N-terminal domain is 
essential for a stable interaction between APE1 and the nCaRE sequences; in this 
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context, it is conceivable that K residues present within this region, and acquired during 
phylogenetic evolution in mammals [85][86][218], may play a major role in protein binding 
to these DNA elements.  
Figure 18 - APE1 N-terminal domain is essential for APE1 binding to nCaRE sequences contained in the human 
SIRT1 promoter.  
Panel A. Schematic representation and multiple sequence alignment of two candidate nCaRE-B-like sequences 
identified in human SIRT1 gene promoter with the nCaRE sequence found on the human PTH promoter.  
Panel B. EMSA analysis with ds oligonucleotides corresponding to nCaRE SIRT1-A and SIRT1-B sequence challenged 
with APE1
WT
, APE1
NΔ33
 and zAPE1. Reactions were performed with 2.5 pmol of oligonucleotide and 10 pmol of purified 
APE1
WT
 (lanes 2, 6), APE1
NΔ33
 (lanes 3, 7) and zAPE1 (lanes 4, 8). Lanes 1 and 5 represent probe alone; F shows the 
position of the free oligonucleotide probe. Specific APE1/nCaRE interaction is indicated by the arrow. Coomassie 
staining of the purified recombinant proteins challenged in EMSA is shown on the left. 
Then the affinity of APE1 for nCaRE sequences was estimated through Surface 
Plasmon Resonance (SPR) analysis (Figure 19). SPR analyses were performed in 
collaboration with the Institute of Biostructures and Bioimaging, National Research 
Council of Naples, Italy. Biotinylated versions of the nCaRE or polyT sequences were 
immobilized onto a streptavidin chip to be used as ligands in SPR assays. APE1WT and 
APE1NΔ33 were then analyzed for their DNA binding activity. When testing APE1WT as 
analyte, a KD value of 3.90±0.08 µM was measured [218]; corresponding kinetic 
parameters are shown in Table 3. Conversely, when using APE1NΔ33, any SPR signal 
variation was observed (data not shown), in accordance with the EMSA analysis (Figure 
18B). This result confirmed that the APE1 region 1-33 is essential for a stable interaction 
with these DNA elements. As DNA-repair enzyme APE1 has an intrinsic ability to bind 
DNA in a sequence-independent manner, and independent observations clearly pointed 
to a role of the nucleic acid secondary structure in positively modulating this activity [218], 
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the protein capacity to bind a single-stranded 24-mer oligo-dT (here called polyT) was 
also evaluated. A KD value of 308±3 µM was measured in the case of APE1
WT, while no 
binding was observed for APE1NΔ33 (Figure 19 and  
Table 3), in agreement with EMSA analysis. These experiments indicated that 
APE1 poorly recognizes an oligonucleotide formed by stretch of thymidines, having a 
non-structured conformation, thus confirming that this protein may bind to DNA with 
different affinities and that the oligo-dT sequence may be used in EMSA analysis as non-
specific competitor.  
Figure 19 - Sequence specificity of APE1 binding to wild type nCaRE motif.  
SPR analysis on the hAPE1–nCaRE interaction. Recombinant hAPE1 and biotinylated nCaRE SIRT1-B were used as 
analyte and ligand, respectively. Plot of RUmax from each binding vs. hAPE1 concentrations (0.5-8 M); data were fitted 
by non-linear regression analysis. 
 
Table 3 - Dissociation constant and kinetic parameter values as determined for hAPE1 by SPR analysis. 
Ligand Ka (Ms 105) Kd (1/s) KD (μM) 
SIRT1-B nCaRE 0.270 0.105 3.90±0.08 
SIRT1-B mutated 0.0198 0.236 119±8 
polyT 0.00364 0.112 308±3 
 
EMSA analysis on APE1 binding activity to the nCaRE sequences showed a poor 
affinity for recombinant APE1; therefore, I tested whether additional factors present in 
nuclear extracts of cells may increase the protein binding affinity to its nucleotide target. 
To this aim, further EMSA analyses were performed with HeLa cells nuclear fractions, 
confirming that a nuclear activity able to specifically bind nCaRE sequences was indeed 
present (Figure 20A). The high affinity complex measured even using much lower 
0
25
50
75
100
125
hAPE1 (M)
R
U
m
a
x
0 2 4 6 8 10
Results 
Tesi di dottorato di Giulia Antoniali, discussa presso l’Università degli Studi di Udine                            58 
amounts of APE1 (0.63 pmol, as estimated separately [5]) with respect to that obtained 
with the recombinant purified protein alone (10 pmol) (Figure 18B), suggested that 
additional factors are required for an efficient APE1 binding to SIRT-1 nCaRE sequences. 
To demonstrate the presence of APE1 in the retarded complex observed in Figure 20A, I 
used nuclear extracts obtained from a HeLa lines (CL.3) where endogenous APE1 
protein expression has been previously knocked-down through stable shRNA transfection 
[13]. As apparent from lane 3 in Figure 20A, an overall reduction of the intensity of the 
retarded nCaRE-bound complex was observed, similarly to what occurred also for the 
clone expressing APE1NΔ33 (lane 5). Nuclear extracts obtained from HeLa cells 
reconstituted with ectopic APE1WT (lane 4) showed the same amount of the bound 
complex as the control cell clone expressing a scrambled shRNA vector (indicated as 
SCR-1). Pre-incubation of the nuclear extract from the SCR-1 clone with an anti-APE1 
antibody resulted in the formation of a super-shifted complex (Figure 20B, lane 3); this 
complex was absent when a non-related antibody was used (lane 6), clearly 
demonstrating that APE1, present in the nuclear cell extract, is involved in the recognition 
of the nCaRE elements of the SIRT1 promoter. The reduced intensity of the retarded 
complex band upon APE1 silencing or in the reconstituted cells expressing APE1NΔ33 
(Figure 20A), as well as the lower apparent electrophoretic mobility of the protein-DNA 
retarded complex when using nuclear extracts in place of the recombinant purified protein 
(Figure 18B), suggested that APE1 may be part of a multi-protein complex. Since Ku70 
antigen protein was already demonstrated to bind nCaRE sequences in complex with 
APE1 [18], the HeLa nuclear extract was incubated with an antibody against the Ku70 
antigen; the reaction was then subjected to EMSA analysis. The formation of a super-
shifted complex was evident (Figure 20B, lane 4). Concurrent presence of APE1 and 
Ku70 in the same retarded complex was confirmed by performing a simultaneous pre-
incubation with antibodies against these proteins (Figure 20B, lane 5). Overall, these data 
demonstrated that APE1 must be part of a multi-protein complex containing Ku70 to elicit 
its high-affinity binding potential to the nCaRE sequences present on SIRT1 promoter. 
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Figure 20 - APE1 is part of a nuclear protein complex which binds to SIRT1 nCaRE sequence.  
Panel A. EMSA analysis with nuclear extracts from reconstituted cells on nCaRE SIRT1-B. 2.5 pmol of ds oligonucleotide 
corresponding to nCaRE SIRT1-B were incubated with 5 μg of HeLa nuclear extract of different clones: control clone, 
APE1
SCR-1
 (lane 2), clone silenced for APE1, APE1
CL.3
 (lane 3), clone where the expression of APE1 is reconstituted with 
APE1
WT
 (lane 4) or with APE1
NΔ33
 (lane 5). Lane 1 correspondes to probe alone; F shows the position of the free 
oligonucleotide probe. Specific APE1/nCaRE interaction is indicated by the arrow. Western blotting analysis with APE1 
antibody of the nuclear cell extracts reveals the silencing of endogenous APE1 (APE1
CL.3
), when compared with control 
clone transfected with the empty vector (APE1
SCR-1
) and that expression the ectopic flagged APE1
WT
 and APE1
NΔ33
. 
Tubulin was used as protein loading control.  
Panel B. 2.5 pmol of ds oligonucleotide corresponding to nCaRE SIRT1-B were incubated with HeLa nuclear extract from 
APE1
SCR-1
 clone alone (lane 2) or pre-incubated with monoclonal antibody against APE1 (lane 3) or/and with an antibody 
against Ku-70 (lanes 4 and 5). Lane 6 corresponds to APE1
SCR-1
 nuclear extract incubated with an aspecific antibody (α-
P2Y6). Lane 1 is probe alone; F shows the position of the free oligonucleotide probe. Specific APE1/nCaRE interaction is 
indicated by the arrow. Asterisk indicates super-shift.  
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5.3 nCaRE sequences may fold into a cruciform-like structure 
that is recognized by the N-terminal portion of APE1 
nCaRE element consists of a palindromic sequence that can possibly fold into self-
complementary hairpins (Figure 21A). In silico analyses performed with mFold program 
were suggestive of the capacity of these elements to fold into cruciform-like structures. 
To evaluate whether nCaRE sequences can fold into cruciform duplexes and to 
specifically assess if APE1 binding to the SIRT1 nCaRE elements may depend on such 
secondary structures formation, footprinting analyses were performed by using the T7 
endonuclease I. This is a structure-sensitive enzyme that specifically recognizes 
conformationally-branched DNA and Holliday structures or junctions [219-221]. 
Footprinting data supported the hypothesis of the existence of a secondary structure for 
the nCaRE-B sequences (Figure 21A). In particular, these experiments showed the 
predominant occurrence of two bands (10 and 19 nt in length) in the product digestion, 
which corresponded to a cutting site close to the predicted loop and immediately adjacent 
to the predicted stem (Figure 21A, arrows). Interestingly, pre-incubation of the nCaRE 
oligonucleotide with APE1 impairs T7 endonuclease digestion (Figure 21A, lane 4). 
Consistent with these observations, EMSA analysis demonstrated that digestion of the 
nCaRE oligonucleotide with T7 endonuclease affects APE1 binding to this element but 
conversely, when APE1 was first incubated with the nCaRE probe and then digested with 
T7 endonuclease, the binding was not affected. These data were suggestive for a 
protective role of APE1 to T7 endonuclease action, strongly supporting the hypothesis 
that these proteins may compete for the same binding site on the nCaRE-B sequences 
(Figure 21B).  
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Figure 21 - APE1 recognizes structured nCaRE sequence.  
Panel A. Left, cruciform structure of nCaRE SIRT1-B double-stranded oligonucleotide as predicted using mFold web 
server program. Arrows indicate the position and the length of the estimated cleavege sites by T7 endonuclease; Right, 
T7 endonuclease I footprinting analyisis. 2.5 pmol of ds oligonucleotide corresponding to nCaRE SIRT1-B were pre-
incubated (lane 4) or not (lane 3) with 35 pmol of APE1 recombinant protein for 15 min at 37°C in EMSA binding buffer, 
then 5U of T7 endonuclease I were added to each reaction.  
Panel B. EMSA analysis of APE1 binding to nCaRE sequence after digestion with T7 endonuclease or after pre-
incubation with APE1 and subsequent digestion with T7 endonuclease. 2.5 pmol of ds oligonucleotide corresponding to 
nCaRE SIRT1-B were first digested with T7 endonuclease at 37°C, for 1 h, and subsequently incubated with increasing 
amounts of recombinant APE1 (10 or 30 pmol) at 37°C, for 15 min (lanes 7, 8). Alternatively, 2.5 pmol of nCaRE probe 
were first incubated with APE1 at 37°C, for 15 min, and sequentially digested with T7 endonuclease at 37°C, for 1 h 
(lanes 9, 10). Lane 1 is probe alone; 1
st
 and 2
nd
 indicate if APE1 incubation with the probe was performed temporally 
before (1
st
) or after (2
nd
) T7 digestion; F shows the position of the free oligonucleotide probe. F** indicates the T7 
endonuclease-digested probe. Specific APE1/nCaRE interaction is indicated by the arrow.  
To corroborate structural data obtained for SIRT1 nCaREB sequence with T7 
endonuclease, the same experiment was performed with another enzyme, the mung 
bean nuclease (MB)[222], a single-strand specific endonuclease, typically used for the 
removal of hairpin loops during cDNA synthesis (Figure 22). In accordance to T7 
endonuclease analysis, digestion of SIRT1 nCaREB oligonucleotide with mung bean 
nuclease prevents APE1 binding. EMSA analysis evidenced that the retarded band, 
ascribable to nCaRE-APE1 complex, decreased when a time-course mung bean 
digestion was performed previous to APE1 incubation (Figure 22A) and, similarly to what 
observed for T7 endonuclease, when APE1 was firstly incubated with the nCaRE probe 
and then digested with mung bean nuclease, the binding was not altered (Figure 22B). 
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 The first 33 N-terminal amino acids of APE1 are required for protein binding to 
nCaRE sequences (Figure 18). In order to investigate the role of this protein portion on 
APE1 ability of binding to these DNA sequences, the APE1-nCaRE complex was 
subjected to combined limited proteolysis-mass spectrometry experiments, according to 
previous studies realizing a differential probing of accessible amino acids in isolated and 
complexed proteins [223][224]. These analyses were performed in collaboration with the 
Proteomics & Mass Spectrometry Laboratory, ISPAAM of Naples by Dr. Andrea Scaloni. 
When limited proteolysis experiments were carried out on recombinant APE1 protein in 
the absence or presence of its target nCaRE oligonucleotide, differential peptide maps 
were obatained, which were exploited to infer the residues present at the complex 
interface [225]. Interpretation of the results was based on the concept of "shielding" from 
proteolytic attack. In particular, limited proteolysis experiments were carried out on a 
time-course basis on isolated APE1, protein complexed with SIRT1 nCaRE-B 
oligonucleotide and protein complexed with PTH nCaRE oligonucleotide [194]; the latter 
was used as control. Data interpretation was rationalized according to the X-ray 
crystallographic APE1 structures reported so far [83][226]. 
Figure 22 - EMSA analysis of APE1 binding to SIRT1 nCaRE sequence after mung bean digestion.  
Panel A. 2.5 pmol of ds oligonucleotide corresponding to nCaRE SIRT1-B were digested with mung bean endonuclease at 
30°C for the indicated period of time. The reactions then were incubated at 37°C with 10 pmol of recombinant APE1 protein 
for additional 15 min. Lane 1 is probe alone; F shows the position of the free oligonucleotide probe. Specific APE1/nCaRE 
interaction is indicated by arrow. Panel B. APE1 and mung bean endonuclease compete for the same nCaRE binding site. 
EMSA analysis of APE1 binding to nCaRE sequence after digestion with mung bean endonuclease or after preincubation 
with APE1 and subsequent digestion with mung bean. 2.5 pmol of ds oligonucleotide corresponding to nCaRE SIRT1-B 
were first digested with mung bean endonuclease at 30°C for 4 h and subsequently incubated with increasing amounts of 
recombinant APE1 (10, 30 pmol) at 37°C for 15 min (lanes 7, 8). Alternatively, 2.5 pmol of nCaRE probe were first 
incubated with APE1 at 37°C for 15 min and sequentially digested at 30°C for 4 h with mung bean endonuclease (lanes 9, 
10). Lane 1 is probe alone; 1
st
 and 2
nd
 indicate if APE1 incubation with the probe was performed temporally before (1
st
) or 
after (2
nd
) mung bean digestion; F shows the position of the free oligonucleotide probe. Specific APE1/nCaRE interaction is 
indicated by arrow. 
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Panels A and D of Figure 23 show the time-course LC-ESI-MS analysis of the 
endoprotease AspN digestion on isolated APE1, as carried out by using an 
enzyme/substrate of 1:500 w/w. Under these experimental conditions, APE1 remained 
partly undigested, showing that its native conformation is susceptible to proteolysis at a 
unique, likely flexible site. After 5 min, only the peptide pair 1-17 and 18-321 was 
detected (Figure 23A), and no further fragments were released after 60 (Figure 23D) and 
120 min (data not shown) (Supplementary Table 7 in Appendix). As previously reported 
[225], the definition of the primary cleavage sites was inferred by the identification of the 
complementary peptides released by a single proteolytic event occurring on the intact 
protein. According to these criteria, non-complexed APE1 was preferentially cleaved at 
D18 present within the unstructured protein N-terminal domain. When the APE1-SIRT1 
nCaRE-B oligonucleotide complex was analyzed under the same conditions, no 
proteolytic fragments resulting from D18 cleavage were released even after 60 min 
(Figure 23, panel A and E) (Supplementary Table 7 in Appendix), demonstrating a tighter 
conformation of the complex and a DNA-shielding effect for D18. A very reduced 
digestion at this site was observed only after incubation for 120 min (data not shown). A 
similar condition was verified also for the APE1-PTH nCaRE oligonucleotide complex, 
which showed absent or practically negligible proteolysis at D18 after 5 and 60 min, 
respectively (Figure 23, panel C and F). These results clearly demonstrate that after 
APE1 interaction with DNA, D18 is no longer accessible to the protease action. Thus, it 
may be hypothesized that this residue occurs at the protein-nCaRE oligonucleotide 
complex interface. 
The different accessibility of the basic residues in isolated APE1 and in its complex 
with nCaRE oligonucleotides was similarly probed with trypsin, used at 1:5000 w/w 
enzyme/substrate (Supplementary Table 7 in Appendix). LC-ESI-MS analysis of the 
proteolytic fragments released from the isolated protein led to the identification of the 
complementary peptide pairs 1-9, 10-321 and 1-10, 11-321 already after 5 min of 
reaction, which were generated by single hydrolytic events at K9 and K10, respectively. 
Additional products resulting from fragment subdigestions were also observed, but they 
did not provide information on further accessible amino acids. These results confirmed 
that APE1 N-terminal portion is very flexible and highly exposed to the protease action. 
Conversely, appreciable hydrolysis of recombinant APE1 following protein interaction 
with SIRT1 nCaRE-B or APE1-PTH nCaRE oligonucleotides was observed at K9 only 
after 60 min of reaction (Supplementary Table 7 in Appendix). Due to the nature of the 
proteolytic products observed, these experiments confirmed the masking effect of both 
oligonucleotides over the non-structured protein N-terminal region. 
Results 
Tesi di dottorato di Giulia Antoniali, discussa presso l’Università degli Studi di Udine                            64 
Further experiments were then carried out with broader-specificity proteases, such 
as chymotrypsin and elastase. In the first case, limited proteolysis of isolated APE1 
(enzyme/substrate of 1:1000 w/w) generated only a complementary peptide pair, namely 
1-114 and 115-321, which identified L114 as the primary cleavage site (Supplementary 
Table 7 in Appendix). Additional products resulting from fragment subdigestions were 
also observed, but they did not provide information on further accessible amino acids. 
According to X-ray crystallographic data, this residue is exposed on the molecular 
surface of the globular APE1 domain. No significant differences were observed on a time-
course basis when peptide maps were characterized for both APE1-nCaRE 
oligonucleotide complexes (Supplementary Table 7 in Appendix). In fact, both peptides 1-
114 and 115-321 were detected within the APE1-SIRT1 nCaRE-B and APE1-PTH 
nCaRE oligonucleotide products after 5 and 15 min, respectively, similarly to the non-
complexed protein sample. These data excluded any involvement of L114 in binding to 
the nCaRE elements and further confirmed the suitability of the strategy used here. 
When elastase digestion of isolated APE1 was carried out using an 
enzyme/substrate of 1:1000 w/w, only two peptide pairs (1-12, 13-321, and 1-14, 15-321) 
were detected after 5 min of reaction, whereas an additional pair (1-20, 21-321) was 
observed after 15 min (Supplementary Table 7 in Appendix). These data demonstrated 
that non-complexed APE1 was preferentially cleaved at A12, A14 and L20. When the 
recombinant APE1-SIRT1 nCaRE oligonucleotide and APE1-PTH nCaRE oligonucleotide 
complexes were analyzed under the same conditions, different proteolytic patterns were 
obtained, which proved preferential cleavage site at L20, as demonstrated by the 
identification of the complementary peptides 1-20 and 21-321 after 30 min of reaction 
(Supplementary Table 7 in Appendix). These results clearly demonstrated that, following 
complex formation, A12 and A14 are no longer accessible to elastase, whereas L20 is 
still partially exposed to the protease action. 
The overall results of the limited proteolysis experiments for recombinant APE1 are 
summarized in (Supplementary Table 7 in Appendix), from which a number of general 
considerations can be driven concerning the native protein. Preferential cleavage sites, 
occuring in isolated APE1, gathered into a specific region of the protein, the most 
exposed segment being the unstructured N-terminal domain, which contained 6 
hydrolysis sites (K6, K7, A9, A11, D15 and L17). A further hydrolyzed peptide bond was 
located within the globular APE1 domain (L111). Interestingly, no other cleavage sites 
were detected in other protein regions, although exposed on the molecular surface. After 
complex formation, a marked protection effect exerted by nCaRE oligonucleotides was 
observed, as demonstrated by the large decrease in the number of proteolytic sites 
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present in the N-terminal region (from 6 to 1), thus confirming the involvement of this 
APE1 portion in binding to these DNA elements. 
Figure 23 - Topology of the APE1-nCaRE complex: the APE1 N-terminal domain is involved in this binding.  
Comparative limited proteolysis experiments on isolated or DNA-complexed APE1. Time-course analysis of 
simultaneous trials performed on non-complexed recombinant APE1 (A, D), recombinant APE1-SIRT1 nCaRE-B 
complex (B, E) or recombinant APE1-PTH nCaRE complex (C, F) are shown. LC-ESI-MS profiles from samples taken at 
5 (A-C) and 60 min (D-F) are reported. Identified peptides are reported on the corresponding chromatographic peaks; 1-
321 denotes the intact protein. 
5.4 APE1 regulates SIRT1 expression at the promoter level 
To determine whether the observations obtained in vitro, regarding APE1 binding to 
nCaRE sequences, have any relevance in vivo, I examined the APE1 occupancy of the 
nCaRE sequence in the SIRT1 promoter through chromatin immunoprecipitation (ChIP) 
analyses. To this purpose, HeLa cells were co-transfected with a human SIRT1 
promoter-containing plasmid [157] and FLAG-tagged APE1WT- or APE1NΔ33-expressing 
plasmids. The amount of immunoprecipitated SIRT1 promoter was significantly enriched 
in APE1WT-transfected cells, when compared with that obtained from control cells 
transfected with the empty vector alone (Figure 24A). As expected, APE1NΔ33-transfected 
cells had a remarkable reduction, even though not complete, in the amount of 
immunoprecipitated SIRT1 promoter. A similar degree of reduction was also observed 
when ChIP analysis was performed by using a SIRT1 promoter bearing a mutated 
sequence within the nCaRE motif (Figure 24B), whose reduced specificity was previously 
assessed through SPR analysis ( 
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Table 3). These experiments revealed that the mutation introduced in the nCaRE-B 
sequence significantly reduced the APE1 binding to DNA, lowering the affinity of the 
complex by a 30-fold factor (KD = 119 ± 3 µM). Competitive EMSA analyses were in 
agreement with these findings. In fact, addition of the unlabeled nCaRE ds 
oligonucleotide resulted in an almost complete elimination of bound complex formation. 
On the other hand, competition with the unlabeled mutant nCaRE oligo (nCaRE-mut) 
caused only a slight reduction of the nCaRE-binding complex, in agreement with ChIP 
and SPR data, and supporting the notion of a sequence-dependent binding specificity 
(data not shown). Altogether, these results confirmed our in vitro observations (Figure 18, 
Figure 19 and Figure 20) and support the notion that, under basal conditions, APE1 is 
associated with the nCaRE-B sequence within the SIRT1 promoter also in vivo, possibly 
as part of a multiprotein complex. 
Figure 24 - APE1 is constitutively associated with nCaRE sequence in SIRT1 human promoter.  
Panel A. ChIP assay for in vivo association of APE1 and nCaRE sequence on human SIRT1 promoter. Upper panel, 
schematic representation of the human SIRT1 promoter used for HeLa transfection which included the nearest nCaRE 
sequence from TSS (nCaRE SIRT1-B). For and Rev arrows indicated the position of the RT-PCR primer designed for the 
quantification of the human SIRT1 nCaRE sequence bound to APE1. Middle panel, ChIP assay for APE1-nCaRE 
sequence association. HeLa cells were co-trasfected with both human SIRT1 promoter and with vector expressing 
APE1
WT
, APE1
NΔ33
-FLAG tagged, or the empty vector as ChIP negative control. The values reported were calculated as 
fold percentage of the amount of immunoprecipitated nCaRE DNA relative to that present in total input chromatin. Data 
were further normalized to the amount of immunoprecipitated protein. The significance of sample average difference 
observed was estimated by Student’s t test. * p-value < 0.05. Bottom panel, Western blotting analysis was performed on 
total cell extracts (input) and on immunoprecipitated material (IP) with specific antibody for FLAG and APE1. IB: 
immunoblot. 
 Panel B. ChIP analysis on mutated human SIRT1 promoter. Upper panel, base composition of the nCaRE sequence of 
human SIRT1 promoter (-1754 bp from TSS) and of the the mutated sequence used for site-directed mutagenesis. 
Divergent sequences in the mutant nCaRE are bold. Middle panel, HeLa cells were co-transfected with empty vector or 
with vector expressing APE1
WT
 and, alternatively, with wild type hSIRT1 promoter or hSIRT1 promoter carrying a 
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mutation on its nCaRE-B sequence. The histogram represents the amount of hSIRT1 promoter sequence that was 
immunoprecipitated. Data are presented as percent of input and were normalized to the amount of APE1 
immunoprecipitated, as evaluated by Western blotting analysis (bottom panel). Statistical tests were performed with 
Student’s t test. * p-value < 0.05. 
Then the functional relevance of APE1 on SIRT1 promoter activation was checked 
by performing promoter-reporter assays. HeLa cells were co-transfected with a luciferase 
reporter vector bearing the SIRT1 promoter and APE1WT FLAG-tagged vector to evaluate 
if APE1 binding to SIRT1 promoter may play a role in SIRT1 transcriptional regulation 
(Figure 25A). SIRT1 promoter-reporter assays showed that there was a significant 
increase in the luciferase signal detected in the presence of APE1, compared to that of 
the promoter alone. Therefore, I decided to evaluate the effect of APE1 silencing on 
endogenous SIRT1 mRNA expression levels through an inducible shRNA knock-down 
strategy [53]. Endogenous APE1 knockdown (CL.3) caused a significant reduction in the 
SIRT1 endogenous expression levels (Figure 25B), which was rescued in cells 
reconstituted with a siRNA resistant APE1 cDNA expression plasmid (WT). These data 
demonstrated the positive effect of APE1 on SIRT1 transcriptional activation in 
accordance with our previous observations on gene expression profiling analysis [53], 
where a reduced expression of SIRT1 in APE1 knocked-down HeLa cells was apparent. 
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Figure 25 - APE1 positively regulates SIRT1 expression at the promoter level.  
Panel A. hSIRT1 promoter is activated in presence of APE1. Upper panel, reporter assay with hSIRT1 firefly reporter vector 
co-trasfected with APE1
WT 
FLAG-tagged vector. Firefly luciferase activity observed was normalized to renilla luciferase 
activity. Bottom panel, Western blotting analysis for the normalization of protein levels. Tubulin protein level was used to 
normalize samples.  
Panel B. Analysis of SIRT1 mRNA level with Q-PCR in clones expressing APE1
WT
 or APE1 silenced (CL.3) cells. Upper 
panel, data shown in the histogram are normalized to the amount of GPDH. Statistical tests were performed with Student’s 
test. A p-value < 0.001 was considered as statistically significant (*). Bottom panel, Western blotting analysis on protein 
extract of clones showing the suppression of endogenous APE1 expression, upon ten days of treatment with doxycycline. 
Tubulin protein level was used to normalize samples.  
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5.5 Oxidative stress induces SIRT1 transcription via recruitment 
of BER enzymes 
In order to better understand the transcriptional function exerted by APE1 through 
the binding to nCaRE sequences, we investigated if APE1’s positive role on SIRT1 
transcription could rely on its enzymatic activity on DNA. First, it has been observed that 
under basal conditions APE1 does not present endonuclease activity on the SIRT1 
nCaRE-B sequence, as assessed through an oligonucleotide cleavage assay ( 
Figure 26A). APE1 cleavage at any site on cruciform nCaRE sequence should lead 
to a site-specific single-stranded break that can be detected by the appearance of an 
extra fragment in the cleavage assay. Even using increasing amount of purified 
recombinant APE1 protein we did not detect any nuclease activity that, on the contrary, 
was readily visible when using a radiolabeled 26-mer ds oligonucleotide containing a 
tetrahydrofuran mimicking an AP site (here referred as THF) [14]. Substitution of the 
guanine residue at position 12, within the predicted loop of the nCaRE-B sequence, with 
a THF residue, resulted instead in efficient APE1 cleavage activity on the nCaRE-B 
sequence. This activity depends on the APE1 catalytic function, since the catalytically 
inactive APE1E96A mutant [227] was unable to efficiently cleave the same substrate ( 
Figure 26B). 
Figure 26 - APE1 cleaves SIRT1 nCaRE sequence only in the presence of an AP site within its structure.  
APE1 endonuclease activity on ds nCaRE SIRT1-B radiolabeled oligonucleotide was tested by using an AP 
endonuclease activity assay. A radiolabeled ds THF-containing deoxyoligonulceotide (THF) was used as control. 
Reactions were performed as described in Materials and Methods with 2.5 pmol of each probe and increasing amounts 
(pmol) of recombinant APE1
WT
 protein; they were stopped after 15 min of incubation, at 37°C. The conversion of the 
radiolabeled THF-containing oligonucleotide substrate (S) to the shorter product (P) was evaluated on a denaturing 20% 
polyacrylamide gel. The corresponding gel image of the enzymatic reactions is shown. Panel A. Under basal condition, 
APE1 doesn't cleave the nCaRE SIRT1-B oligonucleotide. Panel B. APE1 AP endonuclease activity on ds nCaRE SIRT1 
radiolabeled oligonucleotide containing a THF site. nCaRE SIRT1-B THF-containing probe were incubated with 
increasing amounts of recombinant APE1
WT
 protein or a catalytic inactive APE1 mutant (APE1
E96A
).  
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THF nCaRE SIRT1-B
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Prompted by these findings, it has been hypothesized that the APE1 positive 
function observed on SIRT1 promoter may be ascribed to APE1 catalytic activity on 
nCaRE sequences; this phenomenon can be exerted after specific stimuli, such as 
oxidative stress, which can lead to abasic site formation on nCaRE sequences. It is well 
known that SIRT1 expression and function are regulated by external stressors, including 
the exposure to genotoxic agents [157][228][229]. I therefore measured the SIRT1 
transcription after oxidative stress conditions, such as that generated by H2O2 exposure. 
First, I demonstrated that SIRT1 promoter activation was increased by H2O2 treatment in 
a concentration-dependent fashion (Figure 27A).  
Figure 27 - H2O2 increases SIRT1 promoter activity which is mediated by APE1.  
Panel A. Reporter assay with HeLa cells transfected with hSIRT1 firefly reporter vector and challenged with increasing 
doses of H2O2, for 1h, as indicated. Firefly luciferase activity observed was normalized to renilla luciferase activity. A p-
value < 0.001 was considered as statistically significant (*). 
 Panel B. Q-PCR analysis of SIRT1 mRNA levels in clones expressing APE1
WT
 or APE1 silenced cells APE1
CL.3
 after 1 
mM H2O2 treatment, for 1 h. Data shown in the histogram are normalized to the amount of GAPDH. The significance of 
sample average difference observed was estimated by Student’s t test. A p-value < 0.05 was considered as statistically 
significant (*). Western blotting analysis on the protein extracts described in the upper panel. Tubulin protein level was 
used to normalize samples. 
Next, it has been examined the effect of APE1 silencing or re-expression on SIRT1 
transcriptional activation in HeLa cell clones upon H2O2-treatment (Figure 27B). The 
control (SCR-1), the APE1-silenced (CL.3) and the APE1WT cell clones were treated with 
1 mM H2O2 for 1 h. SIRT1 mRNA levels were then evaluated by Q-PCR analysis and 
compared with untreated clones. Upon oxidative treatment, SIRT1 mRNA resulted 
significantly increased and, notably, this response was higher in the presence of APE1WT 
protein, whereas it was lower in the case of APE1 knocked-down expressing cells. The 
residual activation of SIRT1 mRNA expression, which was apparent also in APE1 
knocked-down cells, might be ascribable to the presence of remaining endogenous APE1 
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protein and/or to the existence of further limiting factors as already speculated [17-19]. I 
confirmed the general relevance of our model by testing further hypothetical APE1 target 
genes containing an nCaRE element in their promoters and resulted dysregulated in 
APE1-kd cell model (Figure 16). To this aim, the expression levels, upon H2O2-treatment, 
of the Early growth response protein 1 (EGR-1) and Eukaryotic translation initiation factor 
4E-binding protein 1 (EIF4EBP1), in the HeLa cell inducible-kd (CL.3) and in the 
reconstituted cell model (WT) used here, were evaluated by Q-PCR analysis (Figure 28). 
Similar results were also obtained when challenged cells with another genotoxic agent, 
methyl methanesulfonate (MMS) whose DNA-induced damages are repaired through 
BER [230] (Figure 29). These data, showing inducible expression of these genes 
dependent on APE1 expression similar to that observed in the case of SIRT1, were 
suggestive of a general mechanism of gene activation upon DNA damage that involves 
APE1 binding to nCaRE elements. 
 
 
Figure 28 – APE1 regulates gene transcription upon oxidative stress condition.  
Q-PCR analysis of SIRT1, EGR-1 and EIF4EBP mRNA levels in clones expressing APE1
WT
 or APE1 silenced cells 
APE1
CL.3
 after 1 mM H2O2 treatment, for 1 h. Data shown in the histogram are reported as fold of activation after H2O2 
treatment and normalized to the amount of GAPDH. The significance of sample average difference observed was 
estimated by Student’s t test. A p-value < 0.05 was considered as statistically significant (*). 
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Figure 29 - MMS treatment induces SIRT1 transcription.  
Analysis of SIRT1 mRNA level with Q-PCR in clones expressing APE1
WT
 or APE1 silenced cells APE1
CL.3
 after 0.5 mM 
MMS treatment for 8 h. Data shown in the histogram are normalized to the amount of GAPDH. The significance of 
sample average difference observed was estimated by Student’s t test. A p-value < 0.05 was considered as statistically 
significant (*). Below, Western blotting analysis on protein extract of clones used. Tubulin protein level was used to 
normalize sample. 
To find a relationship between SIRT1 transcription induced by oxidative stress and 
the APE1 regulatory activity on the nCaRE sequences located within the promoter, I 
studied the dynamics of oxidative repair enzymes recruitment on the SIRT1 nCaRE-B 
sequence at early time upon H2O2 treatment. DNA base oxidation determines the 
formation of 8-oxoG, which is recognized by the DNA glycosylase OGG1. This enzyme 
initiates the BER pathway by removing the 8-oxoG lesion, which is further processed by 
APE1 that cleaves the apurinic site. To assess the dynamics of the nCaRE sequence 
occupation on the SIRT1 promoter by these enzymes upon oxidative stress, I performed 
a time-course ChIP analysis on the SIRT1 nCaRE-B sequence after 1 mM H2O2 
treatment (Figure 30 and Supplementary Figure 33 in Appendix). I immunoprecipitated 
SIRT1 nCaRE-B sequence with antibodies against 8-oxoG, OGG1 and APE1. It has 
been observed that the signal of 8-oxoG reached its pleteau promptly, 10 min upon H2O2 
treatment and subsequently decreased, concomitantly with the accumulation of OGG1, 
that is recruited immediately later (15 minutes), in accordance with the BER processes. 
The occupancy by APE1 follows the OGG1 recruitment, consequently. To demonstrate a 
direct link between DNA repair and SIRT1 transcriptional initiation, the recruitment of 
RNA polymerase II (RNPII) on SIRT1 promoter was checked. Under basal condition, it 
has been observed that RNPII was found with relatively low abundance on the nCaRE 
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sequence; conversely, the polymerase was progressively recruited as soon as the 
oxidative stress began (15 min after H2O2 treatment). Successively (at 40 min after H2O2 
addition), RNAPII was again recruited on the SIRT1 promoter. This oxidatively induced 
recruitment of RNPII to the SIRT1 promoter, in concert with the observation that APE1 
immunoprecipitated with RNPII with an increased interaction resembling approximately 
the kinetics observed during ChIP analysis, suggested that oxidative stress could be a 
trigger for SIRT1 transcriptional activation (Figure 31). 
Figure 30 - Recruitment of DNA repair proteins at SIRT1 promoter after H2O2 treatment. 
 Histogram reports the trend of four independent ChIP analyses relative to the accumulation of 8-oxoGs, OGG1, APE1 
and RNA polymerase II protein on the SIRT1 promoter after H2O2 treatment. HeLa cells were co-transfected with empty 
vector or with a vector expressing APE1
WT
 and hSIRT1 promoter and challenged with 1 mM H2O2, for different times (as 
reported). Data are presented as percent of input and were normalized to the quantity of DNA immunoprecipitated by α-
tubulin (α-tub). See Supplementary Figure 33 for detailed information. 
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Figure 31 - Time-course interaction of RNA Polymerase II and Ku70 with APE1 after H2O2 treatment.  
HeLa cells were transfected with a plasmid expressing APE1
WT
 and challenged with 1 mM H2O2, for different times (as 
reported). Immunoprecipitated material and whole cell lysate were separated onto SDS-PAGE, immunoblotted and 
analyzed for their Ku70 (upper panel) and RNA Polymerase II (bottom panel) content, as associated with APE1 after 
H2O2 stimulus. Ponceau S staining was used for loading control. Normalized co-immunoprecipitated amounts of Ku70 
and RNA Polymerase II are indicated under each relative bar. Mean values of two independent experiments are reported 
for Ku70. 
It could be envisioned a mechanism in which H2O2 determines an oxidation of the 
guanine at the nCaRE sequence, thus recruiting components of the base excision repair 
system: OGG1 and APE1, together with proteins involved in nCaRE binding such as 
Ku70. When recruited to theSIRT1 promoter, APE1 (through its endonuclease activity) 
produces nicks on the nCaRE sequence, thus favouring the DNA relaxation necessary 
for the formation of chromatin loops that bring RNAPII at the transcription start site 
(Figure 32); the latter enzyme in turn can initiate transcription. Further work is required to 
fully circumstantiate this model for the induced transcriptional regulation of SIRT1 gene 
upon genotoxic conditions. 
70
35
Mr
(kDa)
input mock NT 10 15 20 40 60
IB: Ku70
Ponceau S staining
1mM H2O2 (min) 
Ku70 Co-IP amount
(relative units)
1.0 2.26 2.06 1.58 0.99 0.80
250
36
Mr
(kDa)
input mock NT 10 20 40 60
IB: RNP II
Ponceau S staining
1mM H2O2 (min) 
RNP II Co-IP amount
(relative units)
1.0 1.04 1.53 1.24 0.30
Results 
Tesi di dottorato di Giulia Antoniali, discussa presso l’Università degli Studi di Udine                            74 
 
Figure 32 - Mechanistic model for the role of APE1 in oxidatively mediatated SIRT1 transcription. The model has 
been simplified for clarity. See Discussion for a detailed description. 
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6 Discussion 
After its cloning by independent groups, at first as a DNA repair enzyme [51][7] and 
then as a redox co-activator protein [82], a number of papers have described the APE1 
functions, elucidating its involvement in several biological contexts. As the main 
apurinic/apyrimidinic endonuclease in mammalian cells, APE1 is classically renowned for 
its essential function as a DNA repair enzyme in the BER pathway. Beside this crucial 
role in the maintenance of the genome stability, APE1 was recently demonstrated to be 
also involved in redox signaling and in the regulation of gene expression [97][231], 
supporting the notion that it is a multifunctional protein, with features that go beyond the 
classical activities of a DNA-repair enzyme. Notably, its multifunctional nature ascribes 
APE1 as an ideal candidate protein that links together DNA damage sensing/repair and 
transcriptional regulation of genes during cell response to genotoxic damage. Among 
these non-canonical activities, another interesting APE1 function is represented by its 
ability to bind the nCaRE sequence of some gene promoters, thus acting as a 
transcriptional regulator. Okazaki’s group was the first that identified two nCaRE 
sequences within the PTH gene promoter [16]. The presence of these elements was also 
described in the regulatory region of few other genes, such as the human APE1 [139], 
the rat atrial natriuretic polypeptide [194], the human renin [138] and the bax ones [19]. 
Beside these few genes, no further evidences have been provided so far. However, since 
nCaRE elements are present within ALU repeats that are widely distributed throughout 
the expressed genome, it is expected that APE1 could potentially regulate the expression 
of a large number of genes in particular under genotoxic stress condition.  
Here, it has been performed an unbiased investigation on the whole human 
genome, searching for putative genes whose transcription may be mediated through 
APE1 ability to bind nCaRE elements. Bioinformatic analyses revealed a number of 
genes potentially regulated by APE1, which are involved in several pathways related to 
gene expression (Figure 16). Among the 57 candidate genes retrieved from our 
bioinformatic analysis, I chose to study the human deacetylase sirtuin1 (SIRT1) that 
bears two nCaRE elements in its promoter.  
SIRT1 is the human homolog of yeast Sir2 (silent information regulator 2) and 
belongs to a novel family of histone deacetylase. Sir2 is involved in gene silencing, 
telomere position effects, and cellular aging [232]. SIRT1 is the most conserved 
mammalian NAD(+)-dependent protein deacetylase that has emerged as a key metabolic 
sensor in various metabolic tissues. In response to different environmental stimuli, SIRT1 
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directly links the cellular metabolic status to the chromatin structure and the regulation of 
gene expression, thereby modulating a variety of cellular processes such as energy 
metabolism and stress response. SIRT1 activation leads to the deacetylation of several 
metabolic transcription factors such as PPAR gamma coactivator (PGC)-1α, FOXOs, and 
p53 which in turn prompt mitochondrial biogenensis and oxidative metabolism.  
Remarkable interest in SIRT1 was due to recent articles showing that this 
deacetylase controls the acetylation status of APE1 Lys6/7 [157] and Lys27/31/32/35 [5]. 
Recently and during this work of Thesis, our lab have demonstrated that these particular 
APE1 lysines may undergo acetylation during cell response to genotoxic treatment [85]. 
Yamamori et al. were the first to demonstrate SIRT1 deacetylase activity on APE1 N-
terminal lysine residues. They showed that the deacetylase activity exerted by SIRT1 on 
APE1 Lys6/7 is important in modulating APE1 DNA-repair function by regulating the 
kinetics of its interaction with other enzyme involved in BER. Successively, I also 
demonstrated the ability of SIRT1 to deacetylate Lys27-35 modulating APE1 subnuclear 
distribution and therefore coordinating its enzymatic functions in BER pathway (see also 
list of papers published during PhD course). Taken together these evidences, it has been 
hypothesized the existence of a possible autoregulatory loop that can be established 
between the two proteins: APE1 should modulate SIRT1 expression that, in turn, may 
regulate APE1 functions through deacetylation.  
To investigate the APE1 transcriptional regulatory function on SIRT1 expression, I 
first examined APE1 ability to bind the nCaRE sequences found in the SIRT1 promoter. 
Through different in vitro approaches, it has been showed that APE1 is able to bind 
SIRT1 nCaRE sequences (Figure 18, Figure 19 and Figure 23). In particular, through 
EMSA assays and limited proteolysis analyses I originally demonstrated that the APE1 N-
terminal domain is essential for the proper binding of these elements. The essential role 
of this protein domain in DNA-binding is remarkable, particularly if we consider the 
phylogenesis of the nCaRE elements and that of the APE1 N-terminal region. nCaRE 
sequences are present within ALU repeats, which belong to SINE (short interspersed 
nucleotide elements) family of repetitive sequences that originally derived from the 
reverse transposition of 7SL RNA. This event took place in the genome of an ancestor of 
Supraprimates [199]; therefore, these repetitive elements have been found exclusively in 
primates [233], scandentians [234] and rodents [235], all members of the placental 
mammalian clade Supraprimates (Euarchontoglires) [236]. Similarly, current information 
regarding the sequence homology of the APE1 N-terminal domain across species, have 
pointed out the recent phylogenetic acquisition of this region. Sequence conservation of 
this domain is very high in mammals but almost absent in other organisms with the 
exception of Danio rerio, Dyctostelium and Drosophila. Accordingly, it could be 
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envisioned that once ALU elements appeared in primates and were stabilized in their 
genomes, progressively losing their transcriptional potential, these organisms needed to 
evolve novel mechanisms to cope with the acquired RNA pol II regulatory sites present 
within ALU region. The concomitant acquisition of the APE1 N-terminal domain in 
mammals could explain new modulatory functions towards these DNA elements. The 
observation that specific K residues (i.e. K24-27) within this reduced APE1 portion seem 
to be required for the correct binding of nCaRE (data not shown) is in nice accordance 
with this hypothesis. The zebrafish homologous of APE1, which shares with the human 
protein less than 40% of the N-terminal aminoacidic sequence and that lacks two out of 
five K residues in this region [218], is indeed no longer able to stably bind these nCaRE 
sequences (Figure 18). Similar results were also obtained when using an human 
recombinant APE1 mutant protein bearing specific K to A multiple substitution at 
K27/K31/K32/K35, in which the positive charges at amino acid side chain has been 
removed to mimic a condition similar to that exerted by K acetylation (data not shown).  
APE1 N-terminal domain is required for the stable binding to the nCaRE elements, 
even though it is not sufficient. EMSA analysis, performed with the nuclear extracts of 
HeLa cells expressing the deletion form of APE1, indeed demonstrated that APE1 is 
certainly part of a multiprotein complex, being not the limiting factor in the binding 
reaction. As already speculated by Okazaki and also reported in later works, the binding 
affinity observed for the multiprotein complex is higher with respect to that detected when 
using purified APE1 protein alone (Figure 18). This suggested that other factors are 
necessary and cooperate with APE1 to fully exert this function, confirming previous 
observations [17][18]. The two subunits of Ku antigen (Ku70 and Ku80) were among the 
protein factors already described by Chung et al. to be involved in the specific binding of 
nCaRE-A sequences[18]. Here, it has been demonstrated that Ku70 binding is not 
exclusively limited to the nCaRE-A elements, since I identified this protein in the complex 
that binds to the nCaRE-B sequence of SIRT1. The Ku heterodimer is a main component 
of the non-homologous end-joining (NHEJ) pathway repairing DNA double-strand breaks 
(DSBs), which are generally produced upon extensive oxidative and IR damage to DNA 
[237]. The X-ray crystal structure of Ku demonstrated that this protein is able to recognize 
DSBs and to initiate NHEJ pathway by virtue of its donut-shaped structure. Both Ku 
subunits encircle the DNA molecule and are inter-connected over an extensive binding 
surface. The peculiar structure of Ku allows recognition and tight binding to DSBs, 
together with the recruitment of DNA-PKcs and other factors to form the active protein 
kinase complex DNA-PK that facilitates processing and ligation of the broken ends 
[238][239]. Its involvement in the nCaRE binding is not clear, but emerging evidences 
underline the biological role of its non-canonical functions [240]. Several reports have 
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indeed demonstrated Ku importance in the transcription process. Initial reports identified 
Ku as a transcriptional factor that directly bound to sequence-specific promoter elements 
[241]; other works reported instead Ku association with RNA polymerase II sites [242] 
and its direct association, by itself and as part of DNA-PK complex, with RNA polymerase 
II complex affecting the transcriptional apparatus [243-246]. Starting from these 
observations, I envisage that Ku70 association with nCaRE elements could therefore 
further facilitate APE1 binding, especially after DNA damage, since it has been observed 
an increased interaction between the two proteins upon an oxidative stress condition 
(Figure 31). It also cannot be exclude that Ku could recruit the catalytic component of 
DNA-PK to nCaRE element providing a mechanism for targeting kinase to the 
transcription complex. 
Here, it has also been better characterized the topology of the APE1-nCaRE 
complex. The palindromic nature of nCaRE-B sequences was already described by 
Okazaki et al.. Authors suggested the possible involvement of a dimeric nuclear protein in 
this process [16]. Here, it has been suggested that the SIRT1 nCaRE-B, due to its 
palindromic sequence, can potentially fold into a cruciform-like structure; I also 
demonstrated that APE1 binding activity toward these elements strongly relies on the 
secondary conformation adopted by the oligonucleotide, as already established for other 
DNA and RNA substrates (Figure 21 and Figure 22)[218]. The employment of structure-
specific nucleases, such as the T7 [219][220][221] and the mung bean nucleases [222], 
allowed me to suggest the formation of a cruciform-like structure also for the SIRT1 
nCaRE sequence and to demonstrate that APE1 binds to the SIRT1 nCaRE sequence at 
the predicted loop. Formation of similar cruciform-forming palindromic sequences has 
been already described in eukaryotic cells and their biological consequences has been 
related to different processes, including regulation of transcriptional events when present 
in close proximity of gene promoters [247-251]. We therefore hypothesize a similar 
mechanism for SIRT1 transcriptional regulation, which should imply APE1 binding to 
cruciform-structured nCaRE sequences. However, the requirement of a specific 
recognition motif also cannot be excluded since mutations in the SIRT1 nCaRE 
sequence, determining only a partial disruption of the oligonucleotide secondary 
structure, did not affect totally APE1 binding activity in vivo (Figure 24B). 
I further deepened into APE1 transcriptional function on SIRT1 promoter. It has 
been found that APE1 positively affects SIRT1 gene transcription. Although APE1 was 
implicated in the repression of PTH gene transcription in a Ca2+-dependent fashion, I 
observed that APE1 overexpression activated the SIRT1 promoter (Figure 24) apparently 
through a Ca2+-independent mechanism. This unexpected positive function on the 
transcription of a nCaRE-containing promoter was also reported in other works where 
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authors suggested that the role of the nCaRE sequences in the context of different 
promoters and cells conditions could affect nCaRE activity [138][20]. Interestingly, I 
noticed that the positive effect exerted by APE1 was particularly pronounced during 
oxidative stress, through its binding to nCaRE sequences (Figure 27). Treatment with 
H2O2 leads to an activation of the SIRT1 promoter that determines an increase of the 
corresponding transcription in an APE1-dependent fashion. This positive transcriptional 
effect was also observed when we looked at the expression of other genes that present 
nCaRE elements in their promoters (Figure 28), thus corroborating the hypothesis of a 
general mechanism of SIRT1 activation upon DNA damage that involves functional 
activation of APE1. These findings are in line with previous data from Yamamori et al. 
demonstrating that the genotoxic insult augments SIRT1 expression and, therefore, its 
deacetylase activity on APE1 K6/7, favoring APE1 binding to XRCC1 [157]. Interestingly, 
these authors evidenced that a decrease of APE1 acetylation at later times after oxidative 
treatment is usually accompanied by SIRT1 up-regulation. All together, these findings are 
in accordance with a model of a positive autoregulatory loop between the two proteins. 
Thus, SIRT1 seems to be involved in a feedback mechanism that shuts off the cellular 
response mediated by APE1 acetylation [157]. 
Avvedimento and co-workers suggested that DNA oxidation could trigger positive 
transcription in the context of Myc-mediated transcription through the involvement of BER 
enzymes, including APE1 [252][253]. A mechanistic link between DNA damage and 
repair machinery in regulated gene transcription was also suggested by Ju et al. who 
evidenced a signal-dependent activation of gene transcription after site-specific dsDNA 
break formation operated by the DNA topisomerase IIβ [254]. Similarly, it has been 
speculated that the APE1 positive effect observed on SIRT1 transcription might depend 
on APE1 endonuclease activity over the nCaRE elements present within SIRT1 
promoter. Here, it has been proposed a model where oxidative-mediated DNA repair and 
gene transcription are linked together (Figure 32). During oxidative stress conditions, 
DNA oxidation determines the formation of 8-oxodeoxyguanine (8-oxoG) lesions, which 
are recognized and processed by enzymes of the BER pathway, including APE1. In this 
model, the oxidative burst is an early event essential for the formation of a productive 
transcription initiation complex, which relies on the initial recruitment of BER enzymes. 
The nicks introduced at the chromatin level by APE1, during 8-oxoG removal, might 
promote the local relaxation required for the formation of chromatin loops moving closer 
the active form of RNA polymerase II to the TSS of the gene, as previously recruited by 
APE1 on nCaRE sequence, turning on the transcription. My data, therefore, can be 
generalized into a regulatory model for all those genes that contain nCaRE elements. 
Accordingly, a new hypothesis can be proposed for the molecular activation of specific 
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genes during early response to DNA damage that links together DNA-repair enzymes 
and transcriptional regulation effectors. An oxidative base modification is introduced by 
oxidative stress condition in a key sequence involved in transcriptional complex 
formation, i.e. nCaRE. APE1 represents the key factor involved in this peculiar 
mechanism of transcriptional activation because potentially it can link its two functions; 
the DNA repair domain of the molecule is required for removal of the oxidative-induced 
base oxidation product, while the redox effector domain plays an important role in 
transcriptional complex assembly. As a first step toward exploring this possibility, the 
present study tested the hypothesis that APE1 is a component of the oxidative-inducible 
transcriptional complex binding to the nCaRE element of SIRT1 gene. Since among the 
identified genes bearing nCaRE sequences in their promoter, several other genes are 
associated with cellular response to DNA damage, further studies will unveil the 
relevance of this model and its general value. 
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7 Materials and methods 
7.1 Bioinformatic analysis  
All human and mouse DNA sequences were retrieved from the Ensembl database 
(release 56) (http://www.ensembl.org/) by using a dedicated program written in Perl that 
collects entries from this archive. A sequence window that contains 5' genomic DNA of 
every gene coding for a protein was selected. This region extends from 6000 bp 
upstream and 1000 bp downstream of each transcriptional start site. Gene Ontology 
(GO) annotations were obtained from Ensembl database by using the data mining tool 
BioMart (http://www.ensembl.org/) [255]. Human and mouse promoter regions were 
scanned for significant similarities to nCaRE by using Glsearch as program for local 
alignment (available in the Fasta3 program package)[217]. Glsearch was chosen 
because it calculates an alignment that is global in the query and local in the library. The 
following nCaRE sequences were used as query [139]: 
 
Name Sequence (5’ to 3’) 
nCaRE-B (PTH) TTTTTGAGACAGGGTCTCACTCTG 
nCaRE-B1 (APE1) TTTTGAGACAGTCTCAGCTCTG 
nCaRE-B2 (APE1) TTTTGAGACAGAGTTTCACTCTTG 
 
Alignments were computed with Altschul and Gish's statistical estimates, which 
are more suitable for searching of short query sequences (-z 3 option) [256]. Only those 
promoter genes that showed one or more matches for nCaRE sequences were selected, 
allowing up to two mismatches in the case of human genome and up to three 
mismatches in the case of mouse one; in fact, in the latter case, most alignments were 
found with three mismatches. From mouse promoter genes that contained nCaRE 
elements, only orthologous man/mouse genes were retrieved, as obtained from the 
BioMart Ensembl database. For the microarray filter, human genes selected from 
alignment search were cross-checked with microarray data obtained from the gene 
expression profile of HeLa cells silenced for APE1 by RNA interference [53]. GO filter 
identified co-regulated human genes, as determined by microarray analysis, studying the 
prevalence of their GO annotation terms. This analysis was obtained by using a Perl 
program kindly provided by Caselle and coworkers [257], which performs an exact 
Fisher’s test based on hypergeometric distribution to determine whether the term appears 
in the set significantly more often than what expected by chance. This program uses four 
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different entries: i) a file containing the whole GO database structure (OBO version 1.2, 
available at http://www.geneontology.org/); ii) the list of genes from whole human 
genome; iii) a list of all genes with all the GO terms associated with them (as obtained 
from Ensemble-BioMart); iv) the set of genes to be tested. Phylogenetic footprinting 
analysis consisted in the last selection from significant data obtained from GO filter of that 
genes also present in the mouse orthologous dataset.  
7.2 Gene annotations co-occurrence analysis 
Gene identies corresponding to the list of 57 putative genes regulated by APE1 were 
submitted to GeneCodis (http://genecodis.cnb.csic.es/), a web-based tool for the 
ontological analysis [258-260], selecting Homo Sapiens as the source for annotations 
and ‘Biological Process’ as the Gene Ontology category to perform the gene annotation 
co-occurrence analysis. 
7.3 Cell culture and transient transfection experiments 
HeLa cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) 
supplemented with 10% fetal bovine serum (Euroclone, Milan, Italy), 100 U/ml penicillin 
and 10 μg/ml streptomycin sulfate. One day before transfection, cells were seeded in 10-
cm plates at a density of 3×106 cells/plate. Cells were then transiently transfected with 
plasmids of interest by using Lipofectamine 2000 reagent (Invitrogen), according to the 
manufacturer's instructions. Cells were harvested 48 h after transfection. 
7.4 Inducible APE1 knock-down and generation of APE1 knock-
in cell lines 
Inducible silencing of endogenous APE1 and reconstitution with mutant proteins in 
HeLa cell clones was performed as already described [53][13]. For inducible shRNA 
experiments, doxycycline (1 μg/ml) (Sigma) was added to the cell culture medium and 
cells were grown for 10 days. 
7.5 Plasmids and expression of recombinant proteins 
Plasmid containing the human SIRT1 promoter was kindly provided by Dr. Irani, 
University of Pittsburgh, USA. This plasmid consists of a fragment of the human SIRT1 
promoter (–1266 to +137 relative to transcription start site) cloned into the pGL4.1 firefly 
luciferase reporter vector (Promega) [157]. The human SIRT1 promoter carrying the 
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mutation at nCaRE sequences was generated with a Site-Directed Mutagenesis Kit 
(Stratagene), using the following primers:  
SIRT1-B mut for 5'-
TCATCTAGGTTTTATTTATATATTTTTTTGCTAAGGAGCGTCGCTCTTGCTGCCCAGG
CTGGTGTG-3' and SIRT1-B mut rev5'-
CACACCAGCCTGGGCAGCAAGAGCGACGCTCCTTAGCAAAAAAATATATAAATAAAA
CCTAGATGA-3'. 
Expression and purification of recombinant proteins from E. coli were performed as 
previously described [85][13].  
7.6 Antibodies and Western blotting analysis  
For Western blotting analyses, the indicated amounts of cell extracts were resolved in 
10% SDS-PAGE and transferred to nitrocellulose membranes (Schleicher & Schuell). 
Membranes were blocked with 5% w/v non-fat dry milk in PBS containing 0.1% v/v 
Tween 20 and probed with the monoclonal anti-FLAG antibody (Sigma), the monoclonal 
anti-Ku70 (Santa Cruz), the monoclonal anti-RNA polymerase II (Abcam) and the 
monoclonal anti-APE1 antibody [53]; blots were developed by using the ECL enhanced 
chemiluminescence procedure (GE Healthcare) or Western Lightning Ultra (Perkin 
Elmer). Data normalization was performed by using a monoclonal anti-tubulin antibody 
(Sigma). Blots were quantified by using a Chemidoc XRS video densitometer (Bio-Rad). 
7.7 Secondary structure predictions 
Potential secondary structures for nCaRE SIRT1-B oligonucleotide were 
determined by using the mFold Web Server program available at 
(http://mfold.rna.albany.edu/?q=mfold). Structure predictions were run by setting the 
program parameters as close as possible to the conditions used in binding assays (i.e. 
37°C and 50 mM monovalent cation). 
7.8 Chromatin immunoprecipitation (ChIP) Analysis 
ChIP assay was performed by using a protocol described previously [5]. 5×106 
HeLa cells in 10-cm dishes were transiently co-trasfected with the human SIRT1 
promoter plasmid or the mutated one and APE1WT or APE1NΔ33 FLAG-expressing 
plasmids. Before harvesting, cells were fixed with 1% formaldehyde for 10 min, at 37°C, 
to allow reversible cross-linking of proteins. After 2 washes with PBS, cells were scraped 
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with 1 ml of ice-cold PBS supplemented with 1x Protease inhibitor cocktail (Sigma), 0.5 
mM phenylmethylsulfonyl fluoride (PMSF), 1 mM NaF, 1 mM Na3VO4 and clarified by 
centrifugation at 7,000 g, at 4°C, for 5 min. Cells were then lysed in 300 μl of 50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 1 mM EDTA and 1% w/v Triton X-100, completed with the 
same inhibitors quoted above. Chromatin preparations were sonicated (Bioruptor® 
Diagenode, Liege, Belgium) into fragments with an average length of 0.5–1 kb; after 
centrifugation at 12,000 g for 10 min, at 4°C, supernatants were diluted 10 fold in 0.01% 
SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1 and 167 mM NaCl, 
added with protease inhibitors. Immunoprecipitation was performed by using the anti-
FLAG® M2 Affinity Gel (Sigma). To reduce nonspecific background, 0.4 μg of Salmon 
Sperm DNA (Sigma) and 1 μg of BSA (Sigma) were added. Samples were then placed in 
a roller shake for 3 h and centrifuged at 8,000 x g, at 4°C, for 1 min. Supernatants were 
discarded and the resin was washed with 1 ml of Low Salt Immune Complex Wash Buffer 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1 and 150 mM NaCl), 
High Salt Immune Complex Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 
mM Tris-HCl pH 8.1 and 500 mM NaCl), LiCl Immune Complex Wash Buffer (0.25 M 
LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1) and with two 
washes with TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA) for 5 min, at room 
temperature, with rotation. Immune complexes were eluted two times by adding 250 μl of 
Elution Buffer (1% SDS and 0.1 M NaHCO3), incubated 15 min, at room temperature, and 
the two elution fractions combined. Elutes were added with 20 μl of 5 M NaCl and heated 
at 65°C, for 4 h, to reverse the formaldehyde cross-links. Released DNA was digested by 
incubation with a solution consisting of 2 μl of proteinase K (10 mg/ml) (Sigma), 10 μl of 
EDTA 0.5 M and 20 μl of Tris-HCl pH 6.5, for 1 h, at 45°C. Digested DNA was extracted 
with 24:1 v/v phenol/isoamyl alcohol and then precipitated with ethanol. Precipitated 
samples were resuspended in 50 μl of H20 and analyzed by qRT-PCR with an ABI 
PRISM7000 instrument.  
The human SIRT1 promoter containing the nCaRE SIRT1-B sequence was 
amplified by qRT-PCR with CFX96 Real-Time System (Bio-Rad), according to the 
manufacturer’s protocol. The following primers were used: nCaREB_for 5’-
CACCAATCAACCCCTCAT-3’ and nCaREB_rev 5’- CACCAATCAACCCCTCAT-3’, 
which amplified a region of 136 bp. DNA was amplified in 96-well plates using primers for 
nCaREB_for and nCaREB_rev using the 2X iQ™ SYBR® Green Supermix (Bio-Rad) (100 
mM KCl, 40 mM Tris-HCl pH 8.4, 0.4 mM of each deoxynucleoside triphosphate [dNTP], 
50 U/ml iTaq DNA polymerase, 6 mM MgCl2, SYBR green I, 20 nM fluorescein, and 
stabilizers) and 10 μM of the specific sense and antisense primers, in a final volume of 15 
μl for each well. Each analysis was performed in triplicate. As negative control, a sample 
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without template was used. The cycling parameters were: i) denaturation at 95°C, for 10 
s; ii) annealing/extension at 60°C, for 30 s (repeated 40 times). In order to verify the 
specificity of the amplification, a melting-curve analysis was performed, immediately after 
the amplification protocol. The results of the qRT-PCR assay for each sample were 
reported as percent of ng of immunoprecipitated nCaRE DNA relative to that present in 
total input chromatin, using an absolute standard curve (0.002, 0.02, 0.2, 2, 20, 200 and 
2000 pg of hSIRT1 promoter-plasmid standard). 
7.9 Preparation of nuclear cell extracts 
Nuclear protein extracts were prepared as described earlier [261]. Briefly, cells 
were harvested and then centrifuged at 2,000 g for 10 min at 4°C. Supernatant was 
removed, and the pellet was resuspended in buffer A (10 mM Tris-HCl [pH 7.5], 1.5 mM 
MgCl2, and 10 mM KCl supplemented with 1x protease inhibitor cocktail, 0.5 mM PMSF, 
1 mM NaF and 1 mM Na3VO4) at a cell density of 3x10
7 cells/ml and incubated on ice for 
10 min. The nuclei were collected by centrifugation at 2,000 g for 10 min at 4°C and then 
resuspended in buffer B (20 mM Tris-HCl [pH 7.5], 0.42 M KCl, 1.5 mM MgCl2, 20% 
[vol/vol] glycerol supplemented with 1x protease inhibitor cocktail, 0.5 mM PMSF, 1 mM 
NaF, and 1 mM Na3VO4) and rotated for 30 min at 4°C. The suspension was centrifuged 
at 15,000 g for 30 min at 4°C. The protein concentration was determined using Bio-Rad 
protein assay reagent.  
7.10 Electrophoretic Mobility Shift Assay (EMSA) analysis 
APE1 binding to nucleic acids was assessed as already described [85], with some 
modifications. Briefly, the indicated amount of recombinant proteins or 5 μg of the 
reported nuclear extract were incubated at 37°C for 15 minutes with 250 pmol of 
unlabeled poly(dT), or 250 ng of sonicated salmon sperm DNA (Sigma). 2.5 pmol of 32P-
labeled double-stranded (ds) oligonucleotides were then added and incubated for 
additional 15 min and further separated onto a native 6% w/v polyacrylamide gel at 150 
V, for 4 h. When performing super-shift assays, 5 μl of monoclonal anti-APE1 [53], anti-
Ku-70 (sc-12729, Santa Cruz Biotechnology, Inc.) or anti-P2Y6 (Alomone Labs) were 
pre-incubated with HeLa nuclear extract from APE1SCR-1 clone at 4°C, for 3 h.  
Oligonucleotides used for EMSA were the following:  
Name Sequence (5’ to 3’) 
nCaRE SIRT1-A 
 For TTTTTGAGACAGAGTTTCACTCTTG 
 Rev CAAGAGTGAAACTCTGTCTCAAAAA 
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nCaRE SIRT1-B 
 For TTTTTGAGACGGAGTTTCGCTCTTG 
 Rev CAAGAGCGAAACTCCGTCTCAAAAA 
Poly(dT) For TTTTTTTTTTTTTTTTTTTTTTTT 
 
7.11 T7 endonuclease I footprinting 
Footprinting analysis on nCaRE sequence were conducted using T7 endonuclease I. 
Briefly, 5’-32P-end-labeled nCaRE-B was digested with 5U of T7 endonuclease I at 37°C, 
for 1h. The reaction mixtures were then loaded and separated for 2h onto a denaturing 
8M urea sequencing gel. After separation, the gel was incubated for 30’ in a 10% 
methanol and 10% acetic acid solution for 30’ and then wrapped in Saran wrap and 
exposed to film for autoradiograpy. 
7.12 Determination of AP endonuclease activity  
Determination of APE1 AP endonuclease activity was performed using an oligonucleotide 
cleavage assay, as described previously [13]. The indicated amount of recombinant 
APE1 protein was incubated with a 5’-32P-end-labeled 26 mer ds oligonucleotide 
containing a single tetrahydrofuranyl (here called THF) artificial AP site at position 14, 
which is cleaved to a 14-mer in the presence of AP endonuclease activity. Alternatively, a 
5’-32P-end-labeled ds nCaRE SIRT1-B oligonucleotide or a 5’-32P-end-labeled ds nCaRE 
SIRT1-B oligonucleotide, bearing a single tetrahydrofuranyl residue at position 12 
(bolded) nCaREB2 5'- TTTTTGAGACGGAGTTTCGCTCTTG -3' (Integrated DNA 
Technologies) were used. 
7.13 Reporter assays 
For reporter assay experiments, we used a human SIRT1 promoter plasmid 
allowing for promoter activity measurements upon luciferase assay, as already described 
[157]. To this purpose, 2.5x104 HeLa cells were seeded in a 96-well plate and co-
transfected with 15 ng of human SIRT1 promoter, 0.3 ng of a constitutive renilla reporter 
plasmid and 75 ng of a vector expressing FLAG-tagged APE1 protein. When performing 
luciferase assays upon H2O2, cells were challenged with increasing amounts of H2O2 in 
serum-free medium for 1h, at 37°C, and then firefly and renilla luciferase activities were 
measured 24 h after the treatment by using the Dual-Glo Luciferase assay system 
(Promega), according to manufacturer’s recommendations. Firefly activity was 
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normalized to renilla activity to correct for differences in transfection efficiency. Results 
are from triplicate experiments. 
7.14 Q-PCR 
Total RNA from cell lines was extracted with the SV Total RNA isolation System kit 
(Promega). One microgram of total RNA was reverse transcribed using the iScript cDNA 
synthesis kit (Bio-Rad), according to the manufacturer’s instructions. qRT-PCR was 
performed with a CFX96 Real-Time System (Bio-Rad) using iQ™ SYBR® Green 
Supermix (Bio-Rad). Primer sequences for human SIRT1 were those reported in [157]. 
Human GAPDH was used as internal control; sense, 5’- 
CCCTTCATTGACCTCAACTACATG -3’; antisense 5’- 
TGGGATTTCCATTGATGACAAGC -3’. The cycling parameters conditions are identical 
to those reported for ChIP analysis.  
7.15 Surface Plasmon Resonance (SPR) analysis  
SPR analysis was performed at Institute of Biostructures and Bioimaging, National 
Research Council of Naples, Italy. Real time binding assays were performed on a 
Biacore 3000 SPR instrument (GE Healthcare). Biotinylated ds oligonucleotides were 
immobilized on a SA-chip at the desired level, as result of their injection at a 
concentration of 500 nM in HBS (20 mM Hepes, 150 mM NaCl, 3.4 mM EDTA, and 
0.005% v/v P20 surfactant, 0.1 mM tris(2-carboxyethyl)phosphine), at 10 µL/min as flow 
rate. Flow cell 2 contained 100 RU of poly(dT); flow cell 3 and 4 contained 77 and 60 
RU of nCaRE SIRT1-B2 and nCaRE SIRT1-B2 mut respectively, and flow cell 1 (with 
streptavidin) was left blank to be used as a reference surface. APE1 and its deletion 
mutant APE1NΔ33 were serially diluted in running buffer to the indicated concentrations 
and injected at a flow rate of 20 L/min for 4.5 min, at 20°C. Disruption of any complex 
that remained bound after a 3-min dissociation was achieved by using an injection of 1 
M NaCl at 20 µL/min, for 1 min. BIAevaluation analysis package version 4.1 (GE 
Healthcare) was used to subtract blank signal, and to evaluate kinetic and dissociation 
constants. Kinetic parameters were estimated assuming a 1:1 binding model and using 
version 7 4.1 Evaluation Software (GE Healthcare). An affinity steady state model was 
applied to fit the RUmax data versus proteins concentrations and fitting was performed 
with GraphPad Prism v4.00 [85]. 
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7.16 Limited proteolysis and LC-ESI-MS analysis 
Limited proteolysis and LC-ESI-MS analysis were performed at the Proteomics & 
Mass Spectrometry Laboratory, ISPAAM of Naples, Italy. 
Suitable experimental conditions were chosen by testing proteolysis with different 
enzyme/substrate values; no preventive removal of DNA was performed. Thus, limited 
proteolysis experiments on recombinant APE1 were conducted in 50 mM NH4HCO3, pH 
7.5 (reaction buffer) at 37°C, by using an enzyme to substrate ratio ranging from 1:500 to 
1:5000 w/w. Three identical aliquots of APE1 (500 pmol) were combined with reaction 
buffer or DNA nCaRE ds oligonucleotides (PTH and nCaRE SIRT1-B) (5:1 mol 
DNA/protein) dissolved in reaction buffer to generate samples (100 µl final volume each), 
which were incubated for 15 min at 37°C, before protease addition. After digestion 
starting, the extent of proteolysis was monitored on a time-course basis by sampling 10 µl 
of the mixture at time intervals ranging from 5 to 120 min. Reaction samples were 
immediately quenched with 5% formic acid and then frozen in dry-ice before LC-ESI-MS 
analysis.  
APE1 digests were analyzed with Q-TOF Premier mass spectrometer (Waters, 
Milford, MA) equipped with a nanospray source. Peptide mixtures were separated on an 
Atlantis C18 column (100 µm x 100 mm, 3 µm), using a linear gradient ranging from 30 to 
60% acetonitrile in 1% formic acid, over a period of 50 min, at a flow rate of 800 nl/min. 
Spectra were acquired in the m/z 650-2500 range. Data were processed by using the 
MassLynx software (Waters). Mass calibration was performed by means of the multiply 
charged ions from horse heart myoglobin (Sigma). Depending on polypeptide size, mass 
values have been reported as monoisotopic or average values. Observed mass values 
were assigned to specific polypeptides by using the Paws software (Proteometrics Inc.), 
based on APE1 sequence and selectivity of the protease used for protein digestion.  
7.17 Statistical analyses 
Statistical analyses were performed by using the Excel (Microsoft, Redmond, WA) 
data analysis program for Student’s t test analysis. P < 0.05 was considered as 
statistically significant. 
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Supplementary Table 4 
Significant GO terms associated to genes bearing nCaRE elements and present in expression profile data obtained from 
experiment in which APE1 was knocked down.  
Here we are reported only the most significant GO annotation terms obtained when performing the exact Fisher's test. The column titled 
“n_annotation” correspond to the total number of genes associated to that GO term in Gene Ontology database; instead, column “n_both” 
represents the amount of genes in our dataset associated to the same GO term. “Expect” column reports for all GO terms the number of 
genes expected by chance in a set made of the same number of dataset genes, but selected at random from database. The columns titled 
“C”, “F” and “P” correspond to the three branches of the Gene Ontology: cellular component, molecular function and biological process 
respectively. 
GO ID n_annotation n_both expect pv -
GO:0044424 10446 291 187.2580 8.69E-028 intracellular part C
GO:0005622 10863 296 194.7340 7.22E-027 intracellular C
GO:0043229 8870 260 159.0070 8.72E-026 intracellular organelle C
GO:0043226 8885 260 159.2750 1.18E-025 organelle C
GO:0005515 8150 238 146.1000 9.42E-022 protein binding F
GO:0043231 7836 232 140.4710 1.03E-021 intracellular membrane-bounded organelle C
GO:0043227 7845 232 140.6320 1.22E-021 membrane-bounded organelle C
GO:0044464 14446 334 258.9640 4.67E-019 cell part C
GO:0005623 14447 334 258.9820 4.74E-019 cell C
GO:0005634 5052 168 90.5638 1.39E-018 nucleus C
GO:0044446 3929 139 70.4326 5.42E-017 intracellular organelle part C
GO:0044422 3957 139 70.9345 1.00E-016 organelle part C
GO:0044428 1616 79 28.9690 1.56E-016 nuclear part C
GO:0005737 7181 206 128.7290 2.43E-016 cytoplasm C
GO:0005575 15609 344 279.8120 3.50E-016 cellular_component C
GO:0006139 1842 82 33.0203 7.61E-015 nucleobase, nucleoside, nucleotide and nucleic acid metabolic process P
GO:0009987 10893 267 195.2720 5.09E-014 cellular process P
GO:0005488 12806 298 229.5650 6.67E-014 binding F
GO:0006807 2248 90 40.2984 1.42E-013 nitrogen compound metabolic process P
GO:0044260 3877 129 69.5004 1.61E-013 cellular macromolecule metabolic process P
GO:0043232 2536 97 45.4612 1.91E-013 intracellular non-membrane-bounded organelle C
GO:0043228 2536 97 45.4612 1.91E-013 non-membrane-bounded organelle C
GO:0044237 5431 162 97.3579 2.93E-013 cellular metabolic process P
GO:0031981 1231 60 22.0673 1.44E-012 nuclear lumen C
GO:0016070 938 51 16.8149 1.57E-012 RNA metabolic process P
 
  
GO ID n_annotation n_both expect pv -
GO:0008150 14455 319 259.1250 2.69E-012 biological_process P
GO:0031974 1610 69 28.8614 9.32E-012 membrane-enclosed lumen C
GO:0043233 1575 68 28.2340 9.77E-012 organelle lumen C
GO:0070013 1539 67 27.5886 9.91E-012 intracellular organelle lumen C
GO:0044238 5664 161 101.5350 2.39E-011 primary metabolic process P
GO:0043170 4436 135 79.5212 2.73E-011 macromolecule metabolic process P
GO:0043067 740 42 13.2655 4.62E-011 regulation of programmed cell death P
GO:0010941 742 42 13.3013 5.02E-011 regulation of cell death P
GO:0042981 731 41 13.1042 1.15E-010 regulation of apoptosis P
GO:0003674 15294 327 274.1650 1.17E-010 molecular_function F
GO:0032991 3223 106 57.7766 1.29E-010 macromolecular complex C
GO:0008152 6464 173 115.8760 4.09E-010 metabolic process P
GO:0005654 857 42 15.3629 3.91E-009 nucleoplasm C
GO:0048519 1704 63 30.5465 2.85E-008 negative regulation of biological process P
GO:0048523 1550 59 27.7858 3.06E-008 negative regulation of cellular process P
GO:0005856 1386 54 24.8459 6.01E-008 cytoskeleton C
GO:0006996 1386 54 24.8459 6.01E-008 organelle organization P
GO:0044444 4724 129 84.6840 1.06E-007 cytoplasmic part C
GO:0010467 1326 51 23.7703 2.18E-007 gene expression P
GO:0044248 1081 44 19.3784 3.53E-007 cellular catabolic process P
GO:0034645 1164 46 20.8663 4.30E-007 cellular macromolecule biosynthetic process P
GO:0022402 542 28 9.7161 6.19E-007 cell cycle process P
GO:0009059 1182 46 21.1889 6.59E-007 macromolecule biosynthetic process P
GO:0044430 893 38 16.0082 8.12E-007 cytoskeletal part C
GO:0044249 2001 66 35.8706 8.52E-007 cellular biosynthetic process P
GO:0016043 2593 79 46.4830 1.37E-006 cellular component organization P
GO:0044265 783 34 14.0363 2.04E-006 cellular macromolecule catabolic process P
GO:0044267 2446 75 43.8478 2.15E-006 cellular protein metabolic process P
GO:0016071 359 21 6.4356 2.39E-006 mRNA metabolic process P
GO:0009058 2062 66 36.9641 2.40E-006 biosynthetic process P
GO:0043234 2546 77 45.6404 2.55E-006 protein complex C
GO:0034660 248 17 4.4457 2.70E-006 ncRNA metabolic process P
GO:0005730 429 23 7.6904 3.44E-006 nucleolus C
GO:0007010 439 23 7.8697 5.04E-006 cytoskeleton organization P
GO:0006259 538 26 9.6444 5.27E-006 DNA metabolic process P
GO:0006396 540 26 9.6802 5.63E-006 RNA processing P
GO:0000278 352 20 6.3101 6.40E-006 mitotic cell cycle P
  
GO ID n_annotation n_both expect pv -
GO:0006403 95 10 1.7030 7.96E-006 RNA localization P
GO:0043065 360 20 6.4535 8.92E-006 positive regulation of apoptosis P
GO:0042802 624 28 11.1860 9.19E-006 identical protein binding F
GO:0043068 363 20 6.5073 1.01E-005 positive regulation of programmed cell death P
GO:0016874 426 22 7.6366 1.01E-005 ligase activity F
GO:0010942 365 20 6.5431 1.09E-005 positive regulation of cell death P
GO:0007049 738 31 13.2296 1.13E-005 cell cycle P
GO:0005200 83 9 1.4879 1.78E-005 structural constituent of cytoskeleton F
GO:0015629 347 19 6.2204 1.83E-005 actin cytoskeleton C
GO:0005916 10 4 0.1793 1.96E-005 fascia adherens C
GO:0008092 516 24 9.2500 2.27E-005 cytoskeletal protein binding F
GO:0015931 108 10 1.9360 2.48E-005 nucleobase, nucleoside, nucleotide and nucleic acid transport P
GO:0003723 704 29 12.6201 3.11E-005 RNA binding F
GO:0003779 330 18 5.9157 3.18E-005 actin binding F
GO:0019538 2968 82 53.2054 3.42E-005 protein metabolic process P
GO:0043038 70 8 1.2548 3.55E-005 amino acid activation P
GO:0006418 70 8 1.2548 3.55E-005 tRNA aminoacylation for protein translation P
GO:0043039 70 8 1.2548 3.55E-005 tRNA aminoacylation P
GO:0044085 1133 40 20.3105 3.56E-005 cellular component biogenesis P
GO:0022403 399 20 7.1526 3.90E-005 cell cycle phase P
GO:0004812 71 8 1.2728 3.94E-005 aminoacyl-tRNA ligase activity F
GO:0016876 71 8 1.2728 3.94E-005 ligase activity, forming aminoacyl-tRNA and related compounds F
GO:0016875 71 8 1.2728 3.94E-005 ligase activity, forming carbon-oxygen bonds F
GO:0051236 92 9 1.6492 4.08E-005 establishment of RNA localization P
GO:0050657 92 9 1.6492 4.08E-005 nucleic acid transport P
GO:0050658 92 9 1.6492 4.08E-005 RNA transport P
GO:0000049 23 5 0.4123 4.65E-005 tRNA binding F
GO:0006399 142 11 2.5455 5.22E-005 tRNA metabolic process P
GO:0006950 2005 60 35.9423 5.46E-005 response to stress P
GO:0043632 548 24 9.8236 5.90E-005 modification-dependent macromolecule catabolic process P
GO:0019941 548 24 9.8236 5.90E-005 modification-dependent protein catabolic process P
GO:0030529 550 24 9.8595 6.24E-005 ribonucleoprotein complex C
GO:0006402 39 6 0.6991 6.31E-005 mRNA catabolic process P
GO:0065009 933 34 16.7253 7.66E-005 regulation of molecular function P
GO:0006261 58 7 1.0397 7.71E-005 DNA-dependent DNA replication P
GO:0006401 59 7 1.0577 8.62E-005 RNA catabolic process P
GO:0000184 26 5 0.4661 8.70E-005 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay P
  
GO ID n_annotation n_both expect pv -
GO:0006520 263 15 4.7146 8.76E-005 cellular amino acid metabolic process P
GO:0005625 325 17 5.8261 8.79E-005 soluble fraction C
GO:0015630 527 23 9.4472 8.84E-005 microtubule cytoskeleton C
GO:0005829 1141 39 20.4539 8.93E-005 cytosol C
GO:0007067 205 13 3.6749 8.95E-005 mitosis P
GO:0000280 205 13 3.6749 8.95E-005 nuclear division P
  
  
Supplementary Table 5 
The final 57 genes extracted from the application of Gene Ontology and phylogentic footprinting analysis that can be considered 
bona fide as bearing the candidate nCaRE sequences within their regulatory elements and potentially regulated by APE1.  
Ensembl ID Gene title Gene symbol Chr. location
ENSG00000090861 alanyl-tRNA synthetase AARS chr16q22
ENSG00000100823 APEX nuclease (multifunctional DNA repair enzyme) 1 APEX1 chr14q11.2-q12
ENSG00000062725 amyloid beta precursor protein (cytoplasmic tail) binding protein 2 APPBP2 chr17q21-q23
ENSG00000162704 actin related protein 2/3 complex, subunit 5, 16kDa ARPC5 chr1q25.3
ENSG00000113732 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e ATP6V0E chr5q35.1
ENSG00000156735 BCL2-associated athanogene 4 BAG4 chr8p12
ENSG00000060762 brain protein 44-like BRP44L chr6q27
ENSG00000130303 bone marrow stromal cell antigen 2 BST2 chr19p13.2
ENSG00000164941 chromosome 8 open reading frame 52 C8orf52 chr8q22.1
ENSG00000110619 cysteinyl-tRNA synthetase CARS chr11p15.5
ENSG00000160200 cystathionine-beta-synthase CBS chr21q22.3
ENSG00000117877 CD3E antigen, epsilon polypeptide associated protein CD3EAP chr19q13.3
ENSG00000010278 CD9 antigen (p24) CD9 chr12p13.3
ENSG00000153774 craniofacial development protein 1 CFDP1 chr16q22.2-q22.3
ENSG00000149600 COMM domain containing 7 COMMD7 chr20q11.21
ENSG00000175215 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 2 CTDSP2 chr12q13-q15
ENSG00000143079 CTTNBP2 N-terminal like CTTNBP2NL chr1p13.2
ENSG00000108406 DEAH (Asp-Glu-Ala-His) box polypeptide 40 DHX40 chr17q23.2
ENSG00000120738 Early growth response 1 EGR1 chr5q31.1
ENSG00000147677 eukaryotic translation initiation factor 3, subunit 3 gamma, 40kDa EIF3S3 chr8q24.11
ENSG00000187840 eukaryotic translation initiation factor 4E binding protein 1 EIF4EBP1 chr8p12
ENSG00000136628 glutamyl-prolyl-tRNA synthetase EPRS chr1q41-q42
ENSG00000147874 family with sequence similarity 29, member A FAM29A chr9p22.1
ENSG00000104872 hypothetical protein FLJ20643 FLJ20643 chr19q13.33
ENSG00000143575 HCLS1 associated protein X-1 HAX1 chr1q21.3
ENSG00000185359 hepatocyte growth factor-regulated tyrosine kinase substrate HGS chr17q25
ENSG00000189159 hematological and neurological expressed 1 HN1 chr17q25.1
ENSG00000131373 2-hydroxyphytanoyl-CoA lyase HPCL2 chr3p25.1
ENSG00000166411 isocitrate dehydrogenase 3 (NAD+) alpha IDH3A chr15q25.1-q25.2
ENSG00000130522 jun D proto-oncogene JUND chr19p13.2
ENSG00000145725 KIAA0433 protein KIAA0433 chr5q21.1
ENSG00000052749 KIAA0690 KIAA0690 chr10q24.1
ENSG00000112200 KIAA1702 protein KIAA1702 chr6p11
ENSG00000118193 kinesin family member 14 KIF14 chr1pter-q31.3  
  
Ensembl ID Gene title Gene symbol Chr. location
ENSG00000109790 kelch-like 5 (Drosophila) KLHL5 chr4p14
ENSG00000126214 kinesin 2 KNS2 chr14q32.3
ENSG00000130164 low density lipoprotein receptor (familial hypercholesterolemia) LDLR chr19p13.3
ENSG00000133895 multiple endocrine neoplasia I MEN1 chr11q13
ENSG00000109919 mitochondrial carrier homolog 2 (C. elegans) MTCH2 chr11p11.2
ENSG00000102908 nuclear factor of activated T-cells 5, tonicity-responsive NFAT5 chr16q22.1
ENSG00000171246 neuronal pentraxin I NPTX1 chr17q25.1-q25.2
ENSG00000135318 5'-nucleotidase, ecto (CD73) NT5E chr6q14-q21
ENSG00000025293 PHD finger protein 20 PHF20 chr20q11.22-q11.23
ENSG00000149547 translokin PIG8 chr11q21
ENSG00000198056 primase, polypeptide 1, 49kDa PRIM1 chr12q13
ENSG00000034677 ring finger protein 19 RNF19 chr8q22
ENSG00000096717 sirtuin (silent mating type information regulation 2 homolog) 1 (S. cerevisiae) SIRT1 chr10q21.3
ENSG00000105281 solute carrier family 1 (neutral amino acid transporter), member 5 SLC1A5 chr19q13.3
ENSG00000127616 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 SMARCA4 chr19p13.2
ENSG00000163029 SMC6 structural maintenance of chromosomes 6-like 1 (yeast) SMC6L1 chr2p24.2
ENSG00000197694 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) SPTAN1 chr9q33-q34
ENSG00000173465 Sjogren's syndrome/scleroderma autoantigen 1 SSSCA1 chr11q13.1
ENSG00000144043 testis expressed sequence 261 TEX261 chr2p13.3
ENSG00000035862 TIMP metallopeptidase inhibitor 2 TIMP2 chr17q25
ENSG00000198211 tubulin, beta 3 TUBB3 chr16q24.3
ENSG00000165280 valosin-containing protein VCP chr9p13.3
ENSG00000134684 tyrosyl-tRNA synthetase YARS chr1p35.1  
  
  
Supplementary Table 6 
Complete data reporting all the significant functional enrichments obtained performing GeneCodis analysis.  
‘GO term ID’ and ‘Annotations’ columns represent the Gene Ontology codes of annotations and the textual description of annotations, 
respectively. BP refers to ‘biological process’ category of Gene Ontology annotation. Third and fourth columns represent the number of 
genes in the input list and the reference list for a given annotation, respectively. P-values calculated using hypergeometric distribution and 
its correction using the stimulation-based approach are reported. The ‘Genes’ column identifies the set of genes in the input list showing a 
given annotation. 
GO term ID Annotations
# of 
annota
ted 
genes 
in the 
input 
list 
(Total # 
of 
genes 
in the 
input 
list) 
# of 
annotated 
genes in 
the 
reference 
list (Total # 
of genes in 
the 
reference 
list) 
Hyperge
ometric 
Distributi
on 
(Fisher's 
exact 
test)
Correcte
d 
Hyperge
ometric 
Dist. 
(Fisher's 
exact 
test)
Genes
GO:0010467 gene expression (BP) 6(57) 408(34208) 6,02E-05 9,97E-03 EIF4EBP1 YARS AARS EPRS CARS EIF3H
GO:0045944
positive regulation of transcription 
from RNA polymerase II promoter 
(BP)
6(57) 578(34208) 3,96E-04 1,87E-02 SIRT1 EGR1 JUND SMARCA4 MEN1  NFAT5
GO:0006281 DNA repair (BP) 5(57) 285(34208) 1,14E-04 1,26E-02 SIRT1 SMC6 VCP MEN1 APEX1
GO:0006810 transport (BP) 5(57) 604(34208) 3,32E-03 2,89E-02 VCP LDLR NPTX1 ATP6V0E1 MTCH2
GO:0006418
tRNA aminoacylation for protein 
translation (BP)
4(57) 43(34208) 8,14E-07 2,70E-04 YARS AARS EPRS CARS
GO:0008285
negative regulation of cell 
proliferation (BP)
4(57) 341(34208) 2,53E-03 2,46E-02 HGS MEN1 CD9 TIMP2
GO:0045892
negative regulation of transcription, 
DNA-dependent (BP)
4(57) 401(34208) 4,50E-03 2,37E-02 SIRT1 SMARCA4 MEN1 COMMD7
 
  
GO term ID Annotations
# of 
annota
ted 
genes 
in the 
input 
list 
(Total # 
of 
genes 
in the 
input 
list) 
# of 
annotated 
genes in 
the 
reference 
list (Total # 
of genes in 
the 
reference 
list) 
Hyperge
ometric 
Distributi
on 
(Fisher's 
exact 
test)
Correcte
d 
Hyperge
ometric 
Dist. 
(Fisher's 
exact 
test)
Genes
GO:0000122
negative regulation of transcription 
from RNA polymerase II promoter 
(BP)
4(57) 416(34208) 5,13E-03 2,23E-02 SIRT1 EGR1 SMARCA4 MEN1
GO:0007018 microtubule-based movement (BP) 3(57) 90(34208) 4,65E-04 1,92E-02 KLC1 KIF14 TUBB3
GO:0030308
negative regulation of cell growth 
(BP)
3(57) 113(34208) 9,02E-04 2,71E-02 SIRT1 SMARCA4 EI24
GO:0006974
response to DNA damage 
stimulus (BP)
3(57) 129(34208) 1,32E-03 3,12E-02 SIRT1 VCP MEN1
GO:0043065
positive regulation of apoptotic 
process (BP)
3(57) 178(34208) 3,30E-03 3,03E-02 TEX261 SIRT1 MEN1
GO:0006457 protein folding (BP) 3(57) 182(34208) 3,51E-03 1,94E-02 AARS  BAG4 TUBB3
GO:0044267
cellular protein metabolic process 
(BP)
3(57) 284(34208) 1,19E-02 3,40E-02 EIF4EBP1  TUBB3 EIF3H
GO:0060766
negative regulation of androgen 
receptor signaling pathway (BP)
2(57) 10(34208) 1,22E-04 1,01E-02 SIRT1  SMARCA4
GO:0060135
maternal process involved in 
female pregnancy (BP)
2(57) 14(34208) 2,45E-04 1,62E-02 MEN1 CBS
GO:0002076 osteoblast development (BP) 2(57) 16(34208) 3,22E-04 1,78E-02 JUND MEN1
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GO:0045739
positive regulation of DNA repair 
(BP)
2(57) 23(34208) 6,75E-04 2,48E-02 SIRT1  APEX1
GO:0030968
endoplasmic reticulum unfolded 
protein response (BP)
2(57) 25(34208) 7,98E-04 2,64E-02 VCP AARS
GO:0043280
positive regulation of cysteine-type 
endopeptidase activity involved in 
apoptotic process (BP)
2(57) 27(34208) 9,32E-04 2,57E-02 SIRT1 MEN1
GO:0071356
cellular response to tumor 
necrosis factor (BP)
2(57) 28(34208) 1,00E-03 2,55E-02 SIRT1 BAG4
GO:0045768
positive regulation of anti-
apoptosis (BP)
2(57) 41(34208) 2,15E-03 2,22E-02 SIRT1  APEX1
GO:0045669
positive regulation of osteoblast 
differentiation (BP)
2(57) 42(34208) 2,25E-03 2,26E-02 JUND MEN1
GO:0032088
negative regulation of NF-kappaB 
transcription factor activity (BP)
2(57) 46(34208) 2,69E-03 2,55E-02 SIRT1 COMMD7
GO:0042632 cholesterol homeostasis (BP) 2(57) 51(34208) 3,30E-03 2,95E-02 SIRT1 LDLR
GO:0043161
proteasomal ubiquitin-dependent 
protein catabolic process (BP)
2(57) 52(34208) 3,43E-03 1,92E-02 SIRT1 VCP
GO:0043433
negative regulation of sequence-
specific DNA binding transcription 
factor activity (BP)
2(57) 54(34208) 3,69E-03 1,97E-02 SIRT1 MEN1
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chromatin remodeling (BP) 2(57) 54(34208) 3,69E-03 1,97E-02 SMARCA4 MEN1
response to insulin stimulus (BP) 2(57) 62(34208) 4,84E-03 2,50E-02 SIRT1 EGR1
DNA recombination (BP) 2(57) 86(34208) 9,12E-03 3,05E-02 SMC6 APEX1
cellular component movement 
(BP)
2(57) 95(34208) 1,10E-02 3,35E-02 CD9 ARPC5
regulation of cell proliferation (BP) 2(57) 101(34208) 1,24E-02 3,51E-02 SIRT1  CFDP1
insulin receptor signaling pathway 
(BP)
2(57) 139(34208) 2,26E-02 4,89E-02 EIF4EBP1 ATP6V0E1
homocysteine catabolic process 
(BP)
1(57) 1(34208) 1,67E-03 1,78E-02 CBS
cysteine biosynthetic process via 
cystathionine (BP)
1(57) 1(34208) 1,67E-03 1,78E-02 CBS 
transsulfuration (BP) 1(57) 1(34208) 1,67E-03 1,78E-02 CBS
cysteine biosynthetic process from 
serine (BP)
1(57) 1(34208) 1,67E-03 1,78E-02 CBS 
tyrosyl-tRNA aminoacylation (BP) 1(57) 1(34208) 1,67E-03 1,78E-02 YARS 
positive regulation of histone 
methylation (BP)
1(57) 1(34208) 1,67E-03 1,78E-02 MEN1 
adenosine biosynthetic process 
(BP)
1(57) 1(34208) 1,67E-03 1,78E-02 NT5E 
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GO:0072303
positive regulation of glomerular 
metanephric mesangial cell 
proliferation (BP)
1(57) 1(34208) 1,67E-03 1,78E-02 EGR1 
GO:0072110
glomerular mesangial cell 
proliferation (BP)
1(57) 1(34208) 1,67E-03 1,78E-02 EGR1 
GO:0033233
regulation of protein sumoylation 
(BP)
1(57) 1(34208) 1,67E-03 1,78E-02 EGR1
GO:2000655
negative regulation of cellular 
response to testosterone stimulus 
(BP)
1(57) 1(34208) 1,67E-03 1,78E-02 SIRT1
GO:2000480
negative regulation of cAMP-
dependent protein kinase activity 
(BP)
1(57) 1(34208) 1,67E-03 1,78E-02 SIRT1
GO:0006343
establishment of chromatin 
silencing (BP)
1(57) 1(34208) 1,67E-03 1,78E-02 SIRT1 
GO:2000757
negative regulation of peptidyl-
lysine acetylation (BP)
1(57) 1(34208) 1,67E-03 1,78E-02 SIRT1
GO:0034391
regulation of smooth muscle cell 
apoptosis (BP)
1(57) 1(34208) 1,67E-03 1,78E-02 SIRT1 
GO:0031937
positive regulation of chromatin 
silencing (BP)
1(57) 1(34208) 1,67E-03 1,78E-02 SIRT1 
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GO:0031393
negative regulation of 
prostaglandin biosynthetic process 
(BP)
1(57) 1(34208) 1,67E-03 1,78E-02 SIRT1 
GO:0060385
axonogenesis involved in 
innervation (BP)
1(57) 2(34208) 3,33E-03 1,90E-02 NPTX1 
GO:2000481
positive regulation of cAMP-
dependent protein kinase activity 
(BP)
1(57) 2(34208) 3,33E-03 1,90E-02 SIRT1 
GO:2000773
negative regulation of cellular 
senescence (BP)
1(57) 2(34208) 3,33E-03 1,90E-02 SIRT1 
GO:0035617 stress granule disassembly (BP) 1(57) 2(34208) 3,33E-03 1,90E-02 KLC1 
GO:0006424 glutamyl-tRNA aminoacylation (BP) 1(57) 2(34208) 3,33E-03 1,90E-02 EPRS 
GO:0016239
positive regulation of 
macroautophagy (BP)
1(57) 2(34208) 3,33E-03 1,90E-02 SIRT1 
GO:0006433 prolyl-tRNA aminoacylation (BP) 1(57) 2(34208) 3,33E-03 1,90E-02 EPRS 
GO:0006423 cysteinyl-tRNA aminoacylation (BP) 1(57) 2(34208) 3,33E-03 1,90E-02 CARS
GO:0043506
regulation of JUN kinase activity 
(BP)
1(57) 2(34208) 3,33E-03 1,90E-02 CBS 
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GO:0030823
regulation of cGMP metabolic 
process (BP)
1(57) 2(34208) 3,33E-03 1,90E-02 CBS 
GO:0070814
hydrogen sulfide biosynthetic 
process (BP)
1(57) 2(34208) 3,33E-03 1,90E-02 CBS
GO:0019448 L-cysteine catabolic process (BP) 1(57) 2(34208) 3,33E-03 1,90E-02 CBS
GO:0010899
regulation of phosphatidylcholine 
catabolic process (BP)
1(57) 2(34208) 3,33E-03 1,90E-02 LDLR 
GO:0018394 peptidyl-lysine acetylation (BP) 1(57) 2(34208) 3,33E-03 1,90E-02 SIRT1
GO:0080134
regulation of response to stress 
(BP)
1(57) 2(34208) 3,33E-03 1,90E-02 SIRT1 
GO:0002051 osteoblast fate commitment (BP) 1(57) 2(34208) 3,33E-03 1,90E-02 MEN1
GO:0006196 AMP catabolic process (BP) 1(57) 2(34208) 3,33E-03 1,90E-02 NT5E 
GO:0000720
pyrimidine dimer repair by 
nucleotide-excision repair (BP)
1(57) 2(34208) 3,33E-03 1,90E-02 SIRT1
GO:0071506
cellular response to mycophenolic 
acid (BP)
1(57) 2(34208) 3,33E-03 1,90E-02 EGR1 
GO:0032071
regulation of 
endodeoxyribonuclease activity 
(BP)
1(57) 2(34208) 3,33E-03 1,90E-02 SIRT1 
GO:0000492 box C/D snoRNP assembly (BP) 1(57) 3(34208) 4,99E-03 2,20E-02 PIH1D1 
GO:0006565 L-serine catabolic process (BP) 1(57) 3(34208) 4,99E-03 2,20E-02 CBS 
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GO:0030814
regulation of cAMP metabolic 
process (BP)
1(57) 4(34208) 6,65E-03 2,45E-02 TIMP2
GO:0007035 vacuolar acidification (BP) 1(57) 4(34208) 6,65E-03 2,45E-02 ATP6V0E1 
GO:0006020 inositol metabolic process (BP) 1(57) 4(34208) 6,65E-03 2,45E-02 PPIP5K2 
GO:0070842 aggresome assembly (BP) 1(57) 4(34208) 6,65E-03 2,45E-02 VCP
GO:0034983 peptidyl-lysine deacetylation (BP) 1(57) 4(34208) 6,65E-03 2,45E-02 SIRT1
GO:0006868 glutamine transport (BP) 1(57) 4(34208) 6,65E-03 2,45E-02 SLC1A5 
GO:0050667
homocysteine metabolic process 
(BP)
1(57) 4(34208) 6,65E-03 2,45E-02 CBS 
GO:0070857
regulation of bile acid biosynthetic 
process (BP)
1(57) 4(34208) 6,65E-03 2,45E-02 SIRT1
GO:0070932 histone H3 deacetylation (BP) 1(57) 4(34208) 6,65E-03 2,45E-02 SIRT1 
GO:0033158
regulation of protein import into 
nucleus, translocation (BP)
1(57) 4(34208) 6,65E-03 2,45E-02 SIRT1 
GO:0006346
methylation-dependent chromatin 
silencing (BP)
1(57) 5(34208) 8,30E-03 2,80E-02 SIRT1 
GO:0030913 paranodal junction assembly (BP) 1(57) 5(34208) 8,30E-03 2,80E-02 CD9
GO:0006563 L-serine metabolic process (BP) 1(57) 5(34208) 8,30E-03 2,80E-02 CBS
GO:0001678 cellular glucose homeostasis (BP) 1(57) 5(34208) 8,30E-03 2,80E-02 SIRT1
GO:0071504 cellular response to heparin (BP) 1(57) 5(34208) 8,30E-03 2,80E-02 EGR1 
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GO:0030970
retrograde protein transport, ER to 
cytosol (BP)
1(57) 5(34208) 8,30E-03 2,80E-02 VCP 
GO:0043039 tRNA aminoacylation (BP) 1(57) 5(34208) 8,30E-03 2,80E-02 AARS 
GO:0032925
regulation of activin receptor 
signaling pathway (BP)
1(57) 5(34208) 8,30E-03 2,80E-02 MEN1 
GO:0008088 axon cargo transport (BP) 1(57) 6(34208) 9,96E-03 3,05E-02 KLC1 
GO:0046628
positive regulation of insulin 
receptor signaling pathway (BP)
1(57) 6(34208) 9,96E-03 3,05E-02 SIRT1 
GO:0021587 cerebellum morphogenesis (BP) 1(57) 6(34208) 9,96E-03 3,05E-02 CBS 
GO:0003407 neural retina development (BP) 1(57) 6(34208) 9,96E-03 3,05E-02 SMARCA4 
GO:0001561 fatty acid alpha-oxidation (BP) 1(57) 6(34208) 9,96E-03 3,05E-02 HACL1 
GO:0046426
negative regulation of JAK-STAT 
cascade (BP)
1(57) 6(34208) 9,96E-03 3,05E-02 HGS
GO:0006642 triglyceride mobilization (BP) 1(57) 6(34208) 9,96E-03 3,05E-02 SIRT1 
GO:0046621
negative regulation of organ growth 
(BP)
1(57) 6(34208) 9,96E-03 3,05E-02 MEN1 
GO:0006102 isocitrate metabolic process (BP) 1(57) 6(34208) 9,96E-03 3,05E-02 IDH3A 
GO:0071480
cellular response to gamma 
radiation (BP)
1(57) 7(34208) 1,16E-02 3,34E-02 EGR1 
GO:0010867
positive regulation of triglyceride 
biosynthetic process (BP)
1(57) 7(34208) 1,16E-02 3,34E-02 LDLR 
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GO:0051974
negative regulation of telomerase 
activity (BP)
1(57) 7(34208) 1,16E-02 3,34E-02 MEN1 
GO:0000183 chromatin silencing at rDNA (BP) 1(57) 7(34208) 1,16E-02 3,34E-02 SIRT1 
GO:0060351
cartilage development involved in 
endochondral bone 
morphogenesis (BP)
1(57) 7(34208) 1,16E-02 3,34E-02 CBS 
GO:0006734 NADH metabolic process (BP) 1(57) 7(34208) 1,16E-02 3,34E-02 IDH3A 
GO:0031929 TOR signaling cascade (BP) 1(57) 8(34208) 1,33E-02 3,48E-02 EIF4EBP1
GO:0006835 dicarboxylic acid transport (BP) 1(57) 8(34208) 1,33E-02 3,48E-02 SLC1A5 
GO:0000012 single strand break repair (BP) 1(57) 8(34208) 1,33E-02 3,48E-02 SIRT1
GO:0055089 fatty acid homeostasis (BP) 1(57) 8(34208) 1,33E-02 3,48E-02 SIRT1 
GO:0034383
low-density lipoprotein particle 
clearance (BP)
1(57) 8(34208) 1,33E-02 3,48E-02 LDLR 
GO:0006400 tRNA modification (BP) 1(57) 8(34208) 1,33E-02 3,48E-02 AARS 
GO:0030299
intestinal cholesterol absorption 
(BP)
1(57) 8(34208) 1,33E-02 3,48E-02 LDLR
GO:0045348
positive regulation of MHC class II 
biosynthetic process (BP)
1(57) 8(34208) 1,33E-02 3,48E-02 SIRT1
GO:0006342 chromatin silencing (BP) 1(57) 8(34208) 1,33E-02 3,48E-02 SIRT1
GO:0021680
cerebellar Purkinje cell layer 
development (BP)
1(57) 9(34208) 1,49E-02 3,68E-02 AARS
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GO:0015804 neutral amino acid transport (BP) 1(57) 9(34208) 1,49E-02 3,68E-02 SLC1A5
GO:0007342
fusion of sperm to egg plasma 
membrane (BP)
1(57) 9(34208) 1,49E-02 3,68E-02 CD9 
GO:0001542 ovulation from ovarian follicle (BP) 1(57) 9(34208) 1,49E-02 3,68E-02 SIRT1
GO:0070498
interleukin-1-mediated signaling 
pathway (BP)
1(57) 9(34208) 1,49E-02 3,68E-02 EGR1
GO:0051593 response to folic acid (BP) 1(57) 9(34208) 1,49E-02 3,68E-02 CBS 
GO:0031333
negative regulation of protein 
complex assembly (BP)
1(57) 9(34208) 1,49E-02 3,68E-02 EIF4EBP1 
GO:0045749
negative regulation of S phase of 
mitotic cell cycle (BP)
1(57) 9(34208) 1,49E-02 3,68E-02 SMARCA4
GO:0000731
DNA synthesis involved in DNA 
repair (BP)
1(57) 10(34208) 1,65E-02 3,97E-02 SIRT1
GO:0034968 histone lysine methylation (BP) 1(57) 10(34208) 1,65E-02 3,97E-02 MEN1
GO:0043923
positive regulation by host of viral 
transcription (BP)
1(57) 10(34208) 1,65E-02 3,97E-02 SMARCA4 
GO:0043518
negative regulation of DNA 
damage response, signal 
transduction by p53 class mediator 
(BP)
1(57) 10(34208) 1,65E-02 3,97E-02 SIRT1
GO:0006195
purine nucleotide catabolic 
process (BP)
1(57) 11(34208) 1,82E-02 4,15E-02 NT5E
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GO:0045947
negative regulation of translational 
initiation (BP)
1(57) 11(34208) 1,82E-02 4,15E-02 EIF4EBP1
GO:0043488 regulation of mRNA stability (BP) 1(57) 11(34208) 1,82E-02 4,15E-02 APEX1
GO:0010875
positive regulation of cholesterol 
efflux (BP)
1(57) 11(34208) 1,82E-02 4,15E-02 SIRT1
GO:0043408 regulation of MAPK cascade (BP) 1(57) 11(34208) 1,82E-02 4,15E-02 TIMP2 
GO:0031334
positive regulation of protein 
complex assembly (BP)
1(57) 11(34208) 1,82E-02 4,15E-02 VCP
GO:0006476 protein deacetylation (BP) 1(57) 11(34208) 1,82E-02 4,15E-02 SIRT1 
GO:0016180 snRNA processing (BP) 1(57) 12(34208) 1,98E-02 4,37E-02 INTS8 
GO:0050872 white fat cell differentiation (BP) 1(57) 12(34208) 1,98E-02 4,37E-02 SIRT1
GO:0080111 DNA demethylation (BP) 1(57) 12(34208) 1,98E-02 4,37E-02 APEX1 
GO:0032007
negative regulation of TOR 
signaling cascade (BP)
1(57) 12(34208) 1,98E-02 4,37E-02 SIRT1 
GO:0046135
pyrimidine nucleoside catabolic 
process (BP)
1(57) 12(34208) 1,98E-02 4,37E-02 NT5E
GO:0030301 cholesterol transport (BP) 1(57) 13(34208) 2,15E-02 4,67E-02 LDLR  
GO:0030833
regulation of actin filament 
polymerization (BP)
1(57) 13(34208) 2,15E-02 4,67E-02 ARPC5 
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GO:0042176
regulation of protein catabolic 
process (BP)
1(57) 14(34208) 2,31E-02 4,90E-02 HGS 
GO:0009303 rRNA transcription (BP) 1(57) 14(34208) 2,31E-02 4,90E-02 CD3EAP
GO:0050880
regulation of blood vessel size 
(BP)
1(57) 14(34208) 2,31E-02 4,90E-02 CBS 
  
  
Supplementary Table 7  
Results from time-course limited proteolysis experiments as determined by parallel reactions with the indicated proteases on non-
complexed recombinant APE1, recombinant APE1-SIRT1 nCaRE-B complex or recombinant APE1-PTH nCaRE complex. Shown are the 
proteases/protein (w/w) values used for each experiment as well as the measured/theoretical mass values and the deduced primary cleavage 
sites in the recombinant APE1 product. In parenthesis are reported the corresponding cleavage sites in the native protein, which differs from the 
recombinant one for the lack of three amino acids at protein N-terminus. Mi, monoisotopic; av, average. 
 
    APE1 
APE1-SIRT1 
nCaRE complex 
APE1-PTH 
nCaRE complex 
 
Enzym
e 
Time 
(min) 
Peptid
e 
Theoretical 
mass 
Experimental 
mass 
Experimental 
mass 
Experimental 
mass 
Primary cleavage 
site 
T
ry
p
s
in
/A
P
E
1
 1
:5
0
0
0
 (
w
/w
) 
5 
1-9 1041.62mi 1041.60 mi   K9 (K6) 
1-10 1169.72 mi 1169.68 mi   K10 (K7) 
10-321 34856.56av 34854.12 av   K9 (K6) 
11-321 34727.40av 34726.80 av   K10 (K7) 
1-321 35880.86av 35879.87 av 35879.5av 35880.22 av  
15 
1-9 1041.62 mi 1041.58 mi   K9 (K6) 
1-10 1169.72 mi 1169.67 mi   K10 (K7) 
10-321 34856.56av 34856.70 av   K9 (K6) 
  
11-321 34727.40 av 34726.50 av   K10 (K7) 
11-27 1785.84 mi 1785.81 mi    
11-30 2129.06 mi 2128.96 mi    
31-321 32615.10 av 32613.80av    
1-321 35880.86 av 35879.46 av 35879.9av 35879.95av  
30 
1-9 1041.62 mi 1041.59 mi   K9 (K6) 
1-10 1169.72 mi 1169.70 mi   K10 (K7) 
10-321 34856.56av 34858.76 av   K9 (K6) 
11-321 34727.40av 34726.72 av   K10 (K7) 
11-27 1785.84 mi 1785.82 mi    
11-30 2129.06 mi 2128.03 mi    
31-321 32615.10av 32613.75 av    
1-321 35880.86av 35879.92 av 35879.50 av 35880.02 av  
60 
1-9 1041.62 mi 1041.57 mi 1041.58 mi 1041.60 mi K9 (K6) 
1-10 1169.72 mi 1169.65 mi   K10 (K7) 
  
10-321 34856.56 av 34858.83 av 34857.66 av 34858.23 av K9 (K6) 
11-321 34727.40av 34726.51 av   K10 (K7) 
11-27 1785.84mi 1785.79 mi 1785.80 mi 1785.80 mi  
11-30 2129.06mi 2128.95 mi  2129.10 mi  
31-321 32615.1av 32613.28 av 32614.13 av 32614.58 av  
1-321 35880.86av  35879.70 av 35879.30 av  
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n
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0
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w
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5 
1-17 1768.97 mi 1768.95 mi   D18 (D15) 
18-321 34128.79 av 34127.5 av   D18 (D15) 
1-321 35880.96 av 35878.6 av 35879.10 av 35877.50 av  
15 
1-17 1768.97 mi    D18 (D15) 
18-321 34128.79 av 34127.4 av   D18 (D15) 
1-321 35880.96 av 35878.9 av 35878.40 av 35879.20 av  
30 
1-17 1768.97 mi 1768.96 mi   D18 (D15) 
18-321 34128.79 av 34126.9 av   D18 (D15) 
1-321 35880.96 av 35878.6 av 35878.90 av 35878.10 av  
  
60 
1-17 1768.97 mi 1798.94 mi  1798.95 mi D18 (D15) 
18-321 34128.79 av 34127.9 av  34126.20 av D18 (D15) 
1-321 35880.96 av 35879.02 av 35875.60 av 35877.70 av  
C
h
im
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E
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:1
0
0
0
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w
/w
) 
5 
1-114 12501.23 av 12501.02 av 12500.28 av  L114 (L111) 
115-
321 
23397.64 av 23396.86 av 23395.16 av  L114 (L111) 
1-321 35880.86 av 35878.9 av 35878.10 av 35878.40 av  
15 
1-114 12501.23 av 12501.02 av 12500.67 av 12500.50 av L114 (L111) 
8-114 11662.74 av 11662.28 av    
115-
198 
9535.62 av 9535.21 av    
115-
321 
23397.64 av 23396.86 av 23395.43 av 23396.90 av L114 (L111) 
1-321 35880.86 av 35879.50 av 35878.67 av 35879.30 av  
30 1-114 12501.23 av 12500.86 av 12500.80 av 12501.00 av L114 (L111) 
  
8-114 11662.74 av 11662.11 av    
115-
198 
9535.62 av 9534.35 av    
115-
321 
23397.64 av 23395.91 av 23395.60 av 23396.73 av L114 (L111) 
1-321 35880.86 av 35878.5 av 35878.40 av 35879.72 av  
60 
1-114 12501.23 av 12500.20 av 12500.10 av 12500.50 av L114 (L111) 
8-114 11662.74 av 11661.99 av    
21-114 10391.8 av 10391.27 av    
115-
198 
9535.62 av 9535.12 av    
115-
321 
23397.64 av 23395.8 av 23395.80 av 23396.80 av L114 (L111) 
1-321 35880.86 av 35878.70 av 35878.60 av 35879.15 av  
E
la
s
ta
s
e
/
A
P
E
1
 
1
:1
0
0
0
 
(w
/w ) 5 1-12 1297.78 mi 1297.76 mi   A12 (A9) 
  
1-14 1467.88 mi 1467.85 mi   A14 (A11) 
13-321 34600.25 av 34597.6 av   A12 (A9) 
15-321 34430.43 av 34428.2 av   A14 (A11) 
1-321 35880.86 av 35877.5 av 35877.10 av 35876.90 av  
15 
1-12 1297.78 mi 1297.75 mi   A12 (A9) 
1-14 1467.88 mi 1467.87 mi   A14 (A11) 
1-20 2126.13 mi 2126.10 mi   L20 (L17) 
13-321 34600.25 av 34598.3 av   A12 (A9) 
15-321 34430.43 av 34429.0 av   A14 (A11) 
21-321 33771.43 av 33768.5 av   L20 (L17) 
1-321 35880.86 av 35878.6 av 35878.30 av 35879.10 av  
30 
1-12 1297.78 mi 1297.77 mi   A12 (A9) 
1-14 1467.88 mi 1467.86 mi   A14 (A11) 
1-20 2126.13 mi 2126.11 mi 2126.20 mi 2126.14 mi L20 (L17) 
13-321 34600.25 av 34596.8 av   A12 (A9) 
  
15-321 34430.43 av 34427.4 av   A14 (A11) 
21-321 33771.43 av 33767.9 av 33769.20 av 33768.50 av L20 (L17) 
1-321 35880.86 av 35876.9 av 35878.50 av 35877.60 av  
60 
1-12 1297.78 mi 1297.80 mi   A12 (A9) 
1-14 1467.88 mi 1467.87 mi   A14 (A11) 
1-20 2126.13 mi 2126.12 mi 2125.99 mi 2126.10 mi L20 (L17) 
13-321 34600.25 av 34599.1 av   A12 (A9) 
15-321 34430.43 av 34429.5 av   A14 (A11) 
21-321 33771.43 av 33770 av 33768.90 av 33770.80 av L20 (L17) 
1-321 35880.86av  35877.80 av 35880.20 av  
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Supplementary Figure 33 - Recruitment of BER enzymes on hSIRT1 promoter after oxidative condition.  
HeLa cells treated with 1 mM H2O2 for 10, 15, 20, 40, 60 minutes, were analyzed by qChIP using specific antibodies recognizing 8-
oxodG, OGG1 and APE1. The histogram represents the amount of hSIRT1 promoter sequence immunoprecipitated. Data were 
presented as percent of input and normalized to the quantity of DNA immunoprecipitated by α-tubulin (α-tub) and further normalized on 
the amount of immunoprecipitated protein. 
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10 Abbreviations 
8-oxoG, 8-oxoguanine 
AcAPE1, acetylated apurinic/apyrimidinic endonuclease-1 
ANP Atrial natriuretic peptide 
AP, abasic site 
AP-1, activating protein-1 
APE1, apurinic/apyrimidinic endonuclease-1 
APE1
WT
,
 
wild type APE1 
APE1
NΔ33
,
 
N-terminal APE1 deletion mutant 
hAPE1, human APE1 
zAPE1, zebrafish APE1 
BER, base excision repair  
Bax, Bcl-2–associated X  
CAT, chloramphenicol acetyltransferase 
ChIP, chromatin immunoprecipitation 
CREB, cAMP-responsible element binding protein 
DR, direct repair 
Ds, double stranded 
E3330, 2E-3-[5-(2, 3 dimethoxy-6- methyl-1, 4-benzoquinolyl)]-2-nonyl-2- propenoic acid 
Egr-1, early growth response protein-1 
EMSA, electromobility shift assay 
GEC, gastric epithelial cell 
GO, gene ontology 
HAT, histone acetyltransferase 
HDAC, histone deacetylase 
hnRNP-L, Heterogeneous nuclear ribonucleoprotein L  
HR, homologous recombination 
KuAg, Ku antigen 
LC-ESI-MS, liquid chromatography-electrospray ionization-mass spectrometry 
LP-BER, long-patch base excision repair  
MDM2, murine double minute 2 
MMR, mismatch repair 
Abbreviations 
 
MMS, Methylmethanesulfonate 
nCaRE, Negative calcium responsive element 
NER, nucleotide-excision repair 
NF-κB, nuclear factor-kappaB 
NHEJ, nonhomologous end joining 
PARP-1, Poly (adenosine diphosphate-ribose) polymerase 1  
PCNA, proliferating cell nuclear antigen  
PTM, post-translational modification 
PTH, parathyroid hormone  
Rac1, ras-related C3 botulinum toxin substrate 1 
RAS, Renin-angiotensin system  
RNA pol II/III, RNA polymerase  
ROS, reactive oxygen species 
SINE, short interspersed nucleotide elements 
SIRT1, sirtuin 1 
SP-BER, short-patch base excision repair  
SPR, surface Plasmon resonance 
SSB, single strand break 
TF, transcription factor 
THF, tetrahydrofuran 
Trx, thioredoxin 
XRCC1, X-ray cross-species complementing 1 
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Nucleolar accumulation of APE1 depends on 
charged lysine residues that undergo acetylation 
upon genotoxic stress and modulate its BER 
activity in cells
Lisa Lirussia,*, Giulia Antonialia,*, Carlo Vascottoa, Chiara D’Ambrosiob, Mattia Polettoa, 
Milena Romanelloa, Daniela Marascoc,d, Marilisa Leoned, Franco Quadrifoglioa, Kishor K. Bhakate, 
Andrea Scalonib, and Gianluca Tella
aDepartment of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy; bProteomics and Mass 
Spectrometry Laboratory, Istituto di Ricerche per il Sistema Produzione Animale in Ambiente Mediterraneo, National 
Research Council, 80147 Naples, Italy; cDepartment of Biological Sciences, University of Naples “Federico II,” 80134 
Naples, Italy; dInstitute of Biostructures and Bioimaging, National Research Council, 80134 Naples, Italy; eDepartment 
of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555
ABSTRACT Apurinic/apyrimidinic endonuclease 1 (APE1) is the main abasic endonuclease in 
the base excision repair (BER) pathway of DNA lesions caused by oxidation/alkylation in 
mammalian cells; within nucleoli it interacts with nucleophosmin and rRNA through N-termi-
nal Lys residues, some of which (K27/K31/K32/K35) may undergo acetylation in vivo. Here we 
study the functional role of these modifications during genotoxic damage and their in vivo 
relevance. We demonstrate that cells expressing a specific K-to-A multiple mutant are APE1 
nucleolar deficient and are more resistant to genotoxic treatment than those expressing the 
wild type, although they show impaired proliferation. Of interest, we find that genotoxic 
treatment induces acetylation at these K residues. We also find that the charged status of 
K27/K31/K32/K35 modulates acetylation at K6/K7 residues that are known to be involved in the 
coordination of BER activity through a mechanism regulated by the sirtuin 1 deacetylase. Of 
note, structural studies show that acetylation at K27/K31/K32/K35 may account for local confor-
mational changes on APE1 protein structure. These results highlight the emerging role of 
acetylation of critical Lys residues in regulating APE1 functions. They also suggest the exis-
tence of cross-talk between different Lys residues of APE1 occurring upon genotoxic dam-
age, which may modulate APE1 subnuclear distribution and enzymatic activity in vivo.
INTRODUCTION
Apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1) 
plays a central role in the maintenance of genome stability and re-
dox signaling (Bapat et al., 2009, 2010; Tell et al., 2010a; Wilson and 
Simeonov, 2010). Through its C-terminal domain (residues 61–318), 
it acts as an essential enzyme in the base excision repair (BER) path-
way of DNA damages caused by both endogenous and exogenous 
oxidizing/alkylating agents, including many chemotherapeutic 
drugs. In combination with thioredoxin (Ueno et al., 1999; Seemann 
and Hainaut, 2005) and through its N-terminal domain (residues 
1–127), it also functions as a regulatory redox agent to maintain 
cancer-related transcription factors (Egr-1, NF-κB, p53, HIF-1α, AP-1, 
and Pax proteins) in an active reduced state (Hirota et al., 1997; 
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mutants are reintroduced into APE1-silenced cell clones to deter-
mine the role of these crucial amino acids during cell response to 
genotoxic treatment.
RESULTS
Positively charged K27/K31/K32/K35 residues are essential 
for APE1 nucleolar accumulation through stabilization 
of protein interaction with NPM1 and rRNA
We previously demonstrated that charged K residues, located within 
the unstructured APE1 N-terminal domain (i.e., K24/K25/K27/K31/K32), 
are crucial for APE1 interaction with rRNA and NPM1 and for modu-
lating its catalytic activity on abasic DNA through regulation of prod-
uct binding. Of interest, some of these critical amino acids (i.e., K27/
K31/K32 in addition to K35) may undergo in vivo acetylation under 
basal conditions (Fantini et al., 2010). We hypothesized that the de-
gree of positive charges, modified by acetylation at these residues, 
may modulate APE1’s different functions through its redirection to 
different substrates and/or stimulation of its DNA-repair enzymatic 
activity (Fantini et al., 2010). To address this issue, we inspected 
the role of the positively charged residues within the region 27–35 in 
modulating the interaction between APE1 and NPM1. Colocaliza-
tion experiments in HeLa cells transiently transfected with either 
FLAG-tagged, wild-type APE1 (APE1WT), a K-to-A mutant (APE1K4pleA) 
in which the positive charges have been removed as in the case of 
constitutive acetylation, or a nonacetylatable K-to-R APE1 mutant 
(APE1K4pleR) showed that APE1K4pleA mutant has a marked exclusion 
from the nucleoli apparent in all expressing cells (Figure 1A). Silenc-
ing of the endogenous APE1 protein did not alter either the ability 
of the APE1WT and APE1K4pleR proteins to accumulate within the nu-
cleolar compartment or the inability of the APE1K4pleA to accumulate 
within the nucleolus (unpublished data). These data thus demon-
strate that APE1WT and APE1K4pleR nucleolar accumulation is not the 
consequence of their overexpression.
To complement these observations and also to exclude a possi-
ble contribution of the FLAG tag used to generate recombinant ec-
topic proteins, we exploited a live-cell imaging system as suggested 
by Schnell et al. (2012). APE1 cDNA was cloned into a pDendra2 
vector to express APE1 in fusion with the green photoconvertible 
fluorophore Dendra (Chudakov et al., 2007). As reported in Figure 
1B, the fluorophore alone is present in both the cytoplasm and the 
nuclear compartment, but it is completely excluded from the nucle-
oli, as demonstrated by quantitative fluorescence signal analyses. In 
contrast, whereas the expression of Dendra in fusion with APE1WT 
and APE1K4pleR results in an efficient accumulation of the protein 
within the nucleolar compartment, the Dendra-APE1K4pleA mutant 
displays a homogeneous nuclear distribution. This approach con-
firms immunofluorescence-based data on the reduced accumula-
tion of FLAG-tagged APE1K4pleA within the nucleoli and supports the 
evidence that the nucleolar accumulation of APE1 protein does not 
depend on the protein abundance nor does it depend on the spe-
cific tag used to generate the ectopic recombinant proteins (see 
also Supplemental Figure S1).
We supported our immunofluorescence data with biochemical 
interaction experiments. Coimmunoprecipitation analysis showed 
that the APE1K4pleA mutant has a significantly reduced interaction 
with NPM1 (Figure 2A), in accordance with its impaired nucleolar 
accumulation. The altered electrophoretic mobility observed for the 
APE1K4pleA mutant (Figure 2A) was further confirmed by SDS–PAGE 
analysis of recombinant proteins expressed in Escherichia coli and 
purified by chromatography. The effect is likely due to alteration of 
its overall charge, since electrospray ionization mass spectrometry 
analysis confirmed the correctness of protein mass values, and the 
Wei et al., 2000; Ziel et al., 2004; Gray et al., 2005; Pines et al., 2005; 
Tell et al., 2005, 2010a). APE1 can also act as a transcriptional repres-
sor through indirect binding to negative Ca2+-response elements 
(nCaRE), which are regulated by K6/K7 acetylation (Bhakat et al., 
2003). Recently APE1 was demonstrated to bind/cleave abasic RNA 
(Vascotto et al., 2009b; Fantini et al., 2010; Tell et al., 2010b) and to 
control c-Myc expression by cleaving its mRNA (Barnes et al., 2009). 
These discoveries pointed to a new function of APE1 in regulating 
gene expression through posttranscriptional mechanisms and 
brought to light the fact that this protein is a possible target for anti-
cancer therapy.
In this context, we showed that the first 35 amino acids in the 
nonstructured N-terminal domain of APE1 are required for a stable 
interaction with rRNA, nucleophosmin 1 (NPM1), and other proteins 
involved in ribosome biogenesis/RNA processing (Vascotto et al., 
2009b; Tell et al., 2010b). In particular, K residues within the protein 
region spanning amino acids 24–35 are involved in the interaction of 
APE1 with both rRNA and NPM1 and also regulate its in vitro enzy-
matic activity (Fantini et al., 2010). Of interest, some of these critical 
K residues, namely K27/K31/K32/K35, undergo in vivo acetylation. 
These results suggest that protein–protein interactions and/or post-
translational modifications (PTMs) involving the APE1 N-terminal 
domain may play important roles in vivo in coordinating and fine-
tuning the protein’s BER activity and functions on rRNA metabolism. 
Recently it was also demonstrated that APE1 K6/K7 may undergo 
acetylation during cell response to genotoxic treatment (Fantini 
et al., 2008) and that the acetylation status of these K residues, con-
trolled by the sirtuin 1 (SIRT1) deacetylase activity, should be impor-
tant in modulating protein DNA-repair function by regulating the 
kinetics of its interaction with other enzymes involved in BER, for 
example, XRCC1 (Yamamori et al., 2010).
APE1 is mainly a nuclear protein and is critical for controlling cel-
lular proliferative rates (Fung and Demple, 2005; Izumi et al., 2005; 
Vascotto et al., 2009b). We also showed that a considerable amount 
of APE1 is accumulated within the nucleoli of different cell lines 
(Vascotto et al., 2009b; Fantini et al., 2010), but its role within this 
compartment is unknown. Cytoplasmic, mitochondrial, and endo-
plasmic reticulum localizations have also been ascertained (Tell 
et al., 2001; Szczesny and Mitra, 2005; Chattopadhyay et al., 2006; 
Grillo et al., 2006; Mitra et al., 2007). APE1 is an abundant and rela-
tively stable protein in mammalian cells (Tell et al., 2009, 2010a). 
Fine-tuning of the multiple APE1 functions may therefore depend 
on the modulation of its PTMs and, eventually, on its interactome. 
Although a functional role has been determined for some PTMs 
(K6/K7 acetylation and K24/K25/K27 ubiquitination; Bhakat et al., 2003; 
Fantini et al., 2008; Busso et al., 2009), the identity and importance 
of various interacting partners in modulating APE1 biological func-
tions are still under investigation (Parlanti et al., 2007; Busso et al., 
2009; Vascotto et al., 2009b). APE1 may affect cell growth by di-
rectly acting on rRNA quality control mechanisms; in particular, 
APE1 interaction with NPM1 may affect its activity over rRNA mole-
cules. However, many aspects of this new function are undefined 
(Vascotto et al., 2009b; Tell et al., 2010b).
In this study, we address the biological role of APE1 acetylation at 
K27/K31/K32/K35 and, in light of recent evidence showing the emerg-
ing function of the nucleolus as a central sensor of protein trafficking 
during DNA repair after genotoxic treatment (Nalabothula et al., 
2010), the role of the nucleolus itself on the APE1 protective function 
toward genotoxic damage. We used a reconstitution strategy with 
APE1 mutants in which the charged Lys residues were replaced by 
either Ala or Arg to mimic constitutive acetylated (APE1K4pleA) and 
nonacetylatable (APE1K4pleR) protein forms, respectively. These 
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difference in their apparent mobility ob-
served in SDS–PAGE was abolished when 
separating various mutants in urea-contain-
ing denaturing gels (Supplemental Figure 
S2 and unpublished data). It was also ob-
served for other K-to-A mutants of APE1 
(Fantini et al., 2010). We then evaluated 
the contribution of the single K residues to 
the extent of APE1 nucleolar localization 
(Supplemental Figure S3) and the ability to 
interact with NPM1 (Figure 2B). Double mu-
tants APE1K27/35A, APE1K31/32A, APE1K27/35R, 
and APE1K31/32R and a deletion mutant lack-
ing 33 amino acids at the protein N-terminus 
(APE1NΔ33) were compared with APE1WT. 
Whereas APE1WT, APE1K27/35R, and 
APE1K31/32R displayed a nucleolar and 
nucleoplasmic staining, APE1K27/35A and 
APE1K31/32A showed two alternative stain-
ings, exhibiting nucleolar/nucleoplasmic or 
only nucleoplasmic positivity, respectively 
(Supplemental Figure S3). Coimmunopre-
cipitation experiments (Figure 2B) were in 
accordance with immunofluorescence anal-
yses and showed a substantial reduction of 
the interaction in the case of APE1K4pleA and 
APE1NΔ33 mutants and a moderate impair-
ment for APE1K27/35A and APE1K31/32A mu-
tants. Glutathione S-transferase (GST) pull-
down assays with recombinant purified 
proteins confirmed that these results were 
due to effects on direct interaction between 
APE1 and NPM1 (Figure 2C). This confirmed 
previous hypotheses (Fantini et al., 2010). 
We also checked the effect of the K-to-A 
mutation on the ability of APE1 to bind nu-
cleolar rRNA (Vascotto et al., 2009b). As ex-
pected, rRNA–chromatin immunoprecipita-
tion (ChIP) analyses showed that K-to-A 
mutations significantly alter APE1 binding to 
FIGURE 1: Positively charged K27/K31/K32/K35 residues are required for APE1 nucleolar 
accumulation. (A) Confocal microscopy of HeLa cells transfected with APE1WT, APE1K4pleA, or 
APE1K4pleR FLAG-tagged proteins and stained with antibodies against NPM1 (red) and ectopic 
FLAG-APE1 (green). Overlap of staining (yellow) demonstrated colocalization of the two 
proteins. Of note, the APE1K4pleA mutant was completely excluded from nucleoli (white 
arrowheads), whereas both APE1WT and the APE1K4pleR were accumulated within. Images are 
representative of 100% of transfected cells. (B) HeLa cells transfected with pDendra2-N empty 
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vector or encoding APE1 (wild-type and 
mutants) in fusion with Dendra fluorophore 
were analyzed with a live confocal 
microscopy workstation. Cells transfected 
with empty vector (Dendra) showed diffuse 
green fluorescence within cytoplasm and 
nucleus, with exclusion of the nucleolar 
compartment. APE1WT and APE1K4pleR mutant 
mainly localized within the nuclear 
compartment and accumulated within 
nucleoli. In contrast, APE1K4pleA did not show 
any nucleolar accumulation. Images were 
captured by using the same settings (488-nm 
laser at 10% of intensity and PMT at 760 V). 
Fluorescence intensity analysis was carried 
out on a 25-µm-long line (white). Graphs 
represent the fluorescence intensity 
measured through a cross section of the 
nucleus and demonstrate an incremental 
fluorescence in corresponding nucleoli only 
in the case of APE1WT and APE1K4pleR-Dendra 
fusion protein–expressing cells.
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FIGURE 2: Positively charged K27/K31/K32/K35 
residues are required for NPM1 interaction. (A) The 
APE1K4pleA mutant shows impaired interaction with 
NPM1. Coimmunoprecipitation (CoIP) analysis on 
HeLa cells transfected with APE1WT, APE1K4pleA, or 
APE1K4pleR FLAG-tagged proteins with endogenous 
NPM1. Western blot analysis was used to quantify 
the interaction among the different APE1 forms 
and NPM1 by using specific antibodies. IB, 
immunoblot. (B) K27/K31/K32/K35 residues are 
responsible for proper interaction of APE1 with 
NPM1. CoIP analysis on HeLa cells transfected with 
FLAG-tagged APE1WT, APE1NΔ33, or the APE1 
double (APE1K27/35A, APE1K31/32A, APE1K27/35R, and 
APE1K31/32R) or quadruple (APE1K4pleA and 
APE1K4pleR) K-to-A or K-to-R mutants. Western blot 
analysis was performed on total cell extracts (left) 
and on immunoprecipitated material (right) with 
specific antibody for endogenous NPM1. 
Normalized coimmunoprecipitated amounts of 
NPM1 are indicated under each relative bar. 
Anti-FLAG staining was used as loading control. 
(C) Interaction of K-to-A APE1 mutants with NPM1 
and rRNA. A 150-pmol amount of each bait 
GST-APE1 recombinant purified protein (rAPE1) 
was incubated with an equimolar amount of 
recombinant NPM1, as described in Materials and 
Methods. After GST pull-down, samples underwent 
Western blot analysis by using the indicated 
antibodies (right). NPM1 band intensities were 
normalized vs. those of GST-APE1 proteins, and 
the resulting values, expressed as percentage of 
bound with respect to APE1WT, were plotted in the 
histogram (left). Each bar represents the mean of 
two independent experiments whose variation was 
<10%. (D) Interaction of K-to-A APE1 mutants with 
NPM1 and rRNA. After transfection of HeLa cells, 
total cell lysates were prepared as described in 
Materials and Methods, and an RNA-ChIP assay 
was performed to measure the rRNA-binding 
activity of the different APE1 mutants. 
Immunoprecipitated samples underwent either 
Western blot analysis (right) or RNA extraction and 
quantification by reverse transcription and 
quantitative PCR analysis, using 18S and 47S 
rRNA–specific primers. Data are presented as a 
fold percentage of the amount of total 18S or 
47S rRNA with respect to the amount of 
immunoprecipitated FLAG-tagged APE1 protein, 
respectively. The resulting values are plotted in 
the histograms (left), showing the average values 
with SD of three independent experiments. 
(E) Nucleoplasmic interaction between APE1 and 
NPM1 is affected by K-to-A mutation on APE1. 
PLA technology was used to evaluate in vivo the 
effect of positively charged K27/K31/K32/K35 
residues on APE1 interaction with NPM1 in the 
nuclear compartment. Stable HeLa clones 
expressing APE1WT, APE1K4pleA, or APE1K4pleR 
FLAG-tagged proteins were seeded on a glass 
coverslip, and PLA reaction was carried out 
using anti-FLAG and anti-NPM1 antibodies. 
4′,6-Diamidino-2-phenylindole staining is used as a 
reference for the nuclei. The histogram represents 
the average number of PLA blobs scored for at 
least 30 cells per slide. Asterisks represent a 
significant difference between APE1WT and 
mutants.
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rRNA molecules (Figure 2D) and that a partial removal of positive 
charges in the region 27–35 strongly affects the protein binding to 
rRNA molecules.
Interaction between APE1 and NPM1 may also occur in the nu-
cleoplasmic compartment of cells. We measured the effect of the 
K-to-A mutation on the nucleoplasmic interaction of APE1 with 
NPM1 through proximity ligation assay (PLA) analysis, which allows 
in situ detection of two proteins that are at interacting distance of 
<40 nm (Weibrecht et al., 2010). Data displayed in Figure 2E show 
that nucleoplasmic interaction between APE1 and NPM1 was sig-
nificantly affected by the K-to-A mutation. Taken together, these 
data demonstrate that charged lysines within the 27–35 region are 
essential for APE1 maintenance within the nucleoli and for a proper/
stable interaction of this protein with NPM1 or rRNA molecules. 
Moreover, our data suggest that APE1 must lose the positive charge 
at more than two K residues (among K27/K31/K32/K35) to get a signifi-
cant reduction of the APE1/NPM1 interaction in the nucleus and 
loss of APE1 nucleolar accumulation.
Loss of APE1 nucleolar accumulation causes impairment 
of cell proliferation
APE1 protects cells against genotoxic damaging agents (Tell and 
Wilson, 2010). To clarify the biological relevance of the APE1 nucle-
olar accumulation, we estimated the effect of the expression of the 
nucleolar-deficient form of APE1 (i.e., APE1K4pleA) on cell viability 
with respect to APE1WT and APE1K4pleR mutant. To test the effects of 
the mutant proteins and exclude the contribution of the endoge-
nous one, we used inducible APE1-silenced (through small interfer-
ing RNA [siRNA] technology) HeLa cells, which were reconstituted 
with siRNA-resistant APE1 ectopic proteins in place of the endog-
enous one (Figure 3A; Vascotto et al., 2009a). The levels of the ec-
topic proteins expressed by the different cell clones used for the 
following experiments were comparable to that of the wild-type 
endogenous one before silencing, as demonstrated by quantita-
tive Western blot analysis (Supplemental Figure S4); the extent of 
the residual endogenous protein was <10%. Quantification of the 
nuclear amount of ectopic proteins after doxycycline treatment, 
demonstrated by Western blot analysis with a calibration curve, 
gave the following results (expressed as nanograms of APE1 per 
microgram of nuclear extract): 23.22 ± 6.04 for APE1WT, 18.63 ± 
4.84 for APE1K4pleA, and 17.69 ±4.60 for APE1K4pleR (Supplemental 
Figure S4B). Therefore these cell lines represent a reliable system 
for testing our hypothesis. On the basis of previous data showing 
that nucleolar APE1 may act as a cleansing factor in rRNA quality 
control, possibly affecting cellular proliferation through an impair-
ment of the overall protein synthesis machinery (Vascotto et al., 
2009b; Tell et al., 2010b), we investigated the effect of the nucleo-
lar-deficient form APE1K4pleA on cell proliferation rate under basal 
conditions. Of interest, by cell counting assays performed on re-
constituted cell clones, we obtained proof that APE1K4pleA acts as a 
loss-of-function mutation in terms of cell proliferation, whereas 
APE1K4pleR behaves similarly to APE1WT (Figure 3B). These data, 
confirmed by using at least two different clones for each mutant 
cell line, suggest that nucleolar APE1 is required for appropriate 
control of cell proliferation, perhaps through its role in rRNA me-
tabolism (Tell et al., 2010b). Colony formation assays confirmed cell 
proliferation data (Figure 3C). However, although the cell number 
in each colony of APE1K4pleR-expressing cells was always similar to 
that expressing APE1WT, these cells grew in a more widespread 
manner, possibly due to an altered migrating phenotype and/or an 
intercellular adhesion pattern. These data were indicative that abo-
lition of the acetylatable residues of APE1 at K27/K31/K32/K35 may 
significantly affect cell biology, even though it is also possible that 
the lower expression level of the APE1K4pleR (∼76%) with respect to 
APE1WT may also have an effect on this phenotype.
Increased APE1 acetylation at K27/K31/K32/K35 residues upon 
genotoxic damage
APE1 acetylation at K6/K7 is known to be enhanced after genotoxic 
insult by methyl methanesulfonate (MMS) and it has been shown to 
play a role in modulating APE1 interaction with XRCC1, possibly 
coordinating different enzymatic steps in the BER pathway 
(Yamamori et al., 2010). We therefore tested whether MMS treat-
ment, which promotes generation of DNA damage specifically re-
paired through BER, may also induce APE1 acetylation at K27/K31/
K32/K35 residues. Immunopurified APE1 samples from control and 
MMS-treated cells were separated by SDS–PAGE and excised 
bands and then analyzed by peptide mapping experiments. Semi-
quantitative nano–electrospray linear ion trap tandem mass spec-
trometry (nanoLC-ESI-LIT-MS/MS) analysis was performed on iden-
tical quantities of immunopurified APE1WT-FLAG protein samples 
obtained from HeLa cells before and after MMS treatment (Supple-
mental Figure S5). In particular, we evaluated the amount of the 
peptides (15–33)Ac3 and (15–35)Ac4 in each APE1 endoprotease 
AspN digest and compared them to that of the nonmodified coun-
terparts. Analysis was performed by extracting and integrating the 
corresponding nanoLC-ESI-LIT-MS peak areas equivalent to the as-
signed m/z values for the acetylated and nonacetylated peptides in 
the same total ion chromatogram. After MMS treatment, the amount 
of the peptide (15–33)Ac3 was significantly increased, and the pep-
tide (15–35)Ac4 was almost doubled as compared with that of the 
nonmodified counterparts (Figure 4A). The MMS-induced acetyla-
tion on the aforementioned residues was further demonstrated by 
Western blotting using a commercial anti–Ac-Lys antibody on im-
munopurified proteins from HeLa cells transiently transfected with 
the FLAG-tagged APE1WT and the nonacetylatable APE1K4pleR 
forms. It is striking that a significant increase of APE1 acetylation 
was observed after MMS treatment but mainly for APE1WT rather 
than for APE1K4pleR (Supplemental Figure S6). These data show that, 
besides increasing the acetylation status of K6/K7 (see later discus-
sion and Yamamori et al., 2010), MMS treatment also promotes 
acetylation at K27/K31/K32/K35 residues. The mild increase of Lys 
acetylation level in the mutant APE1K4pleR may possibly be ascribed 
to K6/K7 acetylation (see later discussion).
We then investigated the cellular distribution pattern of acety-
lated APE1 at K27/K31/K32/K35 residues by using an ad hoc–devel-
oped antibody that specifically recognized the peptide 25–38 fully 
acetylated at K27/K31/K32/K35, hereafter referred to as anti-APE1K27-35Ac 
(Poletto et al., 2012). This antibody was particularly efficient in rec-
ognizing acetylation at K35 with a measured affinity in the nanomolar 
range (196 nM for the tetra-acetylated stretch vs. 26,800 nM for 
the nonacetylated one, as assessed by surface plasmon resonance 
(SPR; Poletto et al., 2012). Preincubation of the antibody with the 
acetylated and nonacetylated peptides confirmed the specificity of 
the antibody (Poletto et al., 2012). The distribution pattern of 
APE1WT, APE1K4pleA, and APE1K4pleR was compared by using anti-
FLAG and anti-APE1K27-35Ac antibodies. Of interest, staining with the 
anti-APE1K27-35Ac antibody gave a pattern quite similar (i.e., nucleo-
lar exclusion) to that of the anti-FLAG antibody but only in the case 
of the APE1K4pleA mutant (Figure 4B). PLA was also carried out to 
demonstrate the in vivo occurrence of acetylation on endogenous 
APE1 by using either the anti-APE1K27-35Ac antibody alone (as a 
control) or together with an anti-APE1 antibody (Figure 4C). This 
assay clearly highlighted the proximity between the target of both 
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FIGURE 3: Expression of the nucleolus-deficient APE1 mutant causes impaired cell proliferation. (A) Generation of 
reconstituted cell lines expressing APE1K4pleA and APE1K4pleR mutants. HeLa cells were stably transfected with the 
inducible siRNA vectors and siRNA resistant APE1WT, APE1K4pleA, and APE1K4pleR–expressing vectors, as previously 
described (Vascotto et al., 2009a; Fantini et al., 2010). Expression of ectopic APE1 forms without silencing and after the 
suppression of endogenous APE1 expression after 10 d of treatment with doxycycline (Doxy) was assayed by Western 
blotting on total cellular extracts with an anti-APE1 antibody. Normalized expression levels for each clone of ectopic 
and endogenous APE1 protein after the silencing are indicated under each relative band. β-Tubulin was used as loading 
control. (B) Cell proliferation assays for APE1-reconstituted cell lines. APE1-expressing cell clones were seeded in 
60-mm Petri dishes. Growth was followed by measuring cell numbers at various times upon doxycycline treatment, as 
indicated. Cells were harvested at the indicated times, stained with trypan blue, and counted in triplicate. Data, 
expressed as cell number, are the mean ± SD of three independent experiments. (C) Colony formation assays for 
APE1-reconstituted cell lines. After 8 d of doxycycline treatment, 200 cells of APE1WT and the indicated APE1 mutants 
were seeded in 60-mm Petri dishes and grown for 8 d in medium supplemented with doxycycline to promote 
endogenous APE1 silencing. Then cells were stained with crystal violet and images captured by using a Leica S8 
microscope with 80× magnification. Data, expressed as number of cells per colony, are the mean ± SD of 10 colonies for 
each clone.
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antibodies, further suggesting that, in vivo, 
APE1 is acetylated at K27/K31/K32/K35 resi-
dues and that these acetylated forms are 
excluded from the nucleoli. Taken together, 
these data suggest that acetylation at these 
charged amino acids may control the nucle-
olar/nucleoplasmic distribution of APE1 
within cells.
Removal of positively charged K27/K31/
K32/K35 residues increases APE1 
DNA-repair activity in vivo
We tested whether abolition of positive 
charges on acetylatable residues may affect 
the APE1 DNA repair function in cells, as 
previously demonstrated in vitro by using 
recombinant purified proteins bearing two 
different clusters of K-to-A mutation (i.e., on 
residues 24/25/27 and on residues 
24/25/27/31/32; Fantini et al., 2010). For 
this purpose we used nuclear extracts from 
reconstituted cell clones after precise nor-
malization for the APE1 ectopic nuclear con-
tent with a titration curve (as shown in Sup-
plemental Figure S4). This normalization for 
APE1 ectopic protein expression allowed 
comparison of the enzymatic activities of 
the different protein mutants in the nuclear 
fractions from each clone. Figure 5A shows 
that the AP-endonuclease activity of the 
APE1K4pleA mutant, measured through cleav-
age assays performed with nuclear extracts, 
was significantly increased with respect to 
APE1WT-and APE1K4pleR-expressing cells. 
Moreover, Figure 5B shows a lower amount 
of abasic DNA lesions accumulated after 
MMS treatment by the APE1K4pleA- as com-
pared with the APE1WT-expressing cells. 
These results suggest that removal of posi-
tive charges at Lys 27–35, as exerted by 
acetylation, may result in a more enzymati-
cally active protein.
FIGURE 4: Genotoxic treatment promotes APE1 acetylation at K27/K31/K32/K35 residues. 
(A) Relative quantitative changes of APE1 acetylation at K27/K31/K32/K35 after MMS treatment. 
Mass spectrometry analysis of acetylated peptides present in the endoprotease AspN digest of 
FLAG-tagged APE1 WT purified from HeLa cells (see Materials and Methods for details). 
Histograms indicate the relative amounts of the peptides (15–33)Ac3 and (15–35)Ac4 with respect 
to their nonmodified counterparts before and after MMS treatment. Identical ionization 
tendencies were assumed for each peptide pair. Each bar represents the mean of three 
independent experiments. (B) Acetylated APE1 at K27/K31/K32/K35 residues is present within cell 
nucleoplasm but is excluded from nucleoli. Confocal microscopy of HeLa cells transfected with 
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FIGURE 5: Abolition of positively charges K27/K31/K32/K35 residues increases APE1 DNA-repair activity. (A) Nuclear 
extracts from APE1K4pleA mutant present an increased AP endonuclease activity on abasic DNA. AP-site incision activity 
of the nuclear extracts from HeLa-reconstituted cell clones was tested using an AP endonuclease activity assay as 
described in Material and Methods. The nuclear APE1 content in each clone was precisely quantified through a titration 
curve obtained using purified recombinant APE1 (Supplemental Figure S4). Nuclear ectopic APE1 protein levels were 
then normalized between the different cell clones in order to compare their relative enzymatic activities. Top left, 
concentration-dependent conversion of an AP site–containing DNA substrate (S) to the incised product (P). A 
representative image of the denaturing polyacrylamide gel of the enzymatic reactions is shown. The amounts 
(femtomoles) of APE1 used in the reaction and the percentage of substrate converted into product, as determined by 
standard phosphorimager analysis, are indicated. NE, no cell extract control. Bottom left, time-dependent kinetics of 
APE1 (2.15 ng) endonuclease activity from nuclear extracts of the different reconstituted cell clones. The image of a 
representative gel analysis is shown (bottom). Right, graph depicting the time-course kinetics of APE1 from incision 
results shown on the left. Average values are plotted ± SD of three independent experiments. Asterisks represent a 
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amino acids during MMS treatment is unknown. We thus checked 
whether the charged status of K27/K31/K32/K35 residues might play 
a role in modulating the acetylation status of K6/K7 through the 
contribution of SIRT1. First, we evaluated the effect of the modifi-
cation at K27/K31/K32/K35 on the ability of SIRT1 to deacetylate K6/
K7 in APE1. We found that recombinant purified APE1 protein is 
nonenzymatically acetylated after incubation with acetyl-CoA, as 
demonstrated for other proteins (Garbutt and Abraham, 1981). 
Thus, to obtain a significant amount of acetylated recombinant 
APE1 protein on K6/K7 residues, we treated purified recombinant 
rAPE1 obtained from E. coli with acetyl-CoA, as described in the 
Supplemental Information. Then we treated in vitro–acetylated 
rAPE1WT, rAPE1K4pleA, rAPE1K27/35A, or rAPE1K31/32A with purified re-
combinant SIRT1 protein and measured the acetylation level on 
K6/K7 through a specific antibody that recognizes only acetylation 
at these residues (Fantini et al., 2008; Sengupta et al., 2011). Of 
interest, although APE1WT was efficiently deacetylated by SIRT1 at 
K6/K7 (Figure 6A), the APE1K4pleA mutant did not show any deacety-
lation in this region; concomitant K-to-A substitutions at positions 
27 and 35 (APE1K27/35A mutant) or at positions 31 and 32 (APE1K31/32A 
mutant) caused an intermediate effect.
We then verified the ability of SIRT1 to directly deacetylate APE1 
at K27/K31/K32/K35 residues through in vitro deacetylation assays car-
ried out on acetylated purified recombinant rAPE1WT or mutant pro-
teins as substrates (Supplemental Figure S7). Protein acetylation 
level was monitored by using the anti-APE1K27-35Ac (Figure 6B). Incu-
bation with recombinant-purified SIRT1 protein revealed a marked 
decrease in acetyl-APE1 signal but only when APE1WT was used. 
These data were corroborated by qualitative peptide mapping ex-
periments on in vitro–acetylated rAPE1WT before and after incuba-
tion with SIRT1. This analysis demonstrated that SIRT1 was indeed 
able to deacetylate in vitro–acetylated rAPE1WT at least at K25/K27/
K32 residues (Supplemental Table S1).
The ability of SIRT1 to deacetylate in vitro APE1 at K27/K31/K32/K35 
was also analyzed on APE1 (25–38) peptides (Figure 6C), which were 
chemically synthesized either in their nonacetylated or tetra-acety-
lated form at these K residues. These peptides were used in a com-
petitive fluorescence-based assay in which a fluorogenic p53 acety-
lated peptide was used as SIRT1 substrate (Marcotte et al., 2004). 
As expected, we observed a dose-dependent decrease in the 
Cell viability experiments, after MMS treatment, were carried out 
to verify the enzymatic data. Thus, the effect of K27/K31/K32/K35 mu-
tation on cell viability after MMS treatment was measured by 
3-(4-5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium salt (MTS) and clonogenic assays using the 
reconstituted cell clones. The MTS data (Figure 5C) showed that the 
APE1K4pleA-mutant–expressing cells were significantly more resistant 
to MMS treatment than those expressing the nonacetylatable 
APE1K4pleR mutant. Of note, clonogenic assay experiments (Figure 
5D) confirmed these results and highlighted the relevant acetylation 
occurring at the K residues, as demonstrated by the higher sensitiv-
ity of APE1K4pleR-expressing cells after MMS treatment. We extended 
our observations on the protective function of the APE1K4pleA mutant 
by using tert-butyl-hydroperoxide (TBHP) as a reactive oxygen spe-
cies (ROS) generator (Lazzé et al., 2003). We recently demonstrated 
that APE1 knockdown sensitizes HeLa cells to TBHP treatment (Li 
et al., 2012). Therefore we now measured the sensitivity of the differ-
ent reconstituted cell clones to TBHP in a dose–response experi-
ment (Figure 5E). As in the case of MMS treatment, expression of the 
APE1K4pleA mutant exerted a protective function with regard to TBHP 
treatment with respect to APE1WT-expressing cells. Similarly to MMS 
treatment, the APE1K4pleR-mutant–expressing clone evidenced even 
more sensitivity than the APE1WT-expressing one. Taken together, 
these data show that acetylation at residues K27/K31/K32/K35 is asso-
ciated with cell response to DNA damage and confers protection to 
genotoxic treatment. The increased activity of the APE1K4pleA mutant 
may explain its proficient protective effect in vivo against genotoxic 
treatment, even though further explanatory mechanisms, such as its 
altered protein association in the cell or its possible higher stability 
(Vascotto et al., 2011), could also be invoked.
K6/K7 deacetylation by SIRT1 is modulated by the charged 
status of K27/K31/K32/K35residues
It was recently demonstrated that APE1 K6/K7 may undergo acety-
lation during cell response to genotoxic treatment (Fantini et al., 
2008; Yamamori et al., 2010) and that modulation of the acetyla-
tion status of these residues through SIRT1 deacetylase activity is 
important for the regulation of APE1 DNA-repair function after 
MMS treatment (Yamamori et al., 2010). However, the molecular 
mechanism regulating the SIRT1-mediated modification at these 
significant difference between APE1WT and APE1K4pleA. (B) Accumulation of genomic abasic (AP) lesions after MMS 
treatment (0.5 mM, 4 h) of reconstituted cell clones with APE1WT and APE1K4pleA mutant as measured by an aldehyde-
reactive probe. APE1WT and APE1K4pleA-expressing HeLa cells were grown in medium supplemented with Doxy (10 d) to 
silence endogenous APE1 expression and were treated with 0.5 mM MMS for 4 h. Counting at the AP sites was 
performed by using the AP-site quantification kit, as described in Materials and Methods. In the histogram, data are 
expressed as number of AP sites per 105 base pairs and represent the mean ± SD of four independent experiments. 
Asterisks represent a significant difference between the two conditions (untreated and MMS-treated cells). (C) Effects of 
APE1 acetylation mutants on cell viability after MMS treatment in reconstituted cells. APE1WT, APE1K4pleA-, and 
APE1K4pleR-expressing cells were grown in medium supplemented with Doxy to silence APE1 endogenous protein and 
treated with increasing concentrations of MMS for 8 h; the cytotoxic effect of this compound was determined by the 
MTS assay (see Materials and Methods for details). Each point, shown as percentage viability with respect to untreated 
clones, represents the mean ± SD of four observations, repeated in at least two independent assays. Asterisks represent 
a significant difference between APE1K4pleA and APE1K4pleR mutants. (D) Cell growth as measured by colony survival 
assay. One thousand cells of APE1WT-, APE1K4pleA-, and APE1K4pleR-expressing clones treated with increasing 
concentrations of MMS for 8 h were seeded in Petri dishes and then treated with Doxy for 10 d to silence endogenous 
APE1. Data, expressed as the percentage of change with respect to untreated clones, are the mean ± SD of three 
independent experiments. (E) Effects of APE1 acetylation mutants on cell viability after TBHP treatment in APE1WT-, 
APE1K4pleA-, and APE1K4pleR-expressing cells grown in medium supplemented with Doxy to silence APE1 endogenous 
protein. Cells were treated with increasing concentrations of TBHP for 6 h, and the cytotoxic effects were determined 
by the MTS assay. Each point, shown as percentage viability with respect to untreated clones, represents the mean ± SD 
of four observations, repeated in at least two independent assays. Asterisks represent a significant difference between 
APE1K4pleA and APE1K4pleR mutants.
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FIGURE 6: SIRT1 deacetylase activity on K6/K7 depends on the charged status of K27/K31/K32/K35 residues. (A) K6/K7 
acetylation, modulated by SIRT1, depends on the charged status of K27/K31/K32/K35 residues. Western blot analysis on 
purified recombinant APE1 proteins in vitro acetylated with acetyl-CoA and then incubated in the presence/absence of 
recombinant GST-SIRT1, as indicated. The analysis was carried out using an antibody specific for acetylated K6/K7 APE1 
(top). The histogram reports data obtained from densitometric quantification of the bands for each APE1 protein after 
normalization on Ponceau S staining (bottom). Data shown are the mean of two independent experimental sets whose 
variation was <10%. (B) SIRT1 deacetylates rAPE1 at K27/K31/K32/K35. Left, Western blot analysis on the in vitro–
acetylated and deacetylated purified recombinant APE1, further subjected to MS analysis (Supplemental Table S1). 
rAPE1WT was incubated with 0.5 mM acetyl-CoA and then with recombinant SIRT1 protein, as shown. Samples were 
separated onto 10% SDS–PAGE, and Western blot analysis was performed by using the anti-APE1K27-35Ac antibody. 
Ponceau S staining was used as loading control. Right, the histogram shows the densitometric quantification of the 
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could be responsible for APE1 subnuclear trafficking. Thus, we 
examined the subnuclear distribution of SIRT1 on c-myc-SIRT1–
transfected cells through immunofluorescence analysis. We found 
that transiently transfected c-myc-SIRT1 mainly localized in the nu-
cleoplasmic compartment and was not found in the nucleoli (Figure 
8A, left); quantification of the endogenous SIRT1 protein in bio-
chemically purified nucleoli confirmed its absence from this subnu-
clear compartment (Figure 8A, right). Evaluation of the acetylation 
status of APE1 present in nucleolar or nucleoplasmic fractions under 
basal conditions showed that APE1 acetylated at K6/K7 is mainly 
present within the nucleoplasm but almost absent in the nucleolus 
(Figure 8B). Of note, these findings may have important implications 
for SIRT1-mediated deacetylation at K6/K7 and demonstrate the 
possibility that APE1 acetylation modulates the protein’s subnuclear 
distribution and enzymatic functions, corroborating our previous 
work (Fantini et al., 2010).
It is known that Lys acetylation may control local conformational 
stability of proteins, thus affecting their activity, subcellular distribu-
tion, and protein–protein interaction network. To examine the effect 
of acetylation on the local structure of the N-terminal APE1 region, 
we analyzed the conformational behavior of the protein portion of 
residues 14–38, which contain K27/K31/K32/K35 residues acetylatable 
in vivo. To this end, we chemically synthesized and purified four 
peptides bearing differential acetylation at positions 27, 31, 32, and 
35 (Supplemental Table S2). To evaluate the effect of acetylation on 
peptide conformation, we undertook structural analysis of these 
peptides in solution by far-ultraviolet (UV) circular dichroism (CD) 
and nuclear magnetic resonance (NMR) spectroscopy. Figure 8C 
shows the overlay of CD spectra of APE1(14–38) and APE1(14–
38)K27/31/32/35Ac in aqueous buffer, indicating a minimum at ∼200 nm 
and a shoulder at ∼220 nm. These features suggest the presence of 
mixed conformational states in which an unfolded state coexists 
with a certain helical content. The propensity of this domain to 
adopt helical conformation was also confirmed by trifluoroethanol 
(TFE) titration experiments (Supplemental Figure S8A). In particular, 
the CD spectrum of the tetra-acetylated peptide showed a mini-
mum at 220 nm that was deeper than that of the nonacetylated 
counterpart, suggesting a role for the acetyl groups in determining 
structural changes in this protein region. An intermediate behavior 
was observed for the monoacetylated and triacetylated peptides, 
confirming the role of this K modification in modulating the confor-
mation of the N-terminal APE1 region (unpublished data).
To further address this point, we carried out additional NMR ex-
periments. In aqueous buffer, the one-dimensional (1D) spectra pre-
sented poor signal dispersion (Figure 8D, left), confirming a rather 
disordered state for both the tetra-acetylated and nonacetylated 
peptides. This observation was further strengthened by the analysis 
of two-dimensional (2D) [1H, 1H] total correlation spectroscopy 
(TOCSY) spectra (Griesinger et al., 1988; Figure 8D, middle), and 2D 
[1H, 1H] rotating frame nuclear Overhauser effect spectroscopy 
(ROESY) spectra (Bax and Davis, 1985; Figure 8D, right). In the latter 
case, the presence of a restricted set of cross-peaks in the NH-aliphatic 
side-chain proton correlation region made unfeasible the process of 
sequential resonance assignments, as often occurs for small, flexible 
fluorescence signal by using different amounts of the tetra-acety-
lated peptide (25–38); the nonacetylated counterpart was used as 
a negative control substrate. Best data fitting was observed with a 
one-site competition equation, which provided an IC50 value of 
4.6 ± 0.3 µM. These data support the conclusion that the acety-
lated APE1 region spanning amino acids 27–35 is a substrate for 
SIRT1 deacetylase activity. Taken together, these results demon-
strate that SIRT1’s ability to efficiently deacetylate APE1 at K6/K7 
residues relies on the presence of positive charges at K27/K31/K32/
K35. Moreover, SIRT1 is also able to bind and possibly deacetylate 
in vitro–acetylated APE1 K27/K31/K32/K35 residues.
Cross-talk between the charged state of K27/K31/K32/K35 and 
the acetylation status of K6/K7 residues through SIRT1
To understand whether SIRT1 activity on acetylated K6/K7 residues 
might be modulated in vivo by MMS as a function of the charged 
status of K27/K31/K32/K35, we performed coimmunoprecipitation 
experiments on transiently transfected HeLa cells. As shown in 
Figure 7A, an intact N-terminal domain is required for stable APE1 
binding to SIRT1. The APE1/SIRT1 association was induced after 
MMS treatment and was abolished in the case of both APE1NΔ33 
and APE1K4pleA mutants. Substitution of K27/K31/K32/K35 residues 
with nonacetylatable R residues was ineffective, suggesting that 
SIRT1 binding depends on the presence of positively charged 
amino acids spanning the APE1 region 27–35. Measurements of 
K6/K7 acetylation status with the specific antibody (performed on 
the same samples) clearly showed that, in agreement with the 
binding data, K6/K7 residues resulted in more acetylation both un-
der basal and after MMS treatment but only in the case of the 
APE1K4pleA mutant. In addition, the acetylation status of APE1WT 
and APE1K4pleR, both under basal conditions and after MMS treat-
ment, was comparable (Figure 7B), supporting the existence of 
cross-talk between the charged status of K27/K31/K32/K35 and the 
acetylation level of K6/K7.
We then investigated the cross-talk between K6/K7 and K27/K31/
K32/K35 acetylation status through siRNA experiments. HeLa cell lines 
stably expressing both endogenous APE1 and APE1WT, APE1K4pleA, 
and APE1K4pleR ectopic forms were silenced for SIRT1 expression as 
described in Materials and Methods. The acetylation level of K6/K7 
was then measured through Western blotting. Data shown in Figure 
7C demonstrate that the K6/K7 acetylation level of the ectopic APE1 
forms was increased ∼30–40% upon SIRT1 silencing but only in the 
case of APE1WT- and APE1K4pleR-expressing cells, whereas acetylation 
of K6/K7 of APE1K4pleA was <10%. As a control, the acetylation level 
of endogenous APE1 always increased (∼60–70%) upon SIRT1 si-
lencing in all the cell lines tested (unpublished data). Taken together, 
these data demonstrate that the acetylation/charged status of K27/
K31/K32/K35 residues controls the stability of the SIRT1/APE1 com-
plex, thus playing a role in the acetylation level of K6/K7.
Possible relevance of acetylation for APE1 subnuclear 
distribution and protein local conformation
The data suggest that a coordinated acetylation/deacetylation dy-
namic modulated by SIRT1 may occur within the cell nucleus and 
band intensities, after normalization to the nonacetylated APE1 form, of the in vitro–acetylated and deacetylated 
purified APE1 mutants. Data are the mean ± SD of three independent replicates. Asterisks represent a significant 
difference. (C) The acetylated APE1 25–38 peptide is a substrate of SIRT1 activity. Purified APE1 peptides (25–38) either 
in fully acetylated form at K27/K31/K32/K35 residues or not acetylated were analyzed as competitors in an in vitro 
deacetylase SIRT1 assay based on a fluorogenic acetylated peptide derived from p53 (region 379–382). Dose–response 
signals allowed an estimated IC50 value of 4.6 ± 0.3 µM of the acetylated APE1 25–38 region with respect to the p53 
peptide.
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FIGURE 7: Cross-talk between the acetylation status of K27/K31/K32/K35 and K6/K7 residues through SIRT1. 
(A) Positive charges at K27/K31/K32/K35 residues strongly influence the stability of SIRT1 binding to APE1. Western 
blot analysis performed on total cell extracts (left) and on immunoprecipitated material (right) from HeLa cells 
cotransfected with c-myc–tagged SIRT1 and APE1WT, APE1NΔ33, APE1K4pleA, or APE1K4pleR FLAG-tagged proteins and 
treated with 0.5 mM MMS for 8 h. Coimmunoprecipitated amounts of SIRT1 normalized with respect to APE1WT or 
APE1K4pleR, respectively, are indicated under each relative bar. Ponceau S staining was used as loading control. 
(B) Acetylation level of K6/K7 in APE1K4pleA mutant is higher than that of APE1WT both under basal conditions and 
after MMS treatment. Western blot analysis on CoIP material after MMS treatment from HeLa cells transfected with 
APE1WT and FLAG-tagged mutants is shown. The histogram indicates the relative amount of acetylated APE1K6/K7 in 
the different clones obtained from the densitometric quantification of acetylated APE1 bands, normalized with 
respect to the amount of APE1 FLAG-tagged immunopurified protein. Data shown are the mean of two 
independent experimental sets whose variation was <10%. (C) SIRT1 siRNA knockdown increases APE1 K6/K7 
acetylation. HeLa stable clones expressing APE1WT, APE1K4pleA, and APE1K4pleR were transfected with siRNA against 
SIRT1 protein or control siRNA. Western blot analysis was performed to detect differential amount of the 
acetylated K6/K7 APE1 after SIRT1 silencing. Arrows highlight bands of ectopic APE1 protein form; β-tubulin was 
used as a loading control. The histogram shows densitometric quantification of acetylated K6/K7 APE1 form. Data 
are expressed as percentage of induction of the acetylated K6/K7 APE1 after SIRT1 silencing after normalization 
for the total APE1 protein levels. Data shown are the mean of two independent experimental sets whose variation 
was <10%.
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to our previous data obtained in vitro with recombinant purified pro-
teins (Fantini et al., 2010). In many cases, the presence of the unstruc-
tured N-terminal domain of APE1 seemed essential for interaction of 
APE1 with different substrates (i.e., nucleic acids or proteins). Interac-
tion also increased after histone deacetylase (HDAC) inhibition, 
which promotes APE1 acetylation at K6/K7 residues (Bhakat et al., 
2003; Yamamori et al., 2010). This evidence strongly support the no-
tion that this unstructured domain is responsible for the modulation 
of APE1’s different functions through the recruitment of APE1 in dif-
ferent protein complexes by means of various amino acid side-chain 
modification events. From an evolutionary perspective, it can be hy-
pothesized that mammalian APE1 activity was made adjustable 
(through PTMs and/or interaction with other proteins), or expanded 
toward other substrates, with the acquisition of a protein N-terminus 
containing positively charged residues, without major modifications 
on the enzyme catalytic site, which retained the “canonical” function 
toward abasic DNA. The existence of such an N-terminal extension 
in only mammals may suggest its evolutionary significance in the 
face of increased functional complexity. For the noncomplexed pro-
tein in solution, the intrinsic lack of a secondary structure associated 
with this domain can confer functional advantages to mammalian 
APE1, including the ability to bind to different protein targets (e.g., 
NPM1, XRCC1, CSB, RNA, etc.; Vidal et al., 2001; Wong et al., 2007; 
Vascotto et al., 2009a; Tell et al., 2010a), thus allowing efficient con-
trol over the thermodynamics in the binding process to different sub-
strates. Because the protein’s N-terminus is required for the stabiliza-
tion of APE1 interaction with NPM1 or rRNA and for the control of 
the overall endonuclease activity (possibly decreasing the rate of 
product release once in the positively charged state; Fantini et al., 
2010; Figure 5), this region-specific multitasking function can provide 
a “trigger” for molecular regulation with important biological signifi-
cance. This should be regarded, however, in light of BER coordina-
tion to prevent formation of harmful, unprotected DNA strand 
breaks. Therefore subcellular distribution of APE1 and its enzymatic 
activity seem to be finely tuned to demand and in a time-dependent 
manner through multiple interactions with various protein partners 
and the coordinated occurrence of different PTMs, such as acetyla-
tion and ubiquitination (Busso et al., 2009, 2011). The observation 
that acetylation at K27/K31/K32/K35 residues may favor a transition to-
ward a more organized conformation (Supplemental Figure S8) 
would support the notion that this modification may significantly 
modulate the interaction with several protein partners on a structural 
basis. In addition, acetylation at the mentioned K residues may pro-
foundly affect APE1 protein stability, based on a recent report show-
ing that the same K residues can be also polyubiquitinated by UBR3, 
targeting the protein for degradation by the proteasome (Meisenberg 
et al., 2011). Given that acetylation competes with ubiquitination for 
the same K residues, it may represent the switch for controlling pro-
tein turnover rate. In this context, the acetylation at these residues 
that we observed during cell response to genotoxicants may stabilize 
protein half-life, thus preventing its degradation.
Few studies have reported on the effect of acetylation on the 
structure of small, ordered (Hughes and Waters, 2006; Liu and Duan, 
2008) and disordered (Smet-Nocca et al., 2010) peptides. Molecular 
dynamic simulations carried out on a peptide from the histone H3 
N-terminal tail in the nonacetylated and doubly acetylated forms 
revealed that acetylation, although not appreciably disturbing the 
overall structure of the most-populated states, influenced peptide 
stability (Liu and Duan, 2008). The effect of acetylation at K residues 
on the conformational properties of small random-coil peptides 
from the histone H4 N-terminal tail and from nonhistone thymine 
DNA glycosylase indicated that acetylation had little effect on the 
peptides that tumble very rapidly in solution. On the other hand, a 
detailed comparison of the 1D NMR data for the nonacetylated and 
tetra-acetylated APE1 peptides (Figure 8D, left) indicated that acety-
lation causes a small but clear improvement of spectral dispersion, 
which can be particularly appreciated in the NH region (Figure 8D, 
top left). Moreover, the intensity of ROE cross-peaks is increased in 
the spectra of APE1(14-38)K27/31/32/35Ac peptide as compared with the 
nonmodified counterpart (Figure 8D, right). This evidence, together 
with small chemical shift changes, point toward the presence of more 
organized conformations for the tetra-acetylated peptide in aqueous 
solution, in agreement with CD data. Similar conclusions are drawn 
from the analysis of NMR data for APE1(14–38) and APE1(14–
38)K27/31/32/35Ac peptides in phosphate:TFE solution (Supplemental 
Figure S8B), which suggested again the higher propensity of this 
domain in its acetylated form to adopt a more ordered conformation 
in contrast to the nonmodified counterpart. Also in this case, 
monoacetylated and triacetylated peptides showed an intermediate 
behavior (unpublished data). These data suggest that acetylation 
may account for local conformational changes on APE1 structure that 
may modulate its binding ability to different substrates.
DISCUSSION
APE1 is an unusually abundant DNA-repair protein in mammalian 
cells, with a wide nuclear distribution and an essential role in the 
BER pathway of DNA lesions (Tell and Wilson, 2010). We calculated 
that HeLa cells express ∼4 × 107 molecules per cell (Supplemental 
Figure S4A), whereas other enzymes of the BER pathway, such as Pol 
β or XRCC1, are present at an extent of <1/10 (Demple and DeMott, 
2002; Parsons et al., 2008). Therefore APE1 involvement in pre-
formed DNA-repair complexes may only partially explain the energy 
cost used to maintain such high protein concentration within the 
cells. Recently we found that APE1 may interact with rRNA and with 
proteins involved in RNA metabolism and is associated with nucleo-
lar structures through its interaction with NPM1 (Vascotto et al., 
2009b; Tell et al., 2010b). Interaction with rRNA and NPM1 strictly 
depends on the positive charge of K residues within the APE1 region 
24–35 placed within the unstructured protein N-terminal domain, as 
demonstrated by the inability of the corresponding K-to-A mutants 
(resembling constitutive acetylation at these residues) to stably bind 
both rRNA and NPM1 (Fantini et al., 2010). Of interest, some of 
these amino acids (i.e., K27/K31/K32/K35), which have been acquired 
during evolution, may undergo in vivo acetylation (Fantini et al., 
2010). We conjectured that, under physiological conditions, non-
acetylated APE1 may be stored in the nucleolar compartment 
through its binding to NPM1 and rRNA, but the in vivo relevance of 
APE1 nucleolar accumulation was still unclear. This study was aimed 
at addressing this issue.
We also found that APE1K4pleA binds poorly to NPM1 and rRNA in 
vivo and as a result is unable to accumulate within the nucleoli, 
whereas it is present in the nucleoplasm. Moreover, reconstitution of 
HeLa cells with this mutant gave improved protection from geno-
toxic damage induced by alkylating agents, such as MMS, and oxida-
tive stress-generating compounds, such as TBHP, through increased 
DNA-repair activity. As expected for a regulated pheno menon such 
as the response to a genome insult, an in vivo–augmented acetyla-
tion at K27/K31/K32/K35 residues was observed during cell response to 
genotoxic damage. Furthermore, cross-talk involving the SIRT1 
deacetylase occurred within cells between acetylation at K27/K31/K32/
K35 and at K6/K7 residues. Therefore we hypothesized that genotoxic 
stress may shift the equilibrium between the nonacetylated and 
acetylated APE1 forms toward the latter, which would result in the 
most enzymatically active one on abasic DNA. This also corresponds 
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FIGURE 8: Nucleolar APE1 hypoacetylated on K6/K7 and conformational impact of acetylation at K27/K31/K32/K35 on 
APE1 local structure. (A) SIRT1 resides within the nucleoplasm of HeLa cells. Left, confocal microscopy of HeLa cells 
cotransfected with green fluorescent protein–fused APE1 (APE1GFP) and c-myc-SIRT1 after fixing and staining with 
antibodies against NPM1 (red) and c-myc-SIRT1 (top, green; bottom, red). SIRT1, clearly excluded from nucleoli, 
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This is also underway in our laboratory. Of note, data obtained in 
this work not only show that nucleoli may act as a storage site so that 
an appropriate amount of APE1 is readily available for maintenance 
of genome stability, but also emphasize that nucleolar accumulation 
of APE1 controls cell proliferation, possibly through its rRNA cleans-
ing function. Compatible with this, APE1K4pleA-expressing cells, un-
der basal conditions, showed impairment in proliferation rate with 
respect to APEWT-expressing ones (Figure 3). Therefore it can be 
speculated that nucleolar APE1 is responsible for functional activity 
of the nucleolus in ribosome biogenesis. APE1 release from the nu-
cleoli after genotoxic treatment may constitute a signal to block ac-
tive protein synthesis and allow activation of the proper DNA-repair 
mechanisms. Experiments are in progress along these lines to ad-
dress this in light of the possibility that acetylation may control the 
APE1 trafficking from nucleoli to nucleoplasm.
In conclusion, our data shed light on novel molecular aspects 
highlighting the multifunctional nature of APE1 in regulating differ-
ent biological outcomes and point to acetylation as an important 
mechanism for the fine-tuning of protein functions, subcellular dis-
tribution, and stability. They also emphasize the need for additional 
investigation of the APE1 N-terminal domain in order to understand 
the structural details of the regulatory mechanisms for this multi-
functional protein. In addition, recent evidence on APE1 acetylation 
pattern in triple-negative breast cancer reveals that, concomitantly 
with total APE1 overexpression, a profound deregulation of APE1 
acetylation status occurs under pathological conditions (Poletto 
et al., 2012). This underscores the biological relevance of our find-
ings and the need for future investigation.
MATERIALS AND METHODS
Inducible APE1 knockdown and generation of APE1 
knock-in cell lines
Inducible silencing of endogenous APE1 and reconstitution with 
mutant proteins in HeLa cell clones was performed as described 
(Vascotto et al., 2009a,b) and as reported in the Supplemental 
Information. For inducible shRNA experiments, doxycycline (1 µg/ml; 
Sigma-Aldrich, St. Louis, MO) was added to the cell culture medium, 
and cells were grown for 10 d. All biological data were reproduced 
in at least two different cell clones for each model.
Cell culture and transient transfection with plasmids 
or siRNA knockdown
HeLa cells were grown in DMEM (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (EuroClone, Milan, Italy), 
100 U/ml penicillin, and 100 µg/ml streptomycin sulfate. One day 
overall polypeptide structure, while inducing local conformational 
changes (Smet-Nocca et al., 2010). In agreement with these studies, 
APE1(14–38) and APE1(14–38)K27/31/32/35Ac became disordered, as 
shown by the lack of ROE (Bax and Davis, 1985) cross-peak patterns, 
which are characteristic of ordered secondary structure elements. 
However, small differences in the NMR spectra (Figure 8 and Sup-
plemental Figure S8), concerning both chemical shift values and 
signal intensities, seem to indicate that at least local conformational 
changes may occur following acetylation. We cannot ignore that 
these changes may be important for the interaction of APE1 with 
SIRT1 deacetylase and with NPM1; they highlight the role that the 
charged status of K residues within this region may play at the pro-
tein structural level. Based on our data, it can be speculated that full 
acetylation of K27–35 may reduce SIRT1 binding to APE1, thus delay-
ing its enzymatic activity on K6/K7. This mechanism could represent 
a way to coordinate the kinetics of the overall acetylation status of 
the protein. According to this hypothesis, SIRT1 should first deacety-
late K27–35Ac before deacetylating K6/K7Ac. Our ability to identify 
APE1 peptides with varying amounts of acetylation on K27–35 sup-
ports the existence of a dynamic equilibrium between multiple 
acetylated forms of the protein within cells and thus its functional 
regulatory role. Moreover, the presence of SIRT1, found exclusively 
in the nucleoplasm but not in the nucleoli (similar to the APE1 acety-
lated on K27–35 and the reduced nucleolar presence of APE1 acety-
lated on K6/K7; Figure 8, A and B), suggests that acetylation of APE1 
may force its exit from nucleoli to nucleoplasm, where it can be 
deacetylated by SIRT1. This model is further supported by the sig-
nificantly reduced interaction of AcAPE1K27-35 with NPM1 (Figure 2). 
Further studies to identify the acetyltransferase able to acetylate 
APE1 within the nucleoli are in progress. Furthermore, this work sup-
ports findings by Yu et al. (2010), who demonstrated that these K 
residue conformational adjustments were concomitant with DNA 
binding and catalysis or with interaction with Pol β.
The nucleolar role of APE1 storage and regulation, as described 
here, may have profound biological consequences during cell re-
sponse to stressor signals, especially in light of recent evidence 
pointing to the nucleolus as a central hub in DNA damage 
(Nalabothula et al., 2010). Accordingly, the nucleolus seems respon-
sible for actively transmitting signals to the molecular complex regu-
lating p53 activity mediated by ARF–NPM1 interaction (Colombo 
et al., 2002; Lee et al., 2005; Nalabothula et al., 2010), and thus it is 
involved in the maintenance of genome stability. A careful elucida-
tion of the NPM1-ARF-p53 signaling networks and their involve-
ment in the DNA-repair pathway coordinated by APE1 is an impor-
tant subject for molecular carcinogenesis and deserves further study. 
colocalizes with APE1 in the nucleoplasm. The inner part of nucleoli, marked in the granular zone by NPM1, is negative 
for SIRT1. Right, biochemical isolation of nucleoli confirms that SIRT1 localizes in the nucleoplasmic fraction and it is 
excluded from nucleoli, where nucleolin, NPM1, and APE1 reside (see Materials and Methods for details). Nucleolin was 
used as a positive control for nuclear and nucleolar compartment. (B) Acetylated K6/K7-containing APE1 is enriched 
within the nucleoplasmic compartment with respect to nucleoli. After normalization for total APE1 protein amount, the 
levels of acetylated APE1 in nucleolar and nucleoplasmic fractions were analyzed through Western blotting. APE1 
acetylated at K6/K7 residues is predominately present within the nucleoplasmic fraction, whereas it is reduced in the 
nucleolar fraction. The histogram indicates the relative percentage amount of acetylated APE1 obtained from the 
densitometric quantification of acetylated APE1 bands normalized with respect to the amount of total APE1 in each 
fraction. Each bar represents the mean of two independent experiments whose variation was <10%. (C) CD spectra of 
the APE1(14–38) and APE1(14–38)K27/31/32/35Ac peptides in 10 mM phosphate buffer, pH 7. (D) Comparison of 1D (left), 
2D [1H, 1H] TOCSY (middle), and 2D [1H, 1H] ROESY (right) spectra of APE1(14–38) and APE1(14–38)K27/31/32/35Ac peptides 
in 10 mM phosphate buffer, pH 7.0. Two different expansions of the proton 1D spectrum are shown; the region 
between 0.8 and 2.4 ppm, in the lower inset, contains signals from side-chain protons. Acetyl methyl groups originate a 
peak around 2 ppm, which can be clearly seen in the spectrum of the acetylated peptide; peaks of backbone and 
side-chain NH atoms appear between 7.0 and 8.8 ppm in the upper inset. For 2D [
1H, 1H] TOCSY and 2D [1H, 1H] ROESY 
experiments the HN-aliphatic protons correlation region of the spectra are reported.
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ing the ECL enhanced chemiluminescence procedure (GE Health-
care Piscataway, NJ) or Western Lightning Ultra (PerkinElmer, 
Waltham, MA). Normalization was performed by using a monoclonal 
anti-tubulin antibody (Sigma-Aldrich). Blots were quantified by using 
a Chemidoc XRS video densitometer (Bio-Rad, Hercules, CA).
Plasmids and expression of recombinant proteins
Expression and purification of recombinant proteins from E. coli 
were performed as previously described (Vascotto et al., 2009b; 
Fantini et al., 2010). Where recombinant proteins were used for in 
vitro assays, the acronym rAPE1 is used.
GST pull-down assay
A 150-pmol amount of either GST-tagged rAPE1WT or mutant pro-
teins was added to 15 µl of glutathione–Sepharose 4B beads (GE 
Healthcare), together with equimolar amounts of recombinant 
NPM1. Binding was performed in PBS, supplemented with 1 mM 
dithiothreitol (DTT) and 0.5 mM phenylmethylsulfonyl fluoride 
(PMSF) for 2 h, under rotation, at 4°C. Beads were washed three 
times with PBS, supplemented with 0.1% (vol/vol) Igepal CA-630 
(Sigma-Aldrich), 1 mM DTT, and 0.5 mM PMSF and resuspended in 
Laemmli sample buffer for Western blot analysis.
DNA–RNA ChIP assays
DNA–RNA ChIP assays were carried out by using a modified version 
of a protocol described earlier (Gilbert et al., 2000) and as detailed 
in the Supplemental Information.
Enzymatic fluorescence assays
To examine in vitro deacetylase activity on the acetylated APE1 re-
gion 25–38, we used the SIRT Fluorescent Activity Assay Kit (Biomol, 
Plymouth, PA). Optimizing manufacturer’s instructions, we used 
white plates (OPTI PLATE; PerkinElmer) with 384 wells at reduced 
volume (total reaction volume, 20 µl). Purified peptides were incu-
bated in 25 mM Tris-HCl, pH 8.0, 2.7 mM KCl, 137 mM NaCl, 1 mM 
MgCl2, and 1 mg/ml bovine serum albumin containing the enzyme 
(0.04 U/µl) and 25 µM Fluor de Lys-p53 peptide substrate (Arg-His-Lys-
Lys [Ac], from region 379–382 of human p53) in the presence/
absence of 250 µM NAD+ for 30 min at 37°C. Deacetylase activity 
was measured in arbitrary fluorescence units at 460 nm. Dose–
response experiments were carried out by using a 0–500 µM range 
of peptide concentration. Data fitting was performed using the 
GraphPad Prism 4 software, version 4.02 (GraphPad, La Jolla, CA). 
Data were in triplicate/duplicate from three independent assays.
Immunofluorescence confocal and proximity ligation 
analyses
Immunofluorescence procedures and PLA were carried out as de-
scribed earlier (Vascotto et al., 2009b, 2011). To study the interaction 
between APE1 and NPM1 in vivo, we used the in situ Proximity 
Ligation Assay technology (Olink Bioscience, Uppsala, Sweden). 
After incubation with monoclonal anti-APE1 (1:50) or anti-FLAG anti-
body (1:200) for 3 h at 37°C, cells were incubated with polyclonal 
anti-NPM1 (1:200) overnight at 4°C. PLA was performed following 
manufacturer’s instructions. Technical controls, represented by the 
omission of anti-NPM1 primary antibody, resulted in the complete 
loss of PLA signal. Cells were visualized through a Leica TCS SP laser-
scanning confocal microscope (Leica Microsystems, Wetzlar, 
Germany). Determination of PLA signals was performed using 
BlobFinder software (Center for Image Analysis, Uppsala University, 
Uppsala, Sweden). PLA technology was also used to detect acety-
lated APE1 at K27/K31/K32/K35 residues. Cells were incubated with the 
before transfection, cells were seeded in 10-cm plates at a density 
of 3.0 × 106 cells/plate. Cells were then transiently transfected 
with the indicated plasmids using the Lipofectamine 2000 reagent 
(Invitrogen), according to the manufacturer’s instructions. Cells were 
harvested either 24 or 48 h after transfection, as indicated.
For SIRT1-knockdown experiments, HeLa clones were trans-
fected with 150 nM siRNA siGENOME SMART pool or negative 
control siRNA 5′-CCAUGAGGUCAUGGUCUGdTdT-3′ (Dharmacon, 
Lafayette, CO), using Oligofectamine (Invitrogen). After 72 h the 
cells were harvested.
Preparation of total cell extracts and anti-FLAG 
coimmunoprecipitation
Preparation of total cell lysates and coimmunoprecipitation analyses 
were performed as described (Vascotto et al., 2009a,b).
Determination of AP endonuclease activity 
and abasic site assay
Determination of APE1 AP endonuclease activity was performed 
using an oligonucleotide cleavage assay, as described previously 
(Vascotto et al., 2009b) and detailed in the Supplemental 
Information.
Mass spectrometric analysis of APE1 acetylation
Characterization of APE1 acetylation was performed on the immu-
nopurified protein obtained from APE1-FLAG–expressing HeLa 
cells (Vascotto et al., 2009b). APE1 was resolved by SDS–PAGE; 
corresponding protein bands were excised, S-alkylated, and di-
gested with endoprotease AspN (Fantini et al., 2010). Digest ali-
quots were directly analyzed by nanoLC-ESI-LIT-MS/MS using an 
LTQ XL mass spectrometer (ThermoFisher Scientific, Waltham, MA) 
equipped with a Proxeon nanospray source connected to an Easy-
nanoLC (ThermoFisher Scientific; Arena et al., 2010; Scippa et al., 
2010), and analysis of APE1 acetylation was performed as described 
(D’Ambrosio et al., 2006) and detailed in the Supplemental Infor-
mation. A semiquantitative measurement of the amino acid modifi-
cation was obtained by extracting and integrating nanoLC-ESI-LIT-
MS peak areas corresponding to m/z values of the modified and 
nonmodified peptides in the same total ion chromatogram (Salzano 
et al., 2011). Modification extent was then assayed by evaluating 
the peak area of the modified peptide with respect to that of the 
modified peptide plus that of the nonmodified peptide, assuming 
identical ionization properties for modified and nonmodified spe-
cies. All these analyses were performed in triplicate.
Antibodies for immunofluorescence and immunoblotting
Antibodies used were anti-NPM1 monoclonal, anti-nucleolin mono-
clonal (Zymed, Invitrogen), anti-FLAG peroxidase-conjugated, 
anti-GST peroxidase-conjugated, anti-SIRT1 polyclonal (Abcam, 
Cambridge, MA), anti–c-myc (Santa Cruz Biotechnology, Santa Cruz, 
CA), and anti–β-tubulin monoclonal (Sigma-Aldrich). Anti-APE1 
monoclonal (Vascotto et al., 2009a) and anti-APE1K6K7Ac (Bhakat et al., 
2003) were described previously. Anti-APE1K27-35Ac polyclonal anti-
body was generated by PRIMM (Milan, Italy; Poletto et al., 2012).
Western blot analyses
For Western blot analyses, the indicated amounts of cell extracts 
were resolved in 12% SDS–PAGE and transferred to nitrocellulose 
membranes (Schleicher & Schuell BioScience, Dassel, Germany). 
Membranes were blocked with 5% (wt/vol) nonfat dry milk in phos-
phate-buffered saline (PBS) containing 0.1% (vol/vol) Tween 20 and 
probed with the indicated antibodies; blots were developed by us-
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